Enhanced chimeric antigen receptors and uses thereof
Modified CD3ζ CARs lacking ITAMs and BRS regions improve persistence and efficacy in cancer therapy by optimizing antigen recognition and signaling, addressing inefficiencies in current CAR designs.
Patent Information
- Application Number
- JP2024153067
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2017-12-29
- Filing Date
- 2024-09-05
- Publication Date
- 2024-11-28
- Estimated Expiration
- 2038-12-31
AI Technical Summary
Current chimeric antigen receptors (CARs) for cancer therapy rely on signaling domains from CD3ζ and costimulatory receptors like CD28 or 41BB, which are dependent on immunoreceptor activation tyrosine motifs (ITAMs) for function, leading to potential inefficiencies and loss of persistence.
Design of CARs with modified CD3ζ polypeptides lacking or with deletions in ITAMs and basic-rich stretches (BRS), combined with costimulatory signaling domains, to enhance antigen recognition and signaling efficacy.
The modified CARs exhibit improved persistence and efficacy in targeting tumor cells, reducing tumor burden and enhancing immune response without functional loss.
Smart Images

Figure 2024166242000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 612,031, filed December 29, 2017, the contents of which are incorporated by reference in their entirety and to which priority is claimed.
[0002] Introduction The subject matter of the present disclosure provides methods and compositions for enhancing immune responses against cancer and pathogens. It relates to novel designs of chimeric antigen receptors (CARs) and engineered immunoresponsive cells containing them. The engineered immunoresponsive cells containing the novel CARs are antigen-directed and have extended persistence without compromising function. [Background technology]
[0003] Chimeric antigen receptor (CAR) therapy has achieved great clinical success against hematological malignancies (PMID:23515080). It is based on a synthetic receptor with both antigen recognition and signaling functions (PMID:20467460). The single chain variable fragment (scFv) in CAR retains its antigen recognition specificity derived from the variable regions of the heavy and light chains of the original monoclonal antibody. Meanwhile, the signaling of the CAR construct is highly dependent on the signaling domain of the original immune receptor. Currently, all versions of second generation CARs in clinical trials contain domains derived from two immune receptors, one is CD3ζ and the other is a costimulatory receptor such as CD28 or 41BB, and thus have two signaling capabilities / modalities (PMID:26129802). In essence, it combines two signals delivered by different receptors in one synthetic receptor. Presumably, the signaling in CAR is similar to that in CD3ζ and CD28 / 41BB.
[0004] CD3ζ is part of the multimeric T cell antigen receptor (TCR) complex that binds antigens and transduces binding across the plasma membrane into intracellular signals. Whereas the TCRαβ (or TCRγδ) subunits recognize antigens through their specific extracellular domains, CD3ζ performs its signaling function in the complex primarily through its well-conserved three immunoreceptor tyrosine-based activation motifs (ITAMs) (PMID:20516133). First identified on the basis of their sequence homology, ITAMs consist of two consecutive YxxL / I motifs separated by a defined number of amino acids (YxxL / IX 6~8 -YxxL / I) (PMID:2927501). ITAMs are typically found in receptors expressed in hematopoietic cells and have been particularly well studied in the context of TCR signaling. TCR binding to peptide-MHC leads to activation of the Src family kinase Lck, which phosphorylates two tyrosine residues in each of the three ITAMs in CD3ζ (PMID:25861978). Each diphosphorylated ITAM then acquires the ability to bind to two tandem SH2 domains of the Syk family kinase, ZAP-70. This interaction brings ZAP-70 into close proximity with Lck, resulting in the phosphorylation and activation of ZAP-70 by Lck. Activated ZAP-70 further phosphorylates its downstream targets, such as the adaptor proteins LAT and SLP-76. Phosphorylated LAT and SLP-76 provide a scaffold for many other proteins, such as PLC-γ, Grb2 / Sos, Gads, and Itk, Vav, and Nck, ultimately leading to calcium mobilization, Ras / Erk activation, and actin cytoskeleton rearrangement and ultimately activation of gene expression (PMID:20516133). Thus, the three ITAMs in CD3ζ are major, if not the only, signaling moieties in TCR signaling.
[0005] CD28, on the other hand, does not contain any ITAMs. Instead, its cytoplasmic domain contains a YMNM motif that can bind to the p85 subunit of PI3K and Grb2 / Gads when phosphorylated upon binding of CD28 to its ligands CD80 / CD86 (PMID:20534709). In addition, the proline-rich region of CD28 can interact with Itk, Tec, Lck, Grb2 / Vav and filamin A (PMID:20534709). Thus, TCR signaling initiated by antigen binding via CD3ζ and CD28 signaling initiated by CD80 / 86 binding share many common players such as Grb2, Vav, Gads, Lck, Itk, which allow crosstalk between these two pathways. Furthermore, activation of both pathways occurs in signaling complexes that assemble near the plasma membrane at the immunological synapse, physically space signaling molecules originating from the two pathways together. Finally, CD28-induced calcium signaling occurs at least seconds after a TCR-initiated increase in intracellular calcium, reflecting the temporal proximity / closeness of the two pathways (PMID:18848472). Summary of the Invention [Means for solving the problem]
[0006] The present disclosure provides a chimeric antigen receptor (CAR) that binds to an antigen of interest. CAR can bind to tumor antigen or pathogen antigen. In certain non-limiting embodiments, CAR comprises an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain that comprises modified CD3ζ polypeptide.
[0007] In certain embodiments, the modified CD3ζ polypeptide lacks all or a portion of an immunoreceptor tyrosine-based activation motif (ITAM), and the ITAM is ITAM1, ITAM2, and ITAM3. In certain embodiments, the modified CD3ζ polypeptide lacks ITAM2 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide further lacks ITAM3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide further lacks ITAM1 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide lacks ITAM1 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide further lacks ITAM3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide lacks ITAM3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide comprises a deletion of ITAM2 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide comprises a deletion of ITAM3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide comprises a deletion of ITAM1 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide comprises a deletion of ITAM1 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide further comprises a deletion of ITAM3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide comprises a deletion of ITAM3 or a portion thereof.
[0008] In certain embodiments, the modified CD3ζ polypeptide further lacks all or a portion of a basic-rich stretch (BRS) region, the BRS region being BRS1, BRS2, and BRS3. In certain embodiments, the modified CD3ζ polypeptide lacks BRS2 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide further lacks BRS3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide further lacks BRS1 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide further lacks BRS3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide lacks BRS3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide lacks BRS1 or a portion thereof, BRS2 or a portion thereof, and BRS3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide comprises a deletion of BRS2 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide further comprises a deletion of BRS3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide further comprises a deletion of BRS1 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide comprises a deletion of BRS1 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide further comprises a deletion of BRS3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide comprises a deletion of BRS3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide comprises a deletion of BRS1 or a portion thereof, a deletion of BRS2 or a portion thereof, and a deletion of BRS3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide comprises a deletion of ITAM2, ITAM3, BRS2, and BRS3. In certain embodiments, the modified CD3ζ polypeptide lacks ITAM2, ITAM3, BRS2, and BRS3. In certain embodiments, the CAR comprises the amino acid sequence set forth in SEQ ID NO: 45 or SEQ ID NO: 47.
[0009] In certain embodiments, the modified CD3ζ polypeptide lacks all or part of the basic residue-rich extension (BRS) region, and the BRS region is BRS1, BRS2, and BRS3. In certain embodiments, the modified CD3ζ polypeptide lacks BRS2 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide further lacks BRS3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide further lacks BRS1 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide lacks BRS1 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide further lacks BRS3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide lacks BRS3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide lacks BRS1 or a portion thereof, BRS2 or a portion thereof, and BRS3 or a portion thereof.
[0010] In certain embodiments, the modified CD3 zeta polypeptide comprises a BRS variant selected from a BRS1 variant, a BRS2 variant, and a BRS3 variant, wherein the BRS variant comprises one or more loss-of-function mutations.
[0011] In certain embodiments, any of the various CARs disclosed above further comprises a hinge / spacer region comprising a CD8 polypeptide, a CD28 polypeptide, a CD3ζ polypeptide, a CD40 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, a CD84 polypeptide, a CD166 polypeptide, a CD8a polypeptide, a CD8b polypeptide, an ICOS polypeptide, an ICAM-1 polypeptide, a CTLA-4 polypeptide, a CD27 polypeptide, a CD40 / My88 peptide, an NKGD2 peptide, or a combination thereof. In certain embodiments, the hinge / spacer region comprises a CD166 polypeptide. In certain embodiments, the hinge / spacer region comprises a CD166 polypeptide having amino acids 489-527 of SEQ ID NO:3.
[0012] In certain embodiments, the transmembrane domain of any of the various CARs disclosed above comprises a CD8 polypeptide, a CD28 polypeptide, a CD3ζ polypeptide, a CD40 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, a CD84 polypeptide, a CD166 polypeptide, a CD8a polypeptide, a CD8b polypeptide, an ICOS polypeptide, an ICAM-1 polypeptide, a CTLA-4 polypeptide, a CD27 polypeptide, a CD40 / My88 peptide, an NKGD2 peptide, or a combination thereof. In certain embodiments, the transmembrane domain comprises a CD166 polypeptide. In certain embodiments, the transmembrane domain comprises a CD166 polypeptide having amino acids 528-527 of SEQ ID NO:3.
[0013] In certain embodiments, the transmembrane domain and the hinge / spacer region are derived from the same molecule. In certain embodiments, the hinge / spacer region comprises a CD28 polypeptide, and the transmembrane domain comprises a CD28 polypeptide. In certain embodiments, the hinge / spacer region comprises a CD84 polypeptide, and the transmembrane domain comprises a CD84 polypeptide. In certain embodiments, the hinge / spacer region comprises a CD166 polypeptide, and the transmembrane domain comprises a CD166 polypeptide. In certain embodiments, the CAR comprises amino acids 489-553 of SEQ ID NO:3.
[0014] In certain embodiments, the hinge / spacer region comprises a CD8a polypeptide and the transmembrane domain comprises a CD8a polypeptide, hi certain embodiments, the hinge / spacer region comprises a CD8b polypeptide and the transmembrane domain comprises a CD8b polypeptide.
[0015] In certain embodiments, the transmembrane domain and the hinge / spacer region are derived from different molecules, hi certain embodiments, the hinge / spacer region comprises a CD28 polypeptide and the transmembrane domain comprises an ICOS polypeptide.
[0016] In certain embodiments, the intracellular signaling domain of any of the various CARs disclosed above further comprises a costimulatory signaling domain. In certain embodiments, the costimulatory signaling domain comprises a CD28 polypeptide.
[0017] The subject matter of the present disclosure also provides a chimeric antigen receptor (CAR) comprising an extracellular antigen binding domain, a hinge / spacer region, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3ζ polypeptide, wherein the modified CD3ζ polypeptide comprises an ITAM variant comprising one or more loss-of-function mutations, and the ITAM variant is selected from the group consisting of an ITAM1 variant, an ITAM2 variant, and an ITAM3 variant. In certain embodiments, the hinge / spacer region comprises a CD8 polypeptide, a CD28 polypeptide, a CD3ζ polypeptide, a CD40 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, a CD84 polypeptide, a CD166 polypeptide, a CD8a polypeptide, a CD8b polypeptide, an ICOS polypeptide, an ICAM-1 polypeptide, a CTLA-4 polypeptide, a CD27 polypeptide, a CD40 / My88 peptide, an NKGD2 peptide, or a combination thereof. In certain embodiments, the ITAM2 variant has the amino acid sequence set forth in SEQ ID NO:29. In certain embodiments, the ITAM3 variant has the amino acid sequence set forth in SEQ ID NO:33. In certain embodiments, the CAR comprises a hinge / spacer region of a CD166 polypeptide and a transmembrane domain of a CD166 polypeptide. In certain embodiments, the CAR comprises amino acids 489-553 of SEQ ID NO:3. In certain embodiments, the modified CD3ζ polypeptide has amino acids 374-485 of SEQ ID NO:43. In certain embodiments, the CAR has the amino acid sequence set forth in SEQ ID NO:43.
[0018] The subject matter of the present disclosure also provides an immunoresponsive cell comprising the CAR disclosed herein.In certain embodiments, the CAR is recombinantly expressed.In certain embodiments, the CAR is expressed from a vector.In certain embodiments, the CAR is placed in the endogenous locus of the immunoresponsive cell.In certain embodiments, the endogenous locus is the TRAC locus, the TRBC locus or the TRGC locus.In certain embodiments, the endogenous locus is the TRAC locus.In certain embodiments, the placement of the CAR disrupts or disables the endogenous expression of TCR.
[0019] The subject matter of the present disclosure also provides an immunoresponsive cell comprising two or more CARs. In certain embodiments, the immunoresponsive cell comprises: a) a first CAR comprising a first extracellular antigen binding domain that binds to a first antigen, a first transmembrane domain, and a first intracellular signaling domain; and b) a second CAR comprising a second extracellular antigen binding domain that binds to a second antigen, a second transmembrane domain, and a second intracellular signaling domain, wherein the first CAR is the CAR disclosed above, or the first intracellular signaling domain comprises a modified CD3ζ polypeptide comprising one or more ITAM variants comprising one or more loss-of-function mutations, and each of the one or more ITAM variants is independently selected from the group consisting of ITAM1 variants, ITAM2 variants, and ITAM3 variants. In certain embodiments, the first CAR further comprises a first hinge / spacer region. In certain embodiments, the second CAR further comprises a second hinge / spacer region. In certain embodiments, the first and second hinge / spacer regions can each independently be selected from any of the hinge / spacer regions disclosed herein.
[0020] In certain embodiments, the second CAR is the CAR disclosed above. In certain embodiments, the second intracellular signaling domain of the second CAR comprises a modified CD3ζ polypeptide comprising one or more ITAM variants comprising one or more loss-of-function mutations, the ITAM variants being selected from the group consisting of ITAM1 variants, ITAM2 variants, and ITAM3 variants. In certain embodiments, the second intracellular signaling domain of the second CAR comprises a modified CD3ζ polypeptide that is the same as the modified CD3ζ polypeptide comprised in the first intracellular signaling domain of the first CAR. In certain embodiments, the second intracellular signaling domain of the second CAR comprises a modified CD3ζ polypeptide that is different from the modified CD3ζ polypeptide comprised in the first intracellular signaling domain of the first CAR. In certain embodiments, the second intracellular signaling domain of the second CAR comprises a natural CD3ζ polypeptide.
[0021] In certain embodiments, the first intracellular signaling domain of the first CAR is the same as the second intracellular signaling domain of the second CAR. In certain embodiments, the first intracellular signaling domain of the first CAR is different from the second intracellular signaling domain of the second CAR.
[0022] In certain embodiments, the first antigen is different from the second antigen.
[0023] In certain embodiments, the first intracellular signaling domain comprises or has an ITAM2 variant and an ITAM3 variant, and the second intracellular signaling domain comprises or has a deletion of ITAM2 or a portion thereof and a deletion of ITAM3 or a portion thereof.
[0024] In certain embodiments, the first intracellular signaling domain comprises or has an ITAM2 variant and an ITAM3 variant, and the second intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant.
[0025] In certain embodiments, the cell further comprises a third CAR comprising a third extracellular antigen binding domain that binds a third antigen, a third transmembrane domain, and a third intracellular signaling domain.
[0026] In certain embodiments, the first intracellular signaling domain comprises or has an ITAM2 variant and an ITAM3 variant, the second intracellular signaling domain comprises or has an ITAM2 or a deletion of a portion thereof and an ITAM3 or a deletion of a portion thereof, and the third intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant.
[0027] In certain embodiments, the first intracellular signaling domain comprises or has a deletion of ITAM2 or a portion thereof and a deletion of ITAM3 or a portion thereof, the second intracellular signaling domain comprises or has a deletion of ITAM2 or a portion thereof and a deletion of ITAM3 or a portion thereof, and the third intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant.
[0028] In certain embodiments, the first intracellular signaling domain comprises or has an ITAM2 or a portion thereof and an ITAM3 or a portion thereof, the second intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant, and the third intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant.
[0029] In certain embodiments, the first intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant, the second intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant, and the third intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant.
[0030] In certain embodiments, the cell is selected from the group consisting of T cells, natural killer (NK) cells, human embryonic stem cells, and pluripotent stem cells from which lymphoid cells can be differentiated. In certain embodiments, the cell is a T cell. In certain embodiments, the T cell is selected from the group consisting of cytotoxic T lymphocytes (CTLs), regulatory T cells, and natural killer T (NKT) cells. In certain embodiments, the immunoresponsive cell is a myeloid cell, such as a macrophage. In certain embodiments, the immunoresponsive cell is autologous. In certain embodiments, the antigen is a tumor antigen. In certain embodiments, the tumor antigen is CD19, MUC16, MUC1, CAIX, CEA, CD8, CD7, CD10, CD20, CD22, CD30, CLL1, CD33, CD34, CD38, CD41, CD44, CD49f, CD56, CD74, CD133, CD138, EGP-2, EGP-40, EpCAM, erb-B2, 3, 4, FBP, fetal acetylcholine receptor, folate receptor-a, GD2, GD3, HER-2, hTERT, IL-13R-a2, K-light chain, KDR, LeY, L1 cell adhesion molecule, MAGE-A1, mesothelin, ERBB2, MAGEA3, p53, MART1, The antigen is selected from the group consisting of GP100, proteinase 3 (PR1), tyrosinase, survivin, hTERT, EphA2, NKG2D ligand, NY-ES0-1, carcinoembryonic antigen (h5T4), PSCA, PSMA, ROR1, TAG-72, VEGF-R2, WT-1, BCMA, CD123, CD44V6, NKCS1, EGF1R, EGFR-VIII, and CD99, CD70, ADGRE2, CCR1, LILRB2, PRAME, CCR4, CD5, CD3, TRBC1, TRBC2, TIM-3, integrin B7, ICAM-1, CD70, Tim3, CLEC12A and ERBB. In certain embodiments, the antigen is CD19.
[0031] The presently disclosed subject matter further provides a pharmaceutical composition comprising an effective amount of the immunoresponsive cells disclosed herein and a pharma- ceutical acceptable excipient, hi certain embodiments, the pharmaceutical composition is for treating a neoplasm.
[0032] The subject matter of the present disclosure further provides a method of reducing tumor burden in a subject, comprising administering to the subject an effective amount of an immunoresponsive cell or pharmaceutical composition disclosed herein. The subject matter of the present disclosure also provides a method comprising administering to the subject an effective amount of an immunoresponsive cell or pharmaceutical composition comprising the same, wherein the immunoresponsive cell comprises a chimeric antigen receptor (CAR) comprising an extracellular antigen binding domain, a hinge / spacer region, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3ζ polypeptide, the modified CD3ζ polypeptide comprises one or more ITAM variants comprising one or more loss-of-function mutations, and the one or more ITAM variants are each independently selected from the group consisting of an ITAM1 variant, an ITAM2 variant, and an ITAM3 variant. In certain embodiments, the modified CD3ζ polypeptide comprises an ITAM2 variant and an ITAM3 variant. In certain embodiments, one or both of the ITAM2 variant and the ITAM3 variant comprise two loss-of-function mutations. In certain embodiments, the ITAM2 variant has the amino acid sequence set forth in SEQ ID NO:29. In certain embodiments, the ITAM3 variant has an amino acid sequence as set forth in SEQ ID NO: 33. In certain embodiments, one or more loss-of-function mutations are at tyrosine amino acid residues. In certain embodiments, the intracellular signaling domain further comprises a costimulatory signaling domain. In certain embodiments, the costimulatory signaling domain comprises a CD28 polypeptide.
[0033] In certain embodiments, the method reduces the number of tumor cells. In certain embodiments, the method reduces the size of a tumor. In certain embodiments, the method eradicates a tumor in a subject.
[0034] The subject matter of the present disclosure further provides a method for treating or preventing neoplasms. In certain embodiments, the method comprises administering to a subject an effective amount of an immunoresponsive cell or pharmaceutical composition disclosed herein. In certain embodiments, the method comprises administering to a subject an effective amount of an immunoresponsive cell or a pharmaceutical composition comprising the same, wherein the immunoresponsive cell comprises a chimeric antigen receptor (CAR) comprising an extracellular antigen binding domain, a hinge / spacer region, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3ζ polypeptide, wherein the modified CD3ζ polypeptide comprises one or more ITAM variants comprising one or more loss-of-function mutations, and each of the one or more ITAM variants is independently selected from the group consisting of ITAM1 variants, ITAM2 variants, and ITAM3 variants.
[0035] The subject of the present disclosure further provides a method of treating a subject having a recurrence of a neoplasm, the subject receiving an immunoresponsive cell comprising an antigen recognition receptor, the antigen recognition receptor comprising a 4-1BB costimulatory signal. In certain embodiments, the method comprises administering to the subject an effective amount of an immunoresponsive cell or pharmaceutical composition disclosed herein. In certain embodiments, the method comprises administering to the subject an effective amount of an immunoresponsive cell or pharmaceutical composition comprising the same, the immunoresponsive cell comprising a chimeric antigen receptor (CAR) comprising an extracellular antigen binding domain, a hinge / spacer region, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3ζ polypeptide, the modified CD3ζ polypeptide comprising one or more ITAM variants comprising one or more loss-of-function mutations, the one or more ITAM variants each independently selected from the group consisting of an ITAM1 variant, an ITAM2 variant, and an ITAM3 variant. In certain embodiments, the intracellular signaling domain further comprises a costimulatory signaling domain. In certain embodiments, the costimulatory signaling domain comprises a CD28 polypeptide.
[0036] In certain embodiments, the neoplasm or tumor is selected from the group consisting of blood cancer, B-cell leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and ovarian cancer.In certain embodiments, the neoplasm is B-cell leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, or non-Hodgkin's lymphoma, and the CAR binds to CD19.In certain embodiments, the neoplasm is CD19+ALL.In certain embodiments, the neoplasm comprises tumor cells with low expression levels of tumor-specific antigens.
[0037] The subject matter of the present disclosure further provides a method for producing an antigen-specific immunoresponsive cell, comprising introducing into the immunoresponsive cell a nucleic acid sequence encoding a CAR as disclosed herein. In certain embodiments, the nucleic acid sequence is contained in a vector. In certain embodiments, the vector is a retroviral vector.
[0038] The subject matter of the present disclosure further provides an isolated nucleotide acid encoding a CAR disclosed herein. In certain embodiments, the isolated nucleic acid is SEQ ID NO:4. 5 and the nucleotide sequence set forth in SEQ ID NO:47.
[0039] The subject matter of the present disclosure further provides a nucleic acid composition comprising the CAR disclosed herein.In certain embodiments, the nucleic acid sequence is contained in a vector.In certain embodiments, the vector is a retroviral vector.
[0040] The presently disclosed subject matter further provides vectors comprising the nucleic acid compositions disclosed herein.
[0041] The subject matter of the present disclosure further provides a kit comprising the CAR, immunoresponsive cell, pharmaceutical composition, nucleic acid composition or vector disclosed herein.In certain embodiments, the kit comprises written instructions for treating and / or preventing neoplasms, pathogen infections, autoimmune disorders, or allogeneic transplants. The present invention provides, for example, the following items. (Item 1) A chimeric antigen receptor (CAR) comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3ζ polypeptide, wherein the modified CD3ζ polypeptide lacks all or a portion of an immunoreceptor tyrosine-based activation motif (ITAM), and the ITAM is ITAM1, ITAM2, and ITAM3. (Item 2) The CAR of item 1, wherein the modified CD3ζ polypeptide lacks ITAM2 or a portion thereof. (Item 3) The CAR of item 2, wherein the modified CD3ζ polypeptide further lacks ITAM3 or a portion thereof. (Item 4) The CAR of item 2, wherein the modified CD3ζ polypeptide further lacks ITAM1 or a portion thereof. (Item 5) The CAR of item 1, wherein the modified CD3ζ polypeptide lacks ITAM1 or a portion thereof. (Item 6) The CAR of item 5, wherein the modified CD3ζ polypeptide further lacks ITAM3 or a portion thereof. (Item 7) The CAR of item 1, wherein the modified CD3ζ polypeptide lacks ITAM3 or a portion thereof. (Item 8) The CAR of item 1, wherein the modified CD3ζ polypeptide comprises a deletion of ITAM2 or a portion thereof. (Item 9) The CAR of item 8, wherein the modified CD3ζ polypeptide further comprises a deletion of ITAM3 or a portion thereof. (Item 10) The CAR of item 8, wherein the modified CD3ζ polypeptide further comprises a deletion of ITAM1 or a portion thereof. (Item 11) The CAR of item 1, wherein the modified CD3ζ polypeptide comprises a deletion of ITAM1 or a portion thereof. (Item 12) The CAR of item 11, wherein the modified CD3ζ polypeptide further comprises a deletion of ITAM3 or a portion thereof. (Item 13) The CAR of item 1, wherein the modified CD3ζ polypeptide comprises a deletion of ITAM3 or a portion thereof. (Item 14) 14. The CAR of any one of items 1 to 13, wherein the modified CD3 zeta polypeptide lacks all or part of a basic residue-rich stretch (BRS) region, and the BRS regions are BRS1, BRS2, and BRS3. (Item 15) The CAR of item 14, wherein the modified CD3ζ polypeptide lacks BRS2 or a portion thereof. (Item 16) The CAR of item 15, wherein the modified CD3ζ polypeptide further lacks BRS3 or a portion thereof. (Item 17) The CAR of item 16, wherein the modified CD3ζ polypeptide further lacks BRS1 or a portion thereof. (Item 18) The CAR of item 14, wherein the modified CD3ζ polypeptide lacks BRS1 or a portion thereof. (Item 19) The CAR of item 18, wherein the modified CD3ζ polypeptide further lacks BRS3 or a portion thereof. (Item 20) The CAR of item 14, wherein the modified CD3ζ polypeptide lacks BRS3 or a portion thereof. (Item 21) The CAR of item 14, wherein the modified CD3 zeta polypeptide lacks BRS1 or a portion thereof, BRS2 or a portion thereof, and BRS3 or a portion thereof. (Item 22) The CAR of item 1, wherein the modified CD3ζ polypeptide lacks ITAM2, ITAM3, BRS2, and BRS3. (Item 23) The CAR of item 14, wherein the modified CD3ζ polypeptide comprises a deletion of BRS2 or a portion thereof. (Item 24) 24. The CAR of item 23, wherein the modified CD3ζ polypeptide further comprises a deletion of BRS3 or a portion thereof. (Item 25) 25. The CAR of item 24, wherein the modified CD3ζ polypeptide further comprises a deletion of BRS1 or a portion thereof. (Item 26) The CAR of item 14, wherein the modified CD3ζ polypeptide comprises a deletion of BRS1 or a portion thereof. (Item 27) 27. The CAR of item 26, wherein the modified CD3ζ polypeptide further comprises a deletion of BRS3 or a portion thereof. (Item 28) The CAR of item 14, wherein the modified CD3ζ polypeptide comprises a deletion of BRS3 or a portion thereof. (Item 29) The CAR of item 14, wherein the modified CD3 zeta polypeptide comprises a deletion of BRS1 or a portion thereof, BRS2 or a portion thereof, and BRS3 or a portion thereof. (Item 30) The CAR of item 1, wherein the modified CD3ζ polypeptide comprises deletions of ITAM2, ITAM3, BRS2, and BRS3. (Item 31) The CAR of item 1, comprising the amino acid sequence set forth in SEQ ID NO: 45 or SEQ ID NO: 47. (Item 32) A chimeric antigen receptor (CAR) comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3ζ polypeptide, wherein the modified CD3ζ polypeptide lacks all or a portion of a basic residue-rich extension (BRS) region, and the BRS regions are BRS1, BRS2, and BRS3. (Item 33) 33. The CAR of item 32, wherein the modified CD3ζ polypeptide lacks BRS2 or a portion thereof. (Item 34) The CAR of item 33, wherein the modified CD3ζ polypeptide further lacks BRS3 or a portion thereof. (Item 35) The CAR of item 34, wherein the modified CD3ζ polypeptide further lacks BRS1 or a portion thereof. (Item 36) 36. The CAR of item 35, wherein the modified CD3ζ polypeptide lacks BRS1 or a portion thereof. (Item 37) The CAR of item 36, wherein the modified CD3ζ polypeptide further lacks BRS3 or a portion thereof. (Item 38) 38. The CAR of item 37, wherein the modified CD3ζ polypeptide lacks BRS3 or a portion thereof. (Item 39) 33. The CAR of item 32, wherein the modified CD3 zeta polypeptide lacks BRS1 or a portion thereof, BRS2 or a portion thereof, and BRS3 or a portion thereof. (Item 40) A chimeric antigen receptor (CAR) comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3ζ polypeptide, wherein the modified CD3ζ polypeptide comprises a BRS variant selected from a BRS1 variant, a BRS2 variant, and a BRS3 variant, and the BRS variant comprises one or more loss-of-function mutations. (Item 41) 41. The CAR of any one of paragraphs 1 to 40, further comprising a hinge / spacer region comprising a CD8 polypeptide, a CD28 polypeptide, a CD3zeta polypeptide, a CD4 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, a CD166 polypeptide, a CD166 polypeptide, a CD8a polypeptide, a CD8b polypeptide, an ICOS polypeptide, an ICAM-1 polypeptide, a CTLA-4 polypeptide, a CD27 polypeptide, a CD40 / My88 peptide, an NKGD2 peptide, or a combination thereof. (Item 42) 42. The CAR of item 41, wherein the hinge / spacer region comprises a CD166 polypeptide. (Item 43) The CAR of item 42, wherein the CD166 polypeptide has amino acids 489 to 527 of SEQ ID NO:3. (Item 44) A chimeric antigen receptor (CAR) comprising an extracellular antigen binding domain, a hinge / spacer region, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3ζ polypeptide, the modified CD3 zeta polypeptide comprises one or more ITAM variants comprising one or more loss-of-function mutations, wherein the one or more ITAM variants are each independently selected from the group consisting of an ITAM1 variant, an ITAM2 variant, and an ITAM3 variant; A CAR, wherein the hinge / spacer region comprises a CD8 polypeptide, a CD28 polypeptide, a CD3zeta polypeptide, a CD4 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, a CD166 polypeptide, a CD166 polypeptide, a CD8a polypeptide, a CD8b polypeptide, an ICOS polypeptide, an ICAM-1 polypeptide, a CTLA-4 polypeptide, a CD27 polypeptide, a CD40 / My88 peptide, an NKGD2 peptide, or a combination thereof. (Item 45) The method of item 44, wherein the modified CD3ζ polypeptide comprises an ITAM2 variant and an ITAM3 variant. (Item 46) 46. The method of claim 45, wherein the ITAM2 variant has the amino acid sequence set forth in SEQ ID NO:29. (Item 47) 47. The method of claim 45 or 46, wherein the ITAM3 variant has the amino acid sequence set forth in SEQ ID NO: 33. (Item 48) 48. The CAR of any one of items 44 to 47, wherein the modified CD3ζ polypeptide comprises or consists of amino acids 374 to 485 of SEQ ID NO: 43. (Item 49) 49. The CAR of any one of items 44 to 48, comprising the amino acid sequence set forth in SEQ ID NO: 43. (Item 50) 50. The method of any one of items 45 to 49, wherein one or both of the ITAM2 variant and the ITAM3 variant contain two loss-of-function mutations. (Item 51) 51. The method of any one of items 44 to 50, wherein the one or more loss-of-function mutations are in a tyrosine amino acid residue. (Item 52) 52. The CAR of any one of items 1 to 51, wherein the transmembrane domain comprises a CD8 polypeptide, a CD28 polypeptide, a CD3zeta polypeptide, a CD4 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, a CD166 polypeptide, a CD166 polypeptide, a CD8a polypeptide, a CD8b polypeptide, an ICOS polypeptide, an ICAM-1 polypeptide, a CTLA-4 polypeptide, a CD27 polypeptide, a CD40 / My88 peptide, an NKGD2 peptide, or a combination thereof. (Item 53) 53. The CAR of item 52, wherein the transmembrane domain comprises a CD166 polypeptide. (Item 54) 54. The CAR of item 53, wherein the CD166 polypeptide comprises amino acids 528 to 553 of SEQ ID NO:3. (Item 55) 55. The CAR of any one of items 44 to 54, wherein the transmembrane domain and the hinge / spacer region are derived from the same molecule. (Item 56) 56. The CAR of any one of paragraphs 44 to 55, wherein the hinge / spacer region comprises a CD28 polypeptide and the transmembrane domain comprises a CD28 polypeptide. (Item 57) 57. The CAR of any one of paragraphs 44 to 56, wherein the hinge / spacer region comprises a CD84 polypeptide and the transmembrane domain comprises a CD84 polypeptide. (Item 58) 58. The CAR of any one of items 44 to 57, wherein the hinge / spacer region comprises a CD166 polypeptide and the transmembrane domain comprises a CD166 polypeptide. (Item 59) 59. The CAR of item 58, comprising amino acids 489 to 553 of SEQ ID NO: 3. (Item 60) 60. The CAR of any one of items 44 to 59, wherein the hinge / spacer region comprises a CD8a polypeptide and the transmembrane domain comprises a CD8a polypeptide. (Item 61) 61. The CAR of any one of paragraphs 44 to 60, wherein the hinge / spacer region comprises a CD8b polypeptide and the transmembrane domain comprises a CD8b polypeptide. (Item 62) 55. The CAR of any one of items 44 to 54, wherein the transmembrane domain and the hinge / spacer region are derived from different molecules. (Item 63) 63. The CAR of item 62, wherein the hinge / spacer region comprises a CD28 polypeptide and the transmembrane domain comprises an ICOS polypeptide. (Item 64) 64. The CAR of any one of paragraphs 1 to 63, wherein the intracellular signaling domain further comprises a costimulatory signaling domain. (Item 65) 66. The CAR of paragraph 65, wherein the costimulatory signaling domain comprises a CD28 polypeptide. (Item 66) 66. An immunoresponsive cell comprising the CAR of any one of items 1 to 65. (Item 67) 67. The immunoresponsive cell of claim 66, wherein the CAR is recombinantly expressed. (Item 68) 68. The immunoresponsive cell of item 66 or 67, wherein the CAR is expressed from a vector. (Item 69) 69. The immunoresponsive cell of any one of paragraphs 66 to 68, wherein the CAR is positioned at an endogenous locus of the immunoresponsive cell. (Item 70) 70. The immunoresponsive cell of claim 69, wherein the endogenous locus is the TRAC locus, the TRBC locus, or the TRGC locus. (Item 71) 71. The immunoresponsive cell of paragraph 69 or 70, wherein the endogenous locus is the TRAC locus. (Item 72) 72. The immunoresponsive cell of any one of paragraphs 69 to 71, wherein the configuration of the CAR disrupts or disables endogenous expression of the TCR. (Item 73) 73. The immunoresponsive cell of any one of paragraphs 66 to 72, selected from the group consisting of T cells, natural killer (NK) cells, cytotoxic T lymphocytes (CTLs), regulatory T cells, natural killer T (NKT) cells, myeloid cells, human embryonic stem cells, and pluripotent stem cells capable of differentiating into lymphoid cells. (Item 74) 74. The immunoresponsive cell of any one of paragraphs 66 to 73, wherein the immunoresponsive cell is autologous. (Item 75) 75. The immunoresponsive cell of any one of items 66 to 74, wherein the antigen is a tumor antigen. (Item 76) The tumor antigen is CD19, MUC16, MUC1, CA1X, CEA, CD8, CD7, CD10, CD20, CD22, CD30, CLL1, CD33, CD34, CD38, CD41, CD44, CD49f, CD56, CD74, CD133, CD138, EGP-2, EGP-40, EpCAM, erb-B2, 3, 4, FBP, fetal acetylcholine receptor, folate receptor-a, GD2, GD3, HER-2, hTERT, IL-13R-a2, K-light chain, KDR, LeY, L1 cell adhesion molecule, MAGE-A1, mesothelin, ERBB2, MAGEA3, p53, MART1, GP100, proteinase 76. The immunoresponsive cell of claim 75, wherein the immunoresponsive cell is selected from the group consisting of: 3 (PR1), tyrosinase, survivin, hTERT, EphA2, NKG2D ligand, NY-ES0-1, carcinoembryonic antigen (h5T4), PSCA, PSMA, ROR1, TAG-72, VEGF-R2, WT-1, BCMA, CD123, CD44V6, NKCS1, EGF1R, EGFR-VIII, and CD99, CD70, ADGRE2, CCR1, LILRB2, PRAME, CCR4, CD5, CD3, TRBC1, TRBC2, TIM-3, integrin B7, ICAM-1, CD70, Tim3, CLEC12A, and ERBB. (Item 77) 78. The immunoresponsive cell of item 77, wherein the antigen is CD19. (Item 78) 78. A pharmaceutical composition comprising an effective amount of an immunoresponsive cell according to any one of items 66 to 77 and a pharma- ceutically acceptable excipient. (Item 79) 79. The pharmaceutical composition according to item 78, which is for treating a neoplasm. (Item 80) 80. A method for reducing tumor burden in a subject, comprising administering to the subject an effective amount of an immunoresponsive cell according to any one of items 66 to 77 or a pharmaceutical composition according to item 78 or 79. (Item 81) 1. A method of reducing tumor burden in a subject, comprising administering to the subject an effective amount of an immunoresponsive cell or a pharmaceutical composition comprising same, wherein the immunoresponsive cell is 1. A method comprising a chimeric antigen receptor (CAR) comprising an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3ζ polypeptide, wherein the modified CD3ζ polypeptide comprises one or more ITAM variants comprising one or more loss-of-function mutations, wherein the one or more ITAM variants are each independently selected from the group consisting of an ITAM1 variant, an ITAM2 variant, and an ITAM3 variant. (Item 82) 83. The method of item 81 or 82, which reduces the number of tumor cells. (Item 83) 84. The method of any one of items 81 to 83, wherein the tumor size is reduced. (Item 84) 85. The method of any one of items 81 to 84, wherein the method eradicates a tumor in the subject. (Item 85) A method for treating or preventing a neoplasm, comprising administering to a subject an effective amount of an immunoresponsive cell according to any one of items 66 to 77 or a pharmaceutical composition according to item 78 or 79. (Item 86) 1. A method of treating or preventing a neoplasm, comprising administering to a subject an effective amount of an immunoresponsive cell or a pharmaceutical composition comprising the same, wherein the immunoresponsive cell is 1. A method comprising a chimeric antigen receptor (CAR) comprising an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3ζ polypeptide, wherein the modified CD3ζ polypeptide comprises one or more ITAM variants comprising one or more loss-of-function mutations, wherein the one or more ITAM variants are each independently selected from the group consisting of an ITAM1 variant, an ITAM2 variant, and an ITAM3 variant. (Item 87) 87. The method of any one of items 80 to 86, wherein the neoplasm or tumor is selected from the group consisting of hematological cancer, B-cell leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and ovarian cancer. (Item 88) 88. The method of any one of items 80 to 87, wherein the neoplasm is B-cell leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, or non-Hodgkin's lymphoma, and the CAR binds to CD19. (Item 89) 88. The method of any one of items 80 to 87, wherein the neoplasm is B-cell leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, or non-Hodgkin's lymphoma, and the CAR binds to BCMA, ADGRE2, MSLN, PSMA, or a combination thereof. (Item 90) A method of treating a subject having a recurrence of a neoplasm, wherein the subject has a recurrence of disease, the subject has undergone a treatment that results in residual tumor cells, or the subject has received an immunoresponsive cell that comprises an antigen recognition receptor, the antigen recognition receptor comprising a 4-1BB costimulatory signal, the method comprising administering to the subject an effective amount of the immunoresponsive cell of any one of items 66 to 77 or the pharmaceutical composition of item 78 or 79. (Item 91) 1. A method of treating a subject having a recurrence of a neoplasm, wherein the subject has a recurrence of disease, the subject has undergone a treatment that results in residual tumor cells, or the subject has received an immunoresponsive cell that comprises an antigen recognition receptor, the antigen recognition receptor comprising a 4-1BB costimulatory signal, the method comprising administering to the subject an effective amount of the immunoresponsive cell or a pharmaceutical composition comprising the same, the immunoresponsive cell being 1. A method comprising a chimeric antigen receptor (CAR) comprising an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3ζ polypeptide, wherein the modified CD3ζ polypeptide comprises one or more ITAM variants comprising one or more loss-of-function mutations, wherein the one or more ITAM variants are each independently selected from the group consisting of an ITAM1 variant, an ITAM2 variant, and an ITAM3 variant. (Item 92) 92. The method according to item 90 or 91, wherein the neoplasm is selected from the group consisting of hematological cancer, B-cell leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia and non-Hodgkin's lymphoma. (Item 93) 93. The method of any one of paragraphs 90 to 92, wherein the neoplasm is a B-cell leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, or non-Hodgkin's lymphoma, and the CAR binds to CD19. (Item 94) 94. The method of items 90 to 93, wherein the neoplasm is CD19+ ALL. (Item 95) 95. The method of items 90 to 94, wherein the neoplasm comprises tumor cells having a low density of tumor-specific antigens on the surface of the tumor cells. (Item 96) 80. The immunoresponsive cell of any one of items 66 to 77 or the pharmaceutical composition of item 78 or 79 for use in reducing tumor burden, treating or preventing a neoplasm, and / or treating a subject with recurrence of a neoplasm. (Item 97) 1. A chimeric antigen receptor (CAR) comprising an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3ζ polypeptide, for use in reducing tumor burden, treating or preventing a neoplasm, and / or treating a subject with recurrence of a neoplasm, wherein the modified CD3ζ polypeptide comprises one or more ITAM variants comprising one or more loss-of-function mutations, wherein the one or more ITAM variants are each independently selected from the group consisting of an ITAM1 variant, an ITAM2 variant, and an ITAM3 variant. (Item 98) 66. A method for producing an antigen-specific immunoresponsive cell, comprising introducing into the immunoresponsive cell a nucleic acid sequence encoding a CAR of any one of items 1 to 65. (Item 99) 99. The method of item 98, wherein the nucleic acid sequence is contained in a vector. (Item 100) 100. The method of claim 99, wherein the vector is a retroviral vector. (Item 101) 66. An isolated nucleic acid encoding the CAR of any one of items 1 to 65. (Item 102) 102. The isolated nucleic acid according to item 101, comprising the nucleotide sequence set forth in SEQ ID NO: 45 and SEQ ID NO: 47. (Item 103) 66. A nucleic acid composition comprising the CAR of any one of items 1 to 65. (Item 104) 104. The nucleic acid composition of claim 103, wherein the nucleic acid sequence is contained in a vector. (Item 105) 105. The nucleic acid composition of claim 104, wherein the vector is a retroviral vector. (Item 106) 106. A vector comprising the nucleic acid composition of any one of items 103 to 105. (Item 107) A kit comprising the CAR of any one of items 1 to 65, the immunoresponsive cell of any one of items 66 to 77, the pharmaceutical composition of item 78 or 79, the nucleic acid composition of any one of items 103 to 105, or the vector of item 106. (Item 108) The kit of item 107, further comprising written instructions for treating and / or preventing a neoplasm, a pathogen infection, an autoimmune disorder, or an allogeneic transplant. (Item 109) 66. An immunoresponsive cell comprising: a) a first CAR comprising a first extracellular antigen binding domain that binds a first antigen, a first transmembrane domain, and a first intracellular signaling domain; and b) a second CAR comprising a second extracellular antigen binding domain that binds a second antigen, a second transmembrane domain, and a second intracellular signaling domain, wherein the first CAR is the CAR of any one of items 1 to 65, or the first intracellular signaling domain comprises a modified CD3 zeta polypeptide comprising one or more ITAM variants comprising one or more loss-of-function mutations, wherein the one or more ITAM variants are each independently selected from the group consisting of an ITAM1 variant, an ITAM2 variant, and an ITAM3 variant. (Item 110) The immunoresponsive cell of claim 109, wherein the second CAR is a CAR of any one of claims 1 to 65. (Item 111) 110. The immunoresponsive cell of claim 109, wherein the second intracellular signaling domain of the second CAR comprises a modified CD3 zeta polypeptide comprising one or more ITAM variants comprising one or more loss-of-function mutations, wherein the one or more ITAM variants are each independently selected from the group consisting of an ITAM1 variant, an ITAM2 variant, and an ITAM3 variant. (Item 112) The immunoresponsive cell of claim 109, wherein the second intracellular signaling domain of the second CAR comprises a modified CD3ζ polypeptide that is the same as the modified CD3ζ polypeptide contained in the first intracellular signaling domain of the first CAR. (Item 113) The immunoresponsive cell of claim 109, wherein the second intracellular signaling domain of the second CAR comprises a modified CD3ζ polypeptide that is different from the modified CD3ζ polypeptide contained in the first intracellular signaling domain of the first CAR. (Item 114) The immunoresponsive cell of claim 109, wherein the second intracellular signaling domain of the second CAR comprises a native CD3 zeta polypeptide. (Item 115) 114. The immunoresponsive cell of any one of paragraphs 109 to 113, wherein the first intracellular signaling domain of the first CAR is the same as the second intracellular signaling domain of the second CAR. (Item 116) 115. The immunoresponsive cell of any one of paragraphs 109 to 114, wherein the first intracellular signaling domain of the first CAR is different from the second intracellular signaling domain of the second CAR. (Item 117) 117. The immunoresponsive cell of any one of paragraphs 109 to 116, wherein the first antigen is different from the second antigen. (Item 118) 118. The immunoresponsive cell of any one of items 109 to 117, wherein the first CAR further comprises a first hinge / spacer region. (Item 119) 119. The immunoresponsive cell of any one of items 109 to 118, wherein the second CAR further comprises a second hinge / spacer region. (Item 120) 120. The immunoresponsive cell of any one of paragraphs 109 to 119, wherein the first intracellular signaling domain comprises or has an ITAM2 variant and an ITAM3 variant, and the second intracellular signaling domain comprises or has a deletion of ITAM2 or a portion thereof and a deletion of ITAM3 or a portion thereof. (Item 121) 120. The immunoresponsive cell of any one of paragraphs 109 to 119, wherein the first intracellular signaling domain comprises or has an ITAM2 variant and an ITAM3 variant, and the second intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant. (Item 122) 122. The immunoresponsive cell of any one of paragraphs 109 to 121, further comprising a third CAR comprising a third extracellular antigen-binding domain that binds to a third antigen, a third transmembrane domain, and a third intracellular signaling domain. (Item 123) The immunoresponsive cell of item 122, wherein the first intracellular signaling domain comprises or has an ITAM2 variant and an ITAM3 variant, the second intracellular signaling domain comprises or has an ITAM2 or a deletion of a portion thereof and an ITAM3 or a deletion of a portion thereof, and the third intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant. (Item 124) The immunoresponsive cell of item 122, wherein the first intracellular signaling domain comprises or has a deletion of ITAM2 or a portion thereof and a deletion of ITAM3 or a portion thereof, the second intracellular signaling domain comprises or has a deletion of ITAM2 or a portion thereof and a deletion of ITAM3 or a portion thereof, and the third intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant. (Item 125) 123. The immunoresponsive cell of claim 122, wherein the first intracellular signaling domain comprises or has a deletion of ITAM2 or a portion thereof and a deletion of ITAM3 or a portion thereof, the second intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant, and the third intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant. (Item 126) 123. The immunoresponsive cell of claim 122, wherein the first intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant, the second intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant, and the third intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant. (Item 127) 127. A pharmaceutical composition comprising an effective amount of an immunoresponsive cell according to any one of items 109 to 126 and a pharma- ceutically acceptable excipient. (Item 128) The immunoresponsive cell of any one of items 109 to 126 or the pharmaceutical composition of item 127 for use in reducing tumor burden, treating or preventing a neoplasm, and / or treating a subject with recurrence of a neoplasm. (Item 129) 127. A method for reducing tumor burden in a subject, comprising administering to the subject an effective amount of an immunoresponsive cell according to any one of items 109 to 126 or a pharmaceutical composition according to item 127. (Item 130) 130. The method of claim 129, wherein the method reduces the number of tumor cells, reduces tumor size, and / or eradicates tumors in the subject. (Item 131) A method for treating or preventing a neoplasm, comprising administering to a subject an effective amount of an immunoresponsive cell according to any one of items 109 to 126 or a pharmaceutical composition according to item 127. (Item 132) 132. The method of claim 131, wherein the neoplasm or tumor is selected from the group consisting of hematological cancer, B-cell leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and ovarian cancer. (Item 133) 133. The method of item 131 or 132, wherein the neoplasm is B-cell leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, or non-Hodgkin's lymphoma, and the CAR binds to CD19. (Item 134) 134. The method of any one of items 131 to 133, wherein the neoplasm is B-cell leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, or non-Hodgkin's lymphoma, and the CAR binds to BCMA, ADGRE2, MSLN, PSMA, or a combination thereof. (Item 135) A method of treating a subject having a recurrence of a neoplasm, wherein the subject has a recurrence of disease, the subject has undergone a treatment that results in residual tumor cells, or the subject has received an immunoresponsive cell comprising an antigen recognition receptor, the antigen recognition receptor comprising a 4-1BB costimulatory signal, the method comprising administering to the subject an effective amount of the immunoresponsive cell of any one of items 109 to 126 or the pharmaceutical composition of item 127. (Item 136) 136. The method of claim 135, wherein the neoplasm is selected from the group consisting of hematological cancer, B-cell leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia and non-Hodgkin's lymphoma. (Item 137) 137. The method of item 135 or 136, wherein the neoplasm is B-cell leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, or non-Hodgkin's lymphoma, and the CAR binds to CD19. (Item 138) 138. The method of items 135 to 137, wherein the neoplasm is CD19+ ALL. (Item 139) 139. The method of items 135 to 138, wherein the neoplasm comprises tumor cells having a low density of tumor-specific antigens on the surface of the tumor cells.
[0042] The following detailed description, given by way of example and not intended to limit the subject matter of the present disclosure to the particular embodiments described, may be understood in conjunction with the accompanying drawings, in which: [Brief description of the drawings]
[0043] [Figure 1A] Figure 1 shows the cytoplasmic regions of wild-type, mutant, and truncated 1928ζ (1928z) CARs. A) Cytoplasmic regions of different 1928ζ (1928z) CARs. The ζ chain of the original 1928ζ CAR is mutated to construct 1928ζ CAR T cells with unique ζ signaling domains. The three ITAM motifs in the ζ domain are referred to as ITAM1, ITAM2, and ITAM3 from membrane proximal to distal direction. In 1XX, X2X, XX3, and X23 CARs, two tyrosine residues (Y) in each ITAM are point mutated to two phenylalanine residues (F) for the indicated ITAM. In D12 and D23, deletion mutations are made to remove ITAM1 and ITAM2 (D12) or ITAM2 and ITAM3 (D23). B) Cytoplasmic region of 1928z CAR with improved antitumor efficacy compared to the original 1928z structure. In 1XX, the ζ chain of the original 1928ζ CAR is point mutated in ITAM2 and ITAM3 (conversion of tyrosine (T) to phenylalanine (F)) but retains a stretch of amino acids rich in basic residues (BRS-1, -2, -3). In D12 and D23, ITAM1 and ITAM2 (D12) or ITAM2 and ITAM3 (D23) are deleted; D23 contains one BRS region (BRS-1), whereas D12 has no BRS. C) Representative flow cytometry analysis showing expression levels of CAR and LNGFR for 1928ζ and the indicated 1928ζ mutants. UT: non-transduced T cells were used as control. [Figure 1B] Same as above. [Figure 1C] Same as above.
[0044] [Figure 2A] Figures 2A-2B show the therapeutic efficacy of T cells containing the novel CAR design or the control 1928ζ (1928z) CAR. The therapeutic efficacy of 1928ζ (1928z) CAR T cells is improved by mutations of the CD3ζ chain in the CAR construct. Tumor burden (mean radians) of NALM-6-bearing mice treated with 0.05 x 106 CAR T cells (n = 9-10, data pooled from two independent experiments). A) In vivo response of 1928ζ mutants with unmodified CD3ζ, ITAM3 (XX3), ITAM2 (X2X), or a combination of ITAM2 and ITAM3 (X23) at the original CAR position, and mutations of the remaining ITAM motifs. B) Tumor burden in NALM-6 mice treated with the 1928ζ mutant, consisting of one single non-mutated CD3ζ sequence at the first position (ITAM3 for D12 and ITAM1 for D23) and a deletion of the remaining ζ chain domains. [Figure 2B] Same as above.
[0045] [Figure 3A-B] Figures 3A-3B show survival after treatment with the same dose of 1928ζ (1928z) control or CAR T cells expressing the new CAR construct. Mice bearing Nalm-6 were treated with 5x104 CAR+T cells. A) and B) Kaplan-Meier survival analysis of mice comparing the in vivo efficacy of one dose of 1928z WT and 1928z mutants XX3, X23 and X2X (A) or 1928z mutants D12, D23 and 1XX (B). Pooled data from two independent experiments, representing n=10 mice. Control refers to untreated mice (n=3). *p<0.05 (log-rank Mantel-Cox test).
[0046] [Figure 4]Figure 4 shows the counting of CAR T cells in tumor-bearing mice. NALM-6-bearing mice were treated with 5x104 CAR T cells (n=10 / group, data pooled from two independent experiments) and euthanized 17 days after injection; bone marrow CAR T cells and NALM-6 cells were analyzed and counted by FACS. All data are mean ± SD. *P<0.05, ***P<0.001, ****P<0.0001 (unpaired Student's t-test).
[0047] [Figure 5A-B] Figures 5A-5C show analysis of T cell differentiation. Phenotype of CD4+ and CD8+ CAR T cells in bone marrow of mice 10 days after CAR infusion (data are mean ± SEM, each bar represents n=5 mice). A) Percentage of CD62L / CD45RA expression on CAR T cells for the indicated 1928ζ variants compared to 1928ζ WT. B) Percentage of central memory (CD62L+CD45RA-) and C) effector cells (CD62L-CD45RA+) in CD4+ and CD8+ CAR T cells. Data are compared to 1928ζ WT. **P<0.01, ***P<0.001 (unpaired Student's t-test). [Figure 5C] Same as above.
[0048] [Figure 6] Figure 6 shows the analysis of cell numbers of central memory CD4+ CAR T cells (Tells) (CAR+CD4+CD62L+CD45RA-) and IL7R-expressing CD4+ CAR T cells in the bone marrow of mice 10 and 17 days after T cell administration (data are mean ± SEM, each bar represents n = 5 mice). **P<0.01, ***P<0.001 (unpaired Student's t-test).
[0049] [Figure 7]Figure 7 shows the analysis of T cell exhaustion. Mice bearing NALM-6 were treated with 5x104 CAR T cells (n=9-10 per group; data pooled from two independent experiments) and euthanized 10 days after CAR infusion; CAR T cells in bone marrow were analyzed by FACS. The percentage of CD4+ and CD8+ CAR T cells expressing exhaustion markers was quantified by FACS 10 days after CAR infusion. Data are mean ± SEM, each point represents one mouse. *P<0.05, **P<0.01, ***P<0.001 (unpaired Student's t-test).
[0050] [Figure 8] Figure 8 shows in vitro functional testing of CAR T cell potency. A) Cytotoxic activity determined by 51Cr release assay for 4 hours using EL4-CD19 as target (n=2 independent experiments performed in triplicate, data are mean ± SEM). B) and C) Cytotoxic activity using bioluminescence assay for 18 hours with firefly luciferase (FFL)-expressing NALM-6 as target. Data are mean ± SEM (n=5 independent experiments performed in triplicate). Experiments were performed 1 week after expansion of effector cells in irradiated 3T3-CD19.
[0051] [Figure 9A] Figure 9 shows the in vitro cytokine profile of CAR T cells. Percentage of CD4+ and CD8+ CAR T cells with positive expression of single positive (A) and double positive Th1 cytokines determined by intracellular cytokine staining 18 hours after the second stimulation with 3T3-CD19 (data are means ± SEM, compared to 1928ζ WT, paired Student's t test, n = 3-5 independent experiments). *P<0.05, **P<0.01. [Figure 9B] Same as above.
[0052] [Figure 10-1]Figure 10 shows a schematic diagram of 1XX CARs with different hinge (H) and transmembrane domains (TM). Flow cytometry profiles show CAR and LNGFR expression using goat IgG anti-mouse IgG (F(ab')2) fragment and anti-LNGFR, respectively. 1928z-LNGFR CAR containing CD28 / CD28 H / TM regions is used as a control. [Figure 10-2] Same as above. [Figure 10-3] Same as above.
[0053] [Figure 11] Figure 11 shows cumulative CAR T cell counts with weekly stimulation starting with 106 cells / ml of CAR T cells. Arrows indicate stimulation time points. Data are mean ± SEM. n=3.
[0054] [Figure 12] Figure 12 shows the in vitro cytotoxicity of CAR T cells. The cytotoxic activity of CAR T cells is measured using a 4-hour 51Cr release assay at the end of the third stimulation (D21). T cells and EL-4-CD19+ target cells were used at different effector:target ratios (E:T). Data are mean values ± SEM. Data are representative of four independent experiments.
[0055] [Figure 13] Figure 13 shows the in vivo antitumor efficacy of different H / TM CAR T cells using NOD.Cg PrkdcscidIl2rgtm1Wjl / SzJ (NSG) mice. Top panel, tumor burden is tracked by weekly quantification of bioluminescence signal. CAR constructs are shown for each treatment. Bottom panel, Kaplan-Meier analysis of tumor-free survival of mice from the same experiment. Log-rank (Mantel-Cox) test is used for survival comparison. n=7 mice / group.
[0056] [Figure 14]Figure 14 shows an exemplary deimmunization strategy for the new CAR construct. J1 and J2: no modification from the WT junction. J3: substitution of the last amino acid of CD28, Ser (S), with Lys (K). J: junction; X: point mutation.
[0057] [Figure 15] Figure 15 shows different survival curves of mice treated with CAR T cells. NSG mice were injected into the tail vein with 5x105 FFLuc-GFP NALM6 cells (pre-B ALL cell line) and 4 days later with 2x105 19BBz CAR T cells. 10 days after the first T cell injection (non-effective dose that only slows tumor progression), mice were re-injected with either 19BBz CAR T cells or alternatively 1928z or (5x105 / mouse). Arrows indicate the time of injection of CAR T cells. Upper panel, tumor burden is tracked by weekly quantification of bioluminescence signal. Lower panel, Kaplan-Meier analysis of tumor-free survival of mice from the same experiment. Log-rank (Mantel-Cox) test is used for survival comparison. n=7 mice / group.
[0058] [Figure 16A]Figures 16A-16E show that 1928ζ iTAM differentially regulates CAR T cell potency. A) Cytoplasmic regions of wild-type and mutant 1928ζ CARs. The ζ chain of 1928ζ CAR is mutated in one or two of its three ζ signaling domains, designated ITAM1, ITAM2, and ITAM3, from membrane proximal to membrane distal. In 1XX, X2X, XX3, and X23 CARs, two tyrosines (Y) in each ITAM are point mutated to two phenylalanines (F) for the indicated ITAM. B) Flow cytometry analysis showing expression levels of CAR and LNGFR for constructs shown in A). Data are representative of at least five independent experiments with similar results. Non-transduced T (UT) cells were used as controls. C)-E) Mice bearing Nalm6 were treated with 5x104 CAR+ T cells. C) Tumor burden (mean radians) of mice is shown comparing the in vivo efficacy of wild type 1928ζ, 1XX, X2X, XX3, and X23 (n=10 mice / group, results pooled from two independent experiments). Control refers to untreated mice (n=6). D) CAR T cell counts in mouse bone marrow 17 days after injection (results pooled from two independent experiments, n=10 mice / group). E) Phenotype of CAR T cells in mouse bone marrow 10 days after CAR injection, demonstrated by percentage of TCM and TEFF cells. Representative results of two independent experiments are shown (n=5 mice / group). All data are mean±sem. In D) and E), P values were determined by two-tailed Mann-Whitney U test. [Figure 16B] Same as above. [Figure 16C] Same as above. [Figure 16D] Same as above. [Figure 16E] Same as above.
[0059] [Figure 17A-B]Figures 17A-17E show that iTAM location within the 1928ζ CAR determines antitumor efficacy. A) Cytoplasmic domain of 1928ζ CAR with deletion of CD3ζ chain. At D12, the deletion mutation removes ITAM1 and ITAM2, whereas at D23, ITAM2 and ITAM3 are removed. B) Flow cytometry analysis showing expression levels of CAR and LNGFR for the indicated constructs. Data are representative of at least five independent experiments with similar results. UT, non-transduced T cells were used as control. C)-E) Mice bearing Nalm6 were treated with 5x104 CAR+ T cells. C) Tumor burden (mean radians) of mice treated with wild-type 1928ζ, D12, or D23 (wild-type 1928ζ and D23: n=10; D12: n=9, data pooled from two independent experiments). D) CAR T cell counts in mouse bone marrow 17 days after infusion (results pooled from 2 independent experiments, n=10 mice / group). E) CAR T cell phenotype in mouse bone marrow 10 days after CAR infusion, as demonstrated by the percentage of TCM and TEFF cells (data pooled from 2 independent experiments, n=10 mice / group). All data are mean±sem. In D) and E), P values were determined by two-tailed Mann-Whitney U test. [Figure 17C] Same as above. [Figure 17D] Same as above. [Figure 17E] Same as above.
[0060] [Figure 18A-D]Figures 18A-18H show that TRAC-1XX enhances T cell potency by reducing T cell exhaustion and by generating long-lived memory T cells with effective recall responses. A)-D), Mice bearing Nalm6 were treated with 1x105 or 5x105 TRAC-CAR T cells. A) Kaplan-Meier survival analysis of mice treated with 1x105 TRAC-1XX or TRAC-XX3 compared to TRAC-1928ζ (TRAC-1928ζ and TRAC-XX3: n=5 mice / group; TRAC-1XX: n=7). Control refers to untreated mice (n=3). P values were determined by one-sided log-rank Mantel-Cox test. B) Kaplan-Meier survival analysis of mice treated with 5x105 (n=5 mice / group) or 1x105 (TRAC-1928ζ: n=10 mice, TRAC-1XX: n=5 mice) TRAC-CAR T cells. P values were determined by one-sided log-rank Mantel-Cox test. C) and D) Cell numbers (C) and expression of exhaustion markers PD1+TIM3+LAG3+ on bone marrow CAR T cells (D) were determined for TRAC-1XX and TRAC-XX3 and compared to TRAC-1928ζ. Data are shown as mean ± sem and each symbol refers to an individual mouse (n=5 mice / group). P values were determined by two-sided Mann-Whitney U test. E)-H) Mice bearing Nalm6 were treated with 5x105 TRAC-edited naive T cells and rechallenged with Nalm6 cells (n=5 mice / group) as indicated by the arrow. In the case of controls, no further rechallenge of tumors was performed (TRAC-1928ζ: n=6 mice; TRAC-1XX: n=7 mice). E) Tumor burden (mean radians) of mice comparing the in vivo efficacy of TRAC-1928ζ and TRAC-1XX after tumor rechallenge with no further rechallenge. All data are mean ± sem. Two-tailed unpaired Student's t-test was used for statistical analysis of tumor burden at day 59 after CAR administration (TRAC-1928ζ: n=4; TRAC-1XX: n=5).F) and G) Number of total CAR T cells (F), TCM, TEFF, and IL7R+ CAR T cells (G) in bone marrow of treated mice 63 days after CAR administration (with rechallenge: TRAC-1928ζ: n=4 mice, TRAC-1XX: n=5 mice; without rechallenge: n=5 mice / group). All data are means ± sem; a two-tailed unpaired Student's t-test was used for statistical analysis. H) Expression of exhaustion markers PD1+TIM3+LAG3+ on bone marrow CAR T cells. All data are means ± sem. P values were determined by a two-tailed unpaired Student's t-test. [Fig. 18E-F] Same as above. [Fig. 18G-H] Same as above.
[0061] [Figure 19A-1]Figures 19A-19H show that CD3ζ ITAM mutations in 1928ζ CAR establish a unique transcriptional signature. Gene expression profiles of CD8+ TRAC-1928ζ, TRAC-1XX, and TRAC-XX3 CAR T cells (initially sorted naive T cells) 24 hours after stimulation with CD19+ target cells. A) Normalized enrichment scores of significantly up- or down-regulated gene sets in 1928ζ vs. 1XX and 1928ζ vs. XX3 comparisons (n=3 replicates / group) as determined by GSEA using the MSigDB C7 gene ontology set. For all pathways, false discovery rate (FDR) q≦0.02. GSE datasets are shown in brackets. stim, stimulated. B) Differentially expressed genes (FDRq<0.05) (left) between sorted effector and naïve / memory T cells (n=6 replicates / group) and heatmap demonstrating the expression profile of the same genes for CAR T cells (n=3 replicates / group). TF, transcription factor. C) Normalized enrichment scores (FDRq≦0.03) of gene sets significantly enriched in relation to phenotypic and functional T cell traits comparing TRAC-1928ζ vs. TRAC-XX3, TRAC-1928ζ vs. TRAC-1XX, and TRAC-1XX vs. TRAC-XX3, identified by GSEA analysis (n=3 replicates / group). JAK-STAT, Janus kinase signaling activator of transcription. D) Impact of defined CD3z ITAM mutations in 1928ζ CAR T cells on effector- and memory-related T cell attributes. 1XX CAR T cells display balanced effector and memory traits. [Figure 19A-2] Same as above. [Figure 19B-1] Same as above. [Figure 19B-2] Same as above. [Figure 19C] Same as above. [Figure 19D] Same as above.
[0062] [Figure 20A-C]Figures 20A-20E show the effect of ITAM-mutated 1928ζ CAR on in vitro T cell function, T cell differentiation, and in vivo antitumor activity. A) Cytotoxic activity determined by 4-h 51Cr release assay after 1 week of effector cell expansion on irradiated 3T3-CD19 (data shown as mean values of n=2 independent experiments performed in triplicate). B) Cumulative cell counts of indicated CAR T cells upon weekly stimulation with CD19+ target cells (n=3 independent experiments). All data are mean values ± sem. P values were calculated by two-tailed paired Student's t-test. C) Mice bearing NALM6 were treated with 5x104 CAR+ T cells. Kaplan-Meier survival analysis comparing the in vivo efficacy of wild-type 1928ζ or the indicated 1928ζ mutants (n=10 mice, pooled data from 2 independent experiments). Control (Ctl) refers to untreated mice (n=6). P values were determined by one-sided log-rank Mantel-Cox test. D) CAR T cell phenotype demonstrated by percentage of central memory (CD62L+CD45RA-) and effector memory (CD62L-CD45RA-) CD4+CAR T cells 48 hours after the second stimulation with CD19+ target cells. Two-tailed paired Student's t-test was performed and data represent mean ± sem of n=4 independent experiments. E) Mice bearing NALM6 were treated with 5x104 CAR T cells and euthanized 10 days after infusion; bone marrow CAR T cells were analyzed by FACS. Representative flow cytometry analysis of the indicated CAR T cell phenotypes, gated on CAR+CD4+ T cells and determined by CD62L / CD45RA expression. Representative of 5 mice / group in at least n=2 independent experiments with similar results. [Figure 20D] Same as above. [Figure 20E] Same as above.
[0063] [Figure 21A-B]Figures 21A-21C show the analysis of effector function in 1928ζ mutants compared to wild-type 1928ζ. A) Cytotoxic activity of 1928ζ mutants compared to wild-type 1928ζ using an 18-hour bioluminescence assay with FFL-expressing NALM6 cells as targets. Experiments were performed 1 week after expansion of effector cells on CD19+ target cells. Data are means ± sem (n = 4 independent experiments performed in triplicate). *P < 0.05 (21: P = 0.0273, 2-1: P = 0.0387, 2-2: P = 0.0125), **P = 0.0018, calculated by two-tailed paired Student's t-test for the mean values of triplicates. B) and C) Granzyme B (GrB) expression on CD8+ CAR T cells (n=4 independent experiments) (B) and cytokine secretion of CD4+ and CD8+ CAR T cells upon second stimulation with CD19-expressing target cells (C). All data are mean ± sem (IFNγ and IL2, n=4; TNFα, n=5 independent experiments). Unstimulated wild-type 1928ζ cells were used as control. Significant differences compared to 1928ζ were determined by two-tailed paired Student's t-test. [Figure 21C] Same as above.
[0064] [Figure 22]Figures 22A-22D show the effect of ITAM position in the 1928ζ CAR on T cell function and therapeutic efficacy. A) Cytotoxic activity determined by 4-hour 51Cr release assay 1 week after expansion of effector cells on irradiated 3T3-CD19 (data are the mean of n=2 independent experiments performed in triplicate). B) Cumulative cell counts of the indicated CAR T cells upon weekly stimulation with CD19+ target cells (n=3 independent experiments). All data are means ± sem; P values were calculated by two-tailed paired Student's t-test. C) Cytotoxic activity of D12 and D23 compared to wild-type 1928ζ determined by 18-hour bioluminescence assay with FFL-expressing NALM6 cells as targets. Experiments were performed 1 week after expansion of effector cells on CD19+ target cells. Data are means ± sem (n=4 independent experiments performed in triplicate). P values were calculated by two-tailed paired Student's t-test on the mean of triplicates and showed no significant difference between D12 / D23 and wild-type 1928ζ for all E / T ratios (P>0.05). D) Mice bearing NALM6 were treated with 5x104 CAR T cells. Kaplan-Meier survival analysis of mice treated with wild-type 1928ζ or the indicated 1928ζ mutants (n=10 mice / group). Control refers to untreated mice (n=6). P values were calculated by one-tailed log-rank Mantel-Cox test.
[0065] [Figure 23A] Figures 23A-23B show the effect of iTAM location within the 1928ζ CAR on effector function in vitro. A) Granzyme B (GrB) expression on CD8+ CAR T cells (n=5 independent experiments). B) Cytokine secretion of CD4+ and CD8+ CAR T cells upon second stimulation with CD19-expressing target cells. Unstimulated wild-type 1928ζ cells were used as control. All data are mean ± sem (IFNγ and IL2, n=4; TNFα, n=5 independent experiments). Each individual symbol represents one sample. Significant differences compared to 1928ζ were determined by two-tailed paired Student's t-test. [Figure 23B] Same as above.
[0066] [Fig. 24A-B] Figures 24A-24F show T cell differentiation and effector function of TRAC-encoded 1928 ζ mutants. Mice bearing NALM6 were treated with 1x105 CAR T cells and euthanized 17 days after injection. Bone marrow and spleen CAR T cells were analyzed and counted by FACS. A) Histogram and flow cytometry analysis of CAR expression 4 days after integration of the CAR gene into the TRAC locus. Representative of 4 independent experiments with similar results. B) Cell counts of CD4+ and CD8+ CAR T cells, C) Flow cytometry analysis of percentage of CD8+ TCM (CD62L+CD45RA-) and CD62L / CD45RA expression on bone marrow CD8+ CAR T cells (representative of n=5 mice / group of 1 independent experiment). D) Exemplary flow cytometry analysis of the ratio of CAR+IL7R+ to tumor cells and IL7R+ CAR T cells in mouse bone marrow. E) CAR T cell counts in mouse spleens. In B), C), D) and E), all data are mean ± sem and two-tailed Mann-Whitney analysis was performed. n = 5 mice / group. F) Cytotoxic activity of TRAC-1XX, TRAC-XX3 and wild-type TRAC-1928ζ (18-hour bioluminescence assay with NALM6 expressing FFL as target). Experiments were performed 4 days after transduction and 1 and 3 weeks after expansion with weekly CD19 antigen stimulation. Symbols indicate the mean of triplicates (one representative donor). [Fig. 24C-D] Same as above. [Fig. 24E-F] Same as above.
[0067] [Figure 25A]Figures 25A-25G show in vivo T cell exhaustion of TRAC-1928ζ mutants compared to wild-type TRAC-1928ζ. A) Mice bearing NALM6 were treated with 1x105 CAR T cells and euthanized 17 days after infusion. FACS analysis of exhaustion marker expression on CAR+ T cells, representative of n=5 mice / group in one independent experiment. B)-G) Mice bearing NALM6 were treated with 1x105 TRAC-edited naive T cells. 16 days (B and C) and 36 days (E and G) after CAR administration, bone marrow and spleen TRAC-1928ζ and TRAC-1XX cells were exposed to ex vivo stimulation with NALM6 or PMA / ionomycin (Iono). Cytokine and granzyme B (GrB) / CD107a expression on CAR T cells demonstrated by percentage of expression and flow cytometry analysis, representative of n=3 mice in two independent experiments (B) and n=3 replicates (G). Expression of exhaustion markers PD1+LAG3+ on CAR T cells after 10 h co-culture with NALM6 (D) and cytotoxic activity of TRAC-1XX (day 36) (F). All data are mean ± sem, n=3 mice / group. [Figure 25B] Same as above. [Figure 25C] Same as above. [Fig. 25D-E] Same as above. [Figure 25F] Same as above. [Figure 25G-1] Same as above. [Figure 25G-2] Same as above.
[0068] [Figure 26A-B]Figures 26A-26G show T cell memory formation in TRAC-1XX compared to wild type TRAC-1928ζ. Mice bearing NALM6 were treated with 1x105 or 5x105 TRAC edited naive T cells. A)-C) CARs were isolated from bone marrow and spleen 16 and 36 days after administration of 1x105 TRAC-1928ζ and TRAC-1XX. A)-B) Cell counts of CAR T cells (A), central memory (TCM: CD62L+CD45RA-), effector (TEFF: CD62L-CD45RA+) and IL7R expressing bone marrow CAR T cells (B). All data are mean ± sem. n=3 mice / group. C) Representative flow cytometry analysis of CD62L / CD45RA expression on TRAC-1928ζ and TRAC-1XX bone marrow CAR T cells at day 36 in one independent experiment (n=3 mice / group). D)-G) Mice bearing NALM6 were treated with 5x105 TRAC-edited naive T cells and either rechallenged with NALM6 cells (n=5 mice / group) or no further rechallenge of the tumor was performed (TRAC-1928ζ, n=6 mice; TRAC-1XX, n=7 mice). D)-E) Cell counts of total CAR T cells (D), TCM, TEFF and IL7R+ CAR T cells (E) in the spleens of treated mice 63 days after CAR administration (with rechallenge: TRAC-1928ζ, n=4 mice; TRAC-1XX, n=5 mice. Without rechallenge, n=5 mice / group). All data are means ± sem; two-tailed unpaired Student's t-test was used for statistical analysis. F) FACS analysis of IL7R, CD62L, and CD45RA expression on TRAC-1928ζ and TRAC-1XX CAR T cells 63 days after CAR infusion (representative of at least n=3 mice / group in one independent experiment). G) Expression of exhaustion markers PD1+TIM3+LAG3+ on CAR T cells derived from spleen (with rechallenge: TRAC-1928ζ, n=4 mice; TRAC-1XX: n=5 mice, without rechallenge, n=5 mice / group).All data are means±sem; P values were determined by two-tailed, unpaired Student's t test. [Figure 26C] Same as above. [Fig. 26D-E] Same as above. [Figure 26F-1] Same as above. [Figure 26F-2] Same as above. [Figure 26G] Same as above.
[0069] [Figure 27A] Figures 27A-27C show the transcriptional profiles of TRAC-encoded 1928ζ mutants and sorted control T cells. A) Principal component analysis (PCA) of the whole transcriptional profiles of CD8+ TRAC-1XX, TRAC-XX3 and TRAC-1928ζ (left) and sorted control T cell subsets (right): TN, TSCM and TEFF after stimulation with CD19 target cells. Experiments were performed in technical triplicate for each CAR construct and in six replicates for each control subset. B) Representative GSEA enrichment plots (GSE10239) demonstrate downregulation of memory genes compared to effector-associated genes and naive genes compared to effector-associated genes in 1928ζ vs. 1XX and in 1928ζ vs. XX3 (n=3 mice / group). C) Heatmap of 900 differentially expressed genes in CD8 T cell subsets described by Gattinoni et al. (left) compared to differential gene expression in sorted control T cell subsets (TEFF, TSCM and TN). [Figure 27B] Same as above. [Figure 27C] Same as above.
[0070] [Figure 28A-1]Figures 28A-28D show the impact of CD3ζ ITAM mutations in TRAC-1928ζ on T cell differentiation status and effector profile. A) GSEA of the signature of the top 200 genes upregulated in exhausted CD8 T cells compared to naive or memory CD8 T cells derived from GSE41867 demonstrates enrichment of exhaustion signatures in TRAC-1928ζ vs. TRAC-1XX or TRAC-XX3, and in sorted control TEFF vs. TN and TSCM. Experiments were performed in technical triplicate for each CAR construct, and in six replicates for each control subset. B) Gene ontology analysis (n=3) demonstrating significantly enriched gene sets related to inflammation, cytokine, and chemokine signaling in 1928ζ vs. XX3, 1XX vs. XX3, and 1928ζ vs. 1XX. The CAR gene was integrated into the TRAC locus of naive T cells and transcriptional analysis was performed after stimulation with CD19+ target cells. Results are presented in order of significance as -log10 (corrected P-values). P-values were determined by one-tailed Fisher's exact test and corrected for multiple hypothesis testing using the Benjamini-Hochberg method. C) Heatmap of selected differentially expressed genes between CAR constructs related to inflammation, cytokine, and chemokine activity. D) Flow cytometry analysis of T cell differentiation state in CD8+ CAR T cells after stimulation with CD19 antigen (representative of n=2 independent experiments with similar results). [Figure 28A-2] Same as above. [Figure 28A-3] Same as above. [Figure 28B] Same as above. [Figure 28C] Same as above. [Figure 28D] Same as above.
[0071] [Figure 29A]Figures 29A-29B show the gating strategy for analyzing CAR T cells obtained from bone marrow of treated mice. A)-B) Representative flow cytometry analysis of TRAC-1928ζ (A) compared to TRAC-1XX (B) 17 days after CAR infusion. Gating placement was based on FMO controls. [Figure 29B] Same as above. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0072] The subject matter of the present disclosure provides new CAR designs comprising modified CD3ζ chains, and cells comprising genetically modified immunoresponsive cells (e.g., T cells, NK cells, or CTL cells) comprising said CARs. The subject matter of the present disclosure also provides methods of using such cells to induce and / or enhance immune responses to target antigens, and / or to treat and / or prevent neoplasms or other diseases / disorders in which an increased antigen-specific immune response is desirable. The subject matter of the present disclosure is based, at least in part, on the discovery that immunoresponsive cells comprising the CARs of the present disclosure exhibit improved therapeutic efficacy (e.g., reduced cell attrition) compared to control cells comprising conventional CARs.
[0073] 1.Definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art.The following references provide those skilled in the art with the general definitions of many terms used in the subject matter of this disclosure: Singletonetal., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), SpringerVerlag (1991); and Hale& Marham, The Harper Collins Dictionary of Biology (1991).As used herein, the following terms have the meanings ascribed to them unless otherwise specified.
[0074] As used herein, the term "about" or "approximately" means within an acceptable range of error for a particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., on the limits of the measurement system. For example, "about" may mean within 3 standard deviations or within more than 3 standard deviations, per the practice in the art. Alternatively, "about" may mean within a range of up to 20%, e.g., up to 10%, up to 5%, or up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term may mean within an order of magnitude of a value, e.g., within 5-fold or within 2-fold.
[0075] "Activating an immunoresponsive cell" refers to the induction of signal transduction or protein changes in a cell that results in the initiation of an immune response. For example, when CD3 chains cluster in response to ligand binding and immunoreceptor tyrosine-based inhibitory motifs (ITAMs), a signal transduction cascade is produced. In certain embodiments, when endogenous TCR or exogenous CAR binds to an antigen, the formation of an immunological synapse occurs, which includes the clustering of many molecules near the bound receptor (e.g., CD4 or CD8, CD3γ / δ / ε / ζ, etc.). This clustering of membrane-bound signal transduction molecules causes the ITAM motifs contained within the CD3 chains to become phosphorylated. This phosphorylation then initiates the T cell activation pathway, ultimately activating transcription factors such as NF-κB and AP-1. These transcription factors induce the global gene expression of T cells to increase IL-2 production for the proliferation and expression of master regulatory T cell proteins, initiating a T cell-mediated immune response.
[0076] "Stimulating immune responsive cells" refers to signals that result in a robust and sustained immune response. In various embodiments, this occurs after immune cell (e.g., T cell) activation or is mediated simultaneously through receptors including, but not limited to, CD28, CD137 (4-1BB), OX40, CD40, CD27, CD40 / My88, NKGD2, and ICOS. Receiving multiple stimulatory signals may be important to initiate a robust and long-lasting T cell-mediated immune response. T cells can be rapidly inhibited and become unresponsive to antigens. The effects of these costimulatory signals may vary, but they generally result in increased gene expression to generate long-lived, proliferating, anti-apoptotic T cells that robustly respond to antigens for complete and sustained eradication.
[0077] As used herein, the term "antigen recognition receptor" refers to a receptor that can activate immune or immune responsive cells (e.g., T cells) in response to its binding to an antigen. Non-limiting examples of antigen recognition receptors include natural or endogenous T cell receptors ("TCRs"), and chimeric antigen receptors ("CARs").
[0078] As used herein, the term "antibody" refers not only to intact antibody molecules, but also to fragments of antibody molecules that retain immunogen-binding ability. Such fragments are also well known in the art and are routinely used both in vitro and in vivo. Thus, as used herein, the term "antibody" refers not only to intact immunoglobulin molecules, but also to the well-known active fragments F(ab') 2 F(ab') 2 , and Fab fragments, which lack the Fc fragment of an intact antibody, are cleared more rapidly from the circulation and may have the reduced non-specific tissue binding of intact antibodies (Wahletal., J. Nucl. Med. 24:316-325 (1983)). In certain embodiments, antibodies include whole natural antibodies, bispecific antibodies; chimeric antibodies; Fab, Fab', single chain V region fragments (scFv), fusion polypeptides, and atypical antibodies. In certain embodiments, antibodies are glycoproteins comprising at least two heavy chains (H) and two light chains (L) interconnected by disulfide bonds. Each heavy chain comprises a heavy chain variable region (herein referred to as V H ) and heavy chain constant (C H The heavy chain constant region is composed of three domains, CH1, CH2 and CH3. Each light chain comprises a light chain variable region (herein referred to as V L (abbreviated as "C") and light chain constant C L The light chain constant region consists of one domain, C L It consists of: V H and V L The regions can be further subdivided into regions of hypervariability, called complementarity determining regions (CDRs), interspersed with regions that are more conserved, called framework regions (FRs). Hand V L consists of three CDRs and four FRs arranged in the following order from the amino terminus to the carboxy terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant region of the antibody can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.
[0079] As used herein, "CDR" is defined as the amino acid sequence of the complementarity determining region of an antibody, which is the hypervariable region of immunoglobulin heavy and light chains. See, for example, Kabat et al., Sequences of Proteins of Immunological Interest, 4th U.S. Department of Health and Human Services, National Institutes of Health (1987). Generally, an antibody comprises three heavy chain and three light chain CDRs or CDR regions in variable regions. CDRs provide the majority of contact residues for antibody binding to antigen or epitope. In certain embodiments, CDR regions are described using the Kabat system (Kabat, EA, et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242).
[0080] As used herein, the term "single chain variable fragment" or "scFv" refers to a V H ::V L Covalently linked immunoglobulin heavy chains (V H ) and light chain (V L ) is a fusion protein of the variable region of H and V Lare directly connected or V H The N-terminus of L or V H The C-terminus of L The single chain Fv polypeptide antibodies are linked by a peptide-encoding linker (e.g., 10, 15, 20, 25 amino acids) that connects the N-terminus of the Fv polypeptide to the N-terminus of the Fv polypeptide. The linker is usually glycine-rich for flexibility and serine- or threonine-rich for solubility. Despite the removal of the constant region and the introduction of the linker, the scFv protein retains the specificity of the original immunoglobulin. Single chain Fv polypeptide antibodies can be produced using the VFv polypeptide as described by Huston,et al. (Proc. Nat. Acad. Sci. USA, 85:5879-5883, 1988). H and V L from a nucleic acid containing a sequence encoding See also U.S. Patent Nos. 5,091,513, 5,132,405 and 4,956,778; and U.S. Patent Application Publication Nos. 20050196754 and 20050196754. Antagonist scFvs with inhibitory activity have been described (see, e.g., Zhaoetal., Hyrbidoma (Larchmt) 2008 27(6):455-51; Peter et al., J CachexiaSarcopeniaMuscle 2012 August 12; Shieh et al., J Imunol 2009 183(4):2277-85; Giomarrelli et al., Thromb Haemost 2007 97(6):955-63; Fife et al., J Clin Invst 2006 116(8):2252-61; Brockset al., Immunotechnology 1997 3(3):173-84; Moosmayer et al., Ther Immunol 19952(10:31-40)). Agonistic scFvs have been described (see, e.g., Peter et al., J Bioi Chern 2003 25278(38):36740-7; Xie et al., Nat Biotech199715(8):768-71; Ledbetter et al., Crit Rev Immunol 199717(5-6):427-55; Ho et al., BioChim Biophys Acta 2003 1638(3):257-66).
[0081] As used herein, the term "affinity" refers to a measure of binding strength. Affinity may depend on the closeness of the stereochemical fit between the antibody binding site and the antigenic determinant, the size of the contact area between them, and / or the distribution of charged and hydrophobic groups. As used herein, the term "affinity" also includes "avidity", which refers to the strength of antigen-antibody binding after the formation of a reversible complex. Methods for calculating the affinity of an antibody to an antigen are known in the art and include, but are not limited to, various antigen binding experiments, such as functional assays (e.g., flow cytometry assays).
[0082] The term "chimeric antigen receptor" or "CAR" as used herein refers to a molecule that includes an extracellular antigen-binding domain fused to an intracellular signaling domain that can activate or stimulate an immunoresponsive cell, and a transmembrane domain. In certain embodiments, the extracellular antigen-binding domain of the CAR includes an scFv. The scFv can be derived from fusing the variable heavy and light chain regions of an antibody. Alternatively, or in addition, the scFv can be derived from a Fab' (instead of being derived from an antibody, e.g., obtained from a Fab library). In certain embodiments, the scFv is fused to the transmembrane domain and then to the intracellular signaling domain. In certain embodiments, the CAR is selected to have high binding affinity or avidity for an antigen.
[0083] As used herein, the term "nucleic acid molecule" includes any nucleic acid molecule that encodes a polypeptide of interest or a fragment thereof. Such a nucleic acid molecule need not be 100% homologous or identical to an endogenous nucleic acid sequence, but may exhibit substantial identity. A polynucleotide that has "substantial identity" or "substantial homology" to an endogenous sequence can typically hybridize with at least one strand of a double-stranded nucleic acid molecule. "Hybridize" refers to pairing to form a double-stranded molecule with a complementary polynucleotide sequence (e.g., a gene described herein), or a portion thereof, under various stringency conditions. (See, e.g., Wahl, GM and SL Berger (1987) Methods Enzymol. 152:399; Kimmel, AR (1987) Methods Enzymol. 152:507).
[0084] For example, stringent salt concentrations will usually be less than about 750 mM NaCl and less than 75 mM trisodium citrate, such as less than about 500 mM NaCl and less than 50 mM trisodium citrate, or less than about 250 mM NaCl and less than 25 mM trisodium citrate. Low stringency hybridization is obtained in the absence of organic solvents, such as formamide, while high stringency hybridization is obtained in the presence of at least about 35% formamide, such as at least about 50% formamide. Stringent temperature conditions will usually include a temperature of at least about 30°C, at least about 37°C, or at least about 42°C. Additional parameters that vary, such as hybridization time, concentration of detergent, such as sodium dodecyl sulfate (SDS), and inclusion or exclusion of carrier DNA, are well known to those skilled in the art. By combining these various conditions as necessary, various levels of stringency are achieved. In certain embodiments, hybridization is performed in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS at 30° C. In certain embodiments, hybridization is performed in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35% formamide, and 100 μg / ml denatured salmon sperm DNA (ssDNA) at 37° C. In certain embodiments, hybridization is performed in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50% formamide, and 200 μg / ml ssDNA at 42° C. Useful variations on these conditions will be readily apparent to those of skill in the art.
[0085] For many applications, the washing steps after hybridization will also vary in stringency. Wash stringency conditions can be defined by salt concentration and by temperature. As mentioned above, washing stringency can be increased by decreasing salt concentration or increasing temperature. For example, stringent salt concentrations for the washing step can be less than about 30 mM NaCl and less than 3 mM trisodium citrate, such as less than about 15 mM NaCl and less than 1.5 mM trisodium citrate. Stringent temperature conditions for the washing step will usually include a temperature of at least about 25°C, at least about 42°C, or at least about 68°C. In certain embodiments, the washing step is performed at 25°C in 30 mM NaCl, 3 mM trisodium citrate, and 0.1% SDS. In certain embodiments, the washing step is performed at 42°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. In certain embodiments, the washing steps are performed at 68° C. in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. Additional variations on these conditions will be readily apparent to those of skill in the art. Hybridization techniques are well known to those of skill in the art and are described, for example, in Benton and Davis (Science 196:180, 1977); Grunstein and Rogness (Proc. Natl. Acad. Sci., USA 72:3961, 1975); Ausubel et al. (Current Protocols in Molecular Biology, Wiley Interscience, New York, 2001); Berger and Kimmel (Guide to Molecular Cloning Techniques, 1987, Academic Press, New York); and Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York. is.
[0086] "Substantially identical" or "substantially homologous" refers to a polypeptide or nucleic acid molecule that exhibits at least about 50% homology or identity to a reference amino acid sequence (e.g., any one of the amino acid sequences described herein) or nucleic acid sequence (e.g., any one of the nucleic acid sequences described herein). In certain embodiments, such a sequence is at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or at least about 100% homologous or identical to the amino acid or nucleic acid sequence used for comparison.
[0087] Sequence identity was determined using sequence analysis software (e.g., Sequence Analysis The degree of identity can be measured by using the BLAST, BESTFIT, GAP, or PILEUP / PRETTYBOX programs (Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705). Such software matches identical or similar sequences by assigning degrees of homology to various substitutions, deletions, and / or other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. In an exemplary approach to determining the degree of identity, the BLAST program can be used with a probability score of e-3 to e-100 indicating closely related sequences.
[0088] By "analog" is meant a structurally related polypeptide or nucleic acid molecule that has a function of a reference polypeptide or nucleic acid molecule.
[0089] As used herein, the term "ligand" refers to a molecule that binds to a receptor. In certain embodiments, a ligand binds to a receptor on another cell, allowing for cell-cell recognition and / or interaction.
[0090] As used herein, the term "constitutive expression" or "constitutively expressed" refers to expression or being expressed under all physiological conditions.
[0091] By "disease" is meant any condition, disease or disorder that damages or interferes with the normal function of a cell, tissue, or organ, such as neoplasms and pathogenic infection of cells.
[0092] By "effective amount" is meant an amount sufficient to have a therapeutic effect. In certain embodiments, an "effective amount" is an amount sufficient to stop, ameliorate or inhibit the continued proliferation, growth, or metastasis (e.g., invasion or migration) of a neoplasm.
[0093] "Enforcing tolerance" means preventing the activity of autoreactive or immunoresponsive cells that target the transplanted organ or tissue.
[0094] By "endogenous" is meant a nucleic acid molecule or polypeptide that is normally expressed in a cell or tissue.
[0095] "Exogenous" refers to a nucleic acid molecule or polypeptide that is not endogenously present in a cell. Thus, the term "exogenous" encompasses any recombinant nucleic acid molecule or polypeptide that is expressed in a cell, such as foreign, heterologous, overexpressed nucleic acid molecules and polypeptides. "Exogenous" nucleic acid refers to a nucleic acid that is not present in a natural wild-type cell; for example, an exogenous nucleic acid may differ from its endogenous counterpart by sequence, by position / location, or both. For clarity, an exogenous nucleic acid may have the same or different sequence compared to its natural endogenous counterpart; it may be introduced into the cell itself or its precursor cell by genetic engineering, and may be linked to alternative control sequences, such as non-native promoters or secretion sequences, if necessary.
[0096] By "heterologous nucleic acid molecule or polypeptide" is meant a nucleic acid molecule (e.g., a cDNA, DNA or RNA molecule) or a polypeptide that is not normally present in a cell or a sample obtained from a cell. The nucleic acid may be from another organism, or it may be, for example, an mRNA molecule that is not normally expressed in the cell or sample.
[0097] By "immunoresponsive cell" is meant a cell that functions in an immune response, or a precursor or progeny thereof.
[0098] "Modulate" means to change, either positively or negatively. Exemplary modulations include changes of about 1%, about 2%, about 5%, about 10%, about 25%, about 50%, about 75%, or about 100%.
[0099] By "increase" is meant a positive alteration of at least about 5%. The alteration may be about 5%, about 10%, about 25%, about 30%, about 50%, about 75%, about 100% or higher.
[0100] By "reduce" is meant a negative alteration of at least about 5%. The alteration may be about 5%, about 10%, about 25%, about 30%, about 50%, about 75%, or even about 100%.
[0101] By "isolated cell" is meant a cell that has been separated from molecules and / or cellular components that naturally accompany the cell.
[0102] The terms "isolated," "purified," or "biologically pure" refer to material that is free to an altered extent from components that normally accompany it as found in its native state. "Isolate" indicates a degree of separation from the original source or its surroundings. "Purify" indicates a degree of separation greater than isolation. A "purified" or "biologically pure" protein is sufficiently free of other materials such that impurities do not substantially affect the biological properties of the protein or cause other deleterious consequences. That is, a nucleic acid or peptide is purified if it is substantially free of cellular material, viral material, or culture medium if produced by recombinant DNA techniques, or chemical precursors or other chemicals if chemically synthesized. Purity and homogeneity are typically determined using analytical chemistry techniques, such as polyacrylamide gel electrophoresis or high performance liquid chromatography. The term "purified" may indicate that the nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. For proteins that can be subject to modifications, such as phosphorylation or glycosylation, different modifications may give rise to different isolated proteins that can be purified separately.
[0103] As used herein, the term "antigen-binding domain" refers to a domain capable of specifically binding to a particular antigenic determinant or set of antigenic determinants present on a cell.
[0104] As used herein, "linker" shall mean a functional group (e.g., a chemical or polypeptide) that covalently bonds two or more polypeptides or nucleic acids such that they are connected to one another. As used herein, a "peptide linker" refers to a peptide linker that couples two proteins together (e.g., V H and VL In certain embodiments, the linker comprises the sequence set forth in GGGGSGGGSGGGGGS (SEQ ID NO: 66).
[0105] "Neoplasm" refers to a disease characterized by the pathological proliferation of cells or tissues and their subsequent migration or invasion into other tissues or organs. Neoplastic proliferation is typically uncontrolled, progressive, and occurs under conditions that do not initiate or cause the cessation of normal cell replication. Neoplasms can affect a variety of cell types, tissues, or organs, including, but not limited to, organs selected from the group consisting of bladder, bone, brain, breast, cartilage, glia, esophagus, fallopian tube, gallbladder, heart, intestine, kidney, liver, lung, lymph nodes, nervous tissue, ovaries, pancreas, prostate, skeletal muscle, skin, spinal cord, spleen, stomach, testes, thymus, thyroid, trachea, genitourinary tract, ureter, urethra, uterus, and vagina, or tissues or cell types thereof. Neoplasms include cancers such as sarcomas, carcinomas, or plasmacytomas (malignant tumors of plasma cells).
[0106] By "receptor" is meant a polypeptide, or a portion thereof, present on a cell membrane that selectively binds one or more ligands.
[0107] "Recognize" means selectively binding to a target. T cells that recognize a tumor can express a receptor (e.g., TCR or CAR) that binds to a tumor antigen.
[0108] "Reference" or "control" refers to a standard of comparison. For example, the level of scFv-antigen binding by a cell expressing a CAR and an scFv can be compared to the level of scFv-antigen binding in a corresponding cell expressing only a CAR.
[0109] By "secreted" is meant a polypeptide that is released from the cell by the secretory pathway through the endoplasmic reticulum, the Golgi apparatus, and as vesicles that transiently fuse with the cell plasma membrane, releasing the protein to the exterior of the cell.
[0110] By "signal sequence" or "leader sequence" is meant a peptide sequence (eg, 5, 10, 15, 20, 25 or 30 amino acids) present at the N-terminus of a newly synthesized protein that directs its entry into the secretory pathway. Exemplary leader sequences include, but are not limited to, IL-2 signal sequence: MYRMQLLSCIALSLALVTNS (SEQ ID NO: 67) (human), MYSMQLASCVTLTLVLLVNS (SEQ ID NO: 68) (mouse); kappa leader sequence: METPAQLLFLLLLWLPDTTG (SEQ ID NO: 69) (human), METDTLLLWVLLLWVPGSTG (SEQ ID NO: 70) (mouse); CD8 leader sequence: MALPVTALLLPLALLLHAARP (SEQ ID NO: 71) (human); truncated human CD8 signal peptide: MALPVTALLLPLALLLHA (SEQ ID NO: 72) (human); albumin signal sequence: MKWVTFISLLFSSAYS (SEQ ID NO: 73) (human); and prolactin signal sequence: MDSKGSSQKGSRLLLLLVVSNLLLCQGVVS (SEQ ID NO: 74) (human). In certain embodiments, the leader sequence may be an IgG signal peptide or a GM-CSF signal peptide. By "soluble" is meant a polypeptide that is freely diffusible in an aqueous environment (eg, not membrane bound).
[0111] By "specifically binds" is meant a polypeptide or fragment thereof that recognizes and binds to a biological molecule of interest (e.g., a polypeptide) but does not substantially recognize or bind to other molecules in a sample, e.g., a biological sample that naturally contains the polypeptide of the present disclosure.
[0112] The term "tumor antigen" as used herein refers to an antigen (e.g., a polypeptide) that is uniquely or differentially expressed on tumor cells compared to normal or non-IS neoplastic cells. In certain embodiments, tumor antigens include any polypeptide expressed by tumors that can activate or induce an immune response via CAR (e.g., CD19, MUC-16) or suppress an immune response via receptor-ligand binding (e.g., CD47, PD-L1 / L2, B7.1 / 2).
[0113] The terms "comprises" and "comprising" are intended to have the broad meaning ascribed to them in U.S. patent law and may mean "includes," "including," etc.
[0114] As used herein, "treatment" refers to clinical intervention in an attempt to change the disease course of the individual or cell being treated, and can be performed for prophylaxis or during the course of clinical pathology. The therapeutic effects of treatment include, but are not limited to, prevention of disease onset or recurrence, alleviation of symptoms, reduction of any direct or indirect pathological consequences of the disease, prevention of metastasis, slowing the rate of disease progression, improving or alleviating the disease state, and remission or improved prognosis. By preventing the progression of a disease or disorder, treatment can not only prevent the deterioration caused by the disorder in a subject who has been affected or diagnosed or is suspected of having the disorder, but also can prevent the onset of the disorder or symptoms of the disorder in a subject who is at risk of the disorder or is suspected of having the disorder.
[0115] An "individual" or "subject" herein is a vertebrate, such as a human or non-human animal, e.g., a mammal. Mammals include, but are not limited to, humans, primates, farm animals, sport animals, rodents, and pets. Non-limiting examples of non-human animal subjects include rodents, such as mice, rats, hamsters, and guinea pigs, rabbits, dogs, cats, sheep, pigs, goats, cows, horses, and non-human primates, such as apes and monkeys. The term "immunocompromised" as used herein refers to a subject that is immunocompromised. This subject is highly vulnerable to opportunistic infections, which are infections caused by organisms that do not normally cause disease in people with a healthy immune system, but can affect people with poorly functioning or suppressed immune systems.
[0116] Other aspects of the presently disclosed subject matter are described in the disclosure that follows and are within the scope of the presently disclosed subject matter.
[0117] 2. Chimeric antigen receptor The present disclosure provides chimeric antigen receptors (CARs) that bind to an antigen of interest. The CARs can bind to tumor antigens or pathogen antigens.
[0118] 2.1. Antigen In certain embodiments, the CAR binds to a tumor antigen. Any tumor antigen (antigenic peptide) can be used in the tumor-related embodiments described herein. Sources of antigens include, but are not limited to, cancer proteins. Antigens can be expressed as peptides or as intact proteins or portions thereof. The intact proteins or portions thereof can be natural or mutagenized.Non-limiting examples of tumor antigens include carbonic anhydrase IX (CAIX), carcinoembryonic antigen (CEA), CD8, CD7, CD10, CD19, CD20, CD22, CD30, CD33, CLL1, CD34, CD38, CD41, CD44, CD49f, CD56, CD74, CD133, CD138, CD123, CD44V6, antigens of cells infected with cytomegalovirus (CMV) (e.g., cell surface antigens), epithelial glycoprotein-2 (EGP-2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion. molecule (EpCAM), receptor tyrosine protein kinase erb-B2, 3, 4 (erb-B2, 3, 4), folate binding protein (FBP), fetal acetylcholine receptor (AChR), folate receptor-α, ganglioside G2 (GD2), ganglioside G3 (GD3), human epidermal growth factor receptor 2 (HER-2), human telomerase reverse transcriptase (hTERT), interleukin-13 receptor subunit alpha-2 (IL-13Rα2), kappa light chain, kinase insert domain receptor (KDR), Lewis Y (LeY), L1 cell adhesion molecule (L1CAM), melanoma antigen family A, 1 (MAGE-A1), mucin 16 (MUC16), mucin 1 (MUC1), mesothelin (MSLN), ERBB2, MAGEA3, p53, MART1, GP100, proteinase 3 (PR1), tyrosinase, survivin, hTERT, EphA2, NKG2D ligand, cancer-testis antigen NY-ES0-1, carcinoembryonic antigen (h5T4), prostate stem cell antigen (PSCA), prostate-specific membrane antigen ( These include PSMA), ROR1, tumor-associated glycoprotein 72 (TAG-72), vascular endothelial growth factor R2 (VEGF-R2), and Wilms tumor protein (WT-1), BCMA, NKCS1, EGF1R, EGFR-VIII, CD99, CD70, ADGRE2, CCR1, LILRB2, PRAME, CCR4, CD5, CD3, TRBC1, TRBC2, TIM-3, integrin B7, ICAM-1, CD70, Tim3, CLEC12A, and ERBB.
[0119] In certain embodiments, the CAR binds to a CD19 polypeptide. In certain embodiments, the CAR binds to a human CD19 polypeptide. In certain embodiments, the human CD19 polypeptide comprises the amino acid sequence set forth in SEQ ID NO:75.
[0120] [ka]
[0121] In certain embodiments, the CAR binds to the extracellular domain of the CD19 protein.
[0122] In certain embodiments, the CAR binds to a pathogen antigen for use in treating and / or preventing pathogen or other infectious diseases, for example, in immunocompromised subjects. Non-limiting examples of pathogens include viruses, bacteria, fungi, parasites and protozoa that can cause disease.
[0123] Non-limiting examples of viruses include Retroviridae (e.g., human immunodeficiency viruses, such as HIV-1 (also referred to as HDLV-III, LAVE, or HTLV-III / LAV) or other isolates such as HIV-III and HIV-LP); Picornaviridae (e.g., poliovirus, hepatitis A virus; enteroviruses, human coxsackieviruses, rhinoviruses, echoviruses); Calciviridae (e.g., strains that cause gastroenteritis), Togaviridae (e.g., equine encephalitis virus, rubella virus), Flaviridae (e.g., avian encephalitis virus ... idae (e.g., dengue viruses, encephalitis viruses, yellow fever viruses), Coronoviridae (e.g., coronaviruses), Rhabdoviridae (e.g., vesicular stomatitis viruses, rabies viruses), Filoviridae (e.g., Ebola viruses), Paramyxoviridae (e.g., parainfluenza viruses, mumps viruses, measles viruses, respiratory syncytial viruses), Orthomyxoviridae (e.g., influenza viruses), Bunyaviridae (e.g., Hantaviruses, Bungaviruses, Phleboviruses, and Phleboviruses), Bovirus and Nairavirus), Arenaviridae (hemorrhagic fever viruses) rus), Reoviridae (e.g., reoviruses, orbiviridae) ) and rotaviruses), Birnaviridae, Hepadnaviridae (hepatitis B virus), Parvovirida (parvoviruses), Papovaviridae (papillomaviruses, polyomaviruses), Adenoviridae (most adenoviruses), Herpesviridae (herpes simplex viruses (HSV) 1 and 2, varicella-zoster virus, cytomegalovirus (CMV), herpes viruses), Poxviridae (variola virus, vaccinia virus, poxviruses), and Iridoviridae (e.g., African swine fever virus), as well as unclassified viruses (e.g., the etiologic agent of delta hepatitis (thought to be a defective satellite of hepatitis B virus), etiologic agents of non-A, non-B hepatitis (Class 1 = internally transmitted, Class 2 = parenterally transmitted (i.e., hepatitis C), Norwalk and related viruses, and astroviruses).
[0124] Non-limiting examples of bacteria include Pasteurella, Staphylococci, Streptococcus, Escherichia coli, Pseudomonas species, and Salmonella species. Specific examples of infectious bacteria include, but are not limited to, Helicobacter pyloris, Borelia burgdorferi, Legionella pneumophilia, Mycobacteria sps (e.g., M. tuberculosis, M. avium, M. intracellulare, M. kansaii, M. gordonae), Staphylococcus aureus, Neisseria gonorrhoeae, Neisseria meningitidis, Listeria monocytogenes, Streptococcus pyogenes (Group A streptococci), Streptococcus agalactiae (Group B streptococci), Streptococcus pyogenes (Group B streptococci), Streptococcus pyogenes (Group C streptococci), Streptococcus pyogenes (Group D streptococci), Streptococcus pyogenes (Group E streptococci), Streptococcus pyogenes (Group F ... coccus (viridans group), Streptococcus faecalis, Streptococcus bovis, Streptococcus (anaerobic sps.), Streptococcus pneumoniae, pathogenic Campylobacter sp., Enterococcus sp., Haemophilus influenzae, Bacillus antracis, Corynebacterium diphtheriae, Corynebacterium sp., Erysipelothrix rhusiopathiae, Clostridium perfringers, Clostridium tetani, Enterobacter aerogenes, Klebsiella pneumoniae, Pasturella multocida, Bacteroides sp., Fusobacterium nucleatum, Streptobacillus moniliformis, Treponema pallidium, Treponema pertenue, Leptospira, Rickettsia and Actinomyces israelli.
[0125] In certain embodiments, the pathogen antigen is a viral antigen present in cytomegalovirus (CMV), a viral antigen present in Epstein-Barr virus (EBV), a viral antigen present in human immunodeficiency virus (HIV), or a viral antigen present in influenza virus.
[0126] 2.2. Chimeric antigen receptors (CARs) CAR is an engineered receptor that transfers or confers a specificity of interest to immune effector cells. CAR can be used to transfer the specificity of a monoclonal antibody to T cells, with the transfer of its coding sequence facilitated by a retroviral vector.
[0127] There are three generations of CARs. "First generation" CARs are typically composed of an extracellular antigen binding domain (e.g., scFv) fused to a transmembrane domain fused to a cytoplasmic / intracellular signaling domain. "First generation" CARs provide de novo antigen recognition and bind to CD4 through their CD3 ζ chain signaling domain in a single fusion molecule, independent of HLA-mediated antigen presentation. + and CD8 + The "second generation" CARs can cause both activation of T cells and activation of T cells. The "second generation" CARs add intracellular signaling domains derived from various costimulatory molecules (e.g., CD28, 4-1BB, ICOS, OX40, CD27, CD40 / My88, and NKGD2) to the cytoplasmic tail of the CAR to provide additional signals to T cells. "Second generation" CARs include those that provide both costimulation (e.g., CD28 or 4-1BB) and activation (CD3ζ). "Third generation" CARs include those that provide multiple costimulations (e.g., CD28 and 4-1BB) and activation (CD3ζ). In certain embodiments, the CAR is a second generation CAR. In certain embodiments, the CAR comprises an extracellular antigen binding domain that binds to an antigen, a transmembrane domain, and an intracellular signaling domain, and the intracellular signaling domain comprises a costimulatory signaling domain. In certain embodiments, the CAR further comprises a hinge / spacer region.
[0128] In certain non-limiting embodiments, the extracellular antigen binding domain of the CAR (e.g., embodied as an scFv or analog thereof) is about 2×10 -7 M or less dissociation constant (K d In certain embodiments, K d is about 2 x 10 -7 M or less, approximately 1 x 10 -7 M or less, approx. 9 x 10 -8 M or less, approximately 1 x 10 -8 M or less, approx. 9 x 10 -9 M or less, about 5 x 10 -9 M or less, about 4 x 10 -9M or less, about 3 x 10 -9 M or less, approximately 2 x 10 -9 M or less, or about 1 x 10 -9 In certain non-limiting embodiments, K d is about 3 x 10 -9 M or less. In certain non-limiting embodiments, K d is about 1 x 10 -9 M ~ approx. 3×10 -7 In certain non-limiting embodiments, K d is about 1.5 x 10 -9 M ~ approx. 3×10 -7 In certain non-limiting embodiments, K d is about 1.5 x 10 -9 M ~ approx. 2.7×10 -7 In certain non-limiting embodiments, K d is about 1 x 10 -4 M ~ approx. 1×10 -6 In certain non-limiting embodiments, K d is about 1 x 10 -13 M ~ approx. 1×10 -15 It's M.
[0129] The binding of the extracellular antigen-binding domain (e.g., in scFv or its analog) can be confirmed, for example, by enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), FACS analysis, bioassay (e.g., growth inhibition), or Western blot assay. Each of these assays generally detects the presence of a particular protein-antibody complex of interest by using a labeled reagent (e.g., antibody, or scFv) specific to the complex of interest. For example, scFv can be radiolabeled and used in radioimmunoassay (RIA) (see, for example, Weintraub, B., Principles of Radioimmunoassays, Seventh Training Course on Radioligand Assay Techniques, The Endocrine Society, March, 1986, which is incorporated herein by reference). Radioisotopes can be detected by means such as the use of a gamma counter or scintillation counter, or by autoradiography. In certain embodiments, the extracellular antigen-binding domain of CAR is labeled with a fluorescent marker. Non-limiting examples of fluorescent markers include green fluorescent protein (GFP), blue fluorescent protein (e.g., EBFP, EBFP2, Azurite, and mKalama1), cyan fluorescent protein (e.g., ECFP, Cerulean, and CyPet), and yellow fluorescent protein (e.g., YFP, Citrine, Venus, and YPet).
[0130] 2.2.1. Extracellular antigen-binding domain of CAR In certain embodiments, the extracellular antigen-binding domain specifically binds to an antigen. In certain embodiments, the extracellular antigen-binding domain is an scFv. In certain embodiments, the scFv is a human scFv. In certain embodiments, the scFv is a humanized scFv. In certain embodiments, the scFv is a mouse scFv. In certain embodiments, the extracellular antigen-binding domain is an optionally cross-linked Fab. In certain embodiments, the extracellular antigen-binding domain is an F(ab) 2 In certain embodiments, any of the above molecules may be included in a fusion protein with a heterologous sequence forming an extracellular antigen-binding domain. In certain embodiments, the scFvs are identified by screening an scFv phage library containing antigen-Fc fusion proteins. The scFvs can be derived from mice carrying human VL and / or VH genes. The scFvs can also be replaced with camelid heavy chains (e.g., VHHs from camels, llamas, etc.) or partial natural ligands for cell surface receptors. In certain embodiments, the antigen is a tumor antigen, such as those disclosed herein. In certain embodiments, the antigen is a pathogen antigen, such as those disclosed herein.
[0131] In certain embodiments, the extracellular antigen-binding domain is a mouse scFv. In certain embodiments, the extracellular antigen-binding domain is a mouse scFv that binds to a human CD19 polypeptide. In certain embodiments, the extracellular antigen-binding domain is a mouse scFv that comprises the amino acid sequence of SEQ ID NO: 84 and specifically binds to a human CD19 polypeptide (e.g., a human CD19 polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 75). In certain embodiments, a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 84 is set forth in SEQ ID NO: 85. In certain embodiments, the mouse scFv comprises a heavy chain variable region (V) comprising the amino acid sequence set forth in SEQ ID NO: 82. H In certain embodiments, the murine scFv comprises a light chain variable region (V) comprising the amino acid sequence set forth in SEQ ID NO: 83. LIn certain embodiments, the mouse scFv optionally comprises V H and V L (iii) a linker sequence, e.g., a linker peptide, between V and the amino acid sequence set forth in SEQ ID NO: 82; H and V comprising the amino acid sequence set forth in SEQ ID NO:83 L In certain embodiments, the linker comprises amino acids having a sequence set forth in SEQ ID NO: 66. In certain embodiments, the extracellular antigen-binding domain comprises a V that comprises an amino acid sequence that is at least about 80% (e.g., at least about 85%, at least about 90%, or at least about 95%) homologous to SEQ ID NO: 82. H For example, the extracellular antigen-binding domain comprises a V that comprises an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% homologous to SEQ ID NO:82. H In certain embodiments, the extracellular antigen-binding domain comprises a V H In certain embodiments, the extracellular antigen-binding domain comprises a V that comprises an amino acid sequence that is at least about 80% (e.g., at least about 85%, at least 90%, or at least about 95%) homologous to SEQ ID NO: 83. L For example, the extracellular antigen-binding domain comprises a V that comprises an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% homologous to SEQ ID NO:83. L In certain embodiments, the extracellular antigen-binding domain comprises a V L In certain embodiments, the extracellular antigen-binding domain comprises a V that comprises an amino acid sequence that is at least about 80% (e.g., at least about 85%, at least 90%, or at least about 95%) homologous or identical to SEQ ID NO: 82. Hand V comprising an amino acid sequence that is at least about 80% (e.g., at least about 85%, at least 90%, or at least about 95%) homologous or identical to SEQ ID NO:83. L In certain embodiments, the extracellular antigen-binding domain comprises a V H and V comprising the amino acid sequence set forth in SEQ ID NO:83 L In certain embodiments, the extracellular antigen-binding domain comprises a V H CDR1 or a conservative modification thereof, V comprising the amino acid sequence set forth in SEQ ID NO: 77 H CDR2 or a conservative modification thereof, and V comprising the amino acid sequence set forth in SEQ ID NO: 78 H In certain embodiments, the extracellular antigen-binding domain comprises a V CDR3 or a conservative modification thereof. H CDR1, V comprising the amino acid sequence set forth in SEQ ID NO:77 H CDR2, and V comprising the amino acid sequence set forth in SEQ ID NO:78 H In certain embodiments, the extracellular antigen-binding domain comprises a V CDR3 comprising the amino acid sequence set forth in SEQ ID NO:79. L CDR1 or a conservative modification thereof, V comprising the amino acid sequence set forth in SEQ ID NO: 80 L CDR2 or a conservative modification thereof, and V comprising the amino acid sequence set forth in SEQ ID NO: 81 L In certain embodiments, the extracellular antigen-binding domain comprises a V CDR3 or a conservative modification thereof. L CDR1, V comprising the amino acid sequence set forth in SEQ ID NO:80 L CDR2, and V comprising the amino acid sequence set forth in SEQ ID NO:81 L In certain embodiments, the extracellular antigen-binding domain comprises a V CDR3 comprising the amino acid sequence set forth in SEQ ID NO:76. H CDR1 or a conservative modification thereof, V comprising the amino acid sequence set forth in SEQ ID NO: 77 H CDR2 or a conservative modification thereof, V comprising the amino acid sequence set forth in SEQ ID NO: 78 HCDR3 or conservative modifications thereof, V comprising the amino acid sequence set forth in SEQ ID NO:79 L CDR1 or a conservative modification thereof, V comprising the amino acid sequence set forth in SEQ ID NO: 80 L CDR2 or a conservative modification thereof, and V comprising the amino acid sequence set forth in SEQ ID NO: 81 L In certain embodiments, the extracellular antigen-binding domain comprises a V CDR3 or a conservative modification thereof. H CDR1, V comprising the amino acid sequence set forth in SEQ ID NO:77 H CDR2, V comprising the amino acid sequence set forth in SEQ ID NO:78 H CDR3, V comprising the amino acid sequence set forth in SEQ ID NO:79 L CDR1, V comprising the amino acid sequence set forth in SEQ ID NO:80 L CDR2, and V comprising the amino acid sequence set forth in SEQ ID NO:81 L Includes CDR3. [Table 1]
[0132] As used herein, the term "conservative sequence modification" refers to an amino acid modification that does not significantly affect or alter the binding properties of the CAR of the present disclosure (e.g., the extracellular antigen-binding domain of the CAR) that comprises the amino acid sequence. Conservative modifications may include amino acid substitutions, additions, and deletions. Modifications can be introduced into the human scFv of the CAR of the present disclosure by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Amino acids can be classified into groups according to their physicochemical properties, such as charge and polarity. Conservative amino acid substitutions are those in which an amino acid residue is replaced with an amino acid within the same group. For example, amino acids can be classified by charge: positively charged amino acids include lysine, arginine, histidine, negatively charged amino acids include aspartic acid, glutamic acid, and neutrally charged amino acids include alanine, asparagine, cysteine, glutamine, glycine, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine. Furthermore, amino acids can be classified by polarity: polar amino acids include arginine (basic polar), asparagine, aspartic acid (acidic polar), glutamic acid (acidic polar), glutamine, histidine (basic polar), lysine (basic polar), serine, threonine, and tyrosine; non-polar amino acids include alanine, cysteine, glycine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan, and valine. Thus, one or more amino acids in a CDR region can be replaced with other amino acid residues from the same group, and the altered antibody can be tested for retained function (i.e., the functions described in (c) to (l) above) using the functional assays described herein. In certain embodiments, no more than one, no more than two, no more than three, no more than four, no more than five residues in a particular sequence or CDR region are altered.
[0133] A V that has at least about 80%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% (e.g., about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99%) homology or identity to a particular sequence (e.g., SEQ ID NO:82 and SEQ ID NO:83). H and / or V L The amino acid sequence may contain substitutions (e.g., conservative substitutions), insertions, or deletions compared to the specified sequence, but retain the ability to bind to a target antigen (e.g., CD19). In certain embodiments, a total of 1 to 10 amino acids are substituted, inserted, and / or deleted in the specified sequence (e.g., SEQ ID NO: 82 and SEQ ID NO: 83). In certain embodiments, the substitutions, insertions, or deletions are in regions outside the CDRs of the extracellular antigen-binding domain (e.g., in the FRs). In certain embodiments, the extracellular antigen-binding domain is a V-seq sequence selected from the group consisting of SEQ ID NO: 82 and SEQ ID NO: 83, including post-translational modifications of the sequences (SEQ ID NO: 82 and SEQ ID NO: 83). H and / or V L Contains arrays.
[0134] As used herein, the percentage of homology between two amino acid sequences is equivalent to the percentage of identity between two sequences.The percentage of identity between two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps and the length of each gap that need to be introduced for optimal alignment of the two sequences (i.e., homology%=number of identical positions / total number of positions×100).Comparing sequences and determining the percentage of identity between two sequences can be achieved using mathematical algorithms.
[0135] The percent homology between two amino acid sequences can be determined using the algorithm of E. Meyers and W. Miller (Comput. Appl. Biosci., 4:11-17 (1988)) as incorporated into the ALIGN program (version 2.0) using a PAM120 residue weighting table, a gap length penalty of 12, and a gap penalty of 4. Additionally, the percent homology between two amino acid sequences can be determined using the algorithm of Needleman and Wunsch (J. Mol. Biol. 48:444-453 (1970)) using either a Blossum 62 matrix or a PAM250 matrix, and gap weights of 16, 14, 12, 10, 8, 6, or 4, and length weights of 1, 2, 3, 4, 5, or 6. The decision can be made based on the above.
[0136] Additionally or alternatively, the amino acid sequences of the disclosed subject matter can be further used as "query sequences" to perform searches against public databases, e.g., to identify related sequences. Such searches can be performed using the XBLAST program (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403-10. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to the specific sequences disclosed herein (e.g., the heavy and light chain variable region sequences of scFv m903, m904, m905, m906, and m900). To obtain gapped alignments for comparison, Gapped BLAST can be performed using the methods described in Altschule tal., (1997) Nucleic Acids Res. 25(17):3389-3402. d When utilizing BLAST programs, the default parameters of the respective programs (eg, XBLAST and NBLAST) can be used.
[0137] 2.2.2.Transmembrane domain of CAR In certain non-limiting embodiments, the transmembrane domain of the CAR comprises a hydrophobic alpha helix that spans at least a portion of the membrane. Different transmembrane domains result in different receptor stabilities. After antigen recognition, the receptor clusters and signals are transmitted to the cell. According to the subject matter of the present disclosure, the transmembrane domain of the CAR may comprise a natural or modified transmembrane domain of a CD8 polypeptide, a CD28 polypeptide, a CD3ζ polypeptide, a CD40 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, a CD84 polypeptide, a CD166 polypeptide, a CD8a polypeptide, a CD8b polypeptide, an ICOS polypeptide, an ICAM-1 polypeptide, a CTLA-4 polypeptide, a CD27 polypeptide, a CD40 / My88 peptide, an NKGD2 peptide, a synthetic polypeptide (not based on a protein associated with immune response), or a combination thereof.
[0138] CD8 In certain embodiments, the transmembrane domain comprises a CD8 polypeptide. In certain embodiments, the CD8 polypeptide comprises or has an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to a sequence having NCBI reference number NP_001139345.1 (SEQ ID NO: 86) as provided below (homology herein can be determined using standard software such as BLAST or FASTA) or a fragment thereof, and / or may optionally contain up to one, or up to two, or up to three conservative amino acid substitutions. In certain embodiments, the CD8 polypeptide comprises or has an amino acid sequence that is a contiguous portion of SEQ ID NO: 86 that is at least 20, or at least 30, or at least 40, or at least 50, and up to 235 amino acids in length. Alternatively, or in addition, in various non-limiting embodiments, a CD8 polypeptide comprises or has an amino acid sequence of amino acids 1-235, 1-50, 50-100, 100-150, 150-200, or 200-235 of SEQ ID NO: 86. In certain embodiments, a CAR of the disclosure comprises a transmembrane domain that comprises a CD8 polypeptide that comprises or has an amino acid sequence of amino acids 137-209 of SEQ ID NO:86.
[0139] [ka]
[0140] In certain embodiments, a CD8 polypeptide comprises or has an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to a sequence having NCBI Reference Number: AAA92533.1 (SEQ ID NO: 87) as provided below (homology herein can be determined using standard software such as BLAST or FASTA), or a fragment thereof, and / or may optionally contain up to one, or up to two, or up to three conservative amino acid substitutions. In certain embodiments, a CD8 polypeptide comprises or has an amino acid sequence that is a contiguous portion of SEQ ID NO: 87 that is at least about 20, or at least about 30, or at least about 40, or at least about 50, or at least about 60, or at least about 70, or at least about 100, or at least about 200, and up to 247 amino acids in length. Alternatively, or in addition, in various non-limiting embodiments, a CD8 polypeptide comprises or has an amino acid sequence of amino acids 1-247, 1-50, 50-100, 100-150, 150-200, 151-219, or 200-247 of SEQ ID NO: 87. In certain embodiments, a CAR of the disclosure comprises a transmembrane domain that comprises a CD8 polypeptide that comprises or has an amino acid sequence of amino acids 151-219 of SEQ ID NO:87. [ka]
[0141] In certain embodiments, the CD8 polypeptide comprises or has the amino acid sequence set forth in SEQ ID NO:88, provided below: STTTKPVLRTPSPVHPTGTSQPQRPEDCRPRGSVKGTGLDFACDIYIWAPLAGICVALLLSLIITLICY [sequence number 88]
[0142] In accordance with the subject matter of this disclosure, a "CD8 nucleic acid molecule" refers to a polynucleotide that encodes a CD8 polypeptide.
[0143] In certain embodiments, a CD8 nucleic acid molecule encoding a CD8 polypeptide having the amino acid sequence set forth in SEQ ID NO:88 comprises or has a nucleic acid having the sequence set forth in SEQ ID NO:89, provided below.
[0144] [ka]
[0145] CD28 In certain embodiments, the transmembrane domain of the CAR of the present disclosure comprises a CD28 polypeptide. The CD28 polypeptide may have an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to a sequence having NCBI reference number: P10747 or NP_006130 (SEQ ID NO: 90) or a fragment thereof, and / or may optionally include up to one, or up to two, or up to three conservative amino acid substitutions. In certain non-limiting embodiments, the CD28 polypeptide comprises or has an amino acid sequence that is a contiguous portion of SEQ ID NO: 90 that is at least 20, or at least 30, or at least 40, or at least 50, and up to 220 amino acids in length. Alternatively, or in addition, in various non-limiting embodiments, a CD28 polypeptide comprises or has an amino acid sequence of amino acids 1-220, 1-50, 50-100, 100-150, 114-220, 150-200, or 200-220 of SEQ ID NO: 90. In certain embodiments, a CD28 polypeptide comprised in the transmembrane domain of a CAR of the disclosure comprises or has an amino acid sequence of amino acids 153-179 of SEQ ID NO:90. SEQ ID NO:90 is provided below: [ka]
[0146] In accordance with the subject matter of this disclosure, a "CD28 nucleic acid molecule" refers to a polynucleotide that encodes a CD28 polypeptide. In certain embodiments, a CD28 nucleic acid molecule that encodes a CD28 polypeptide having amino acids 153-179 of SEQ ID NO:90 comprises or has a nucleic acid having the sequence set forth in SEQ ID NO:91, provided below. [ka]
[0147] In certain embodiments, the intracellular signaling domain of the CAR comprises a human CD28 transmembrane domain. The human CD28 transmembrane domain may comprise or have an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to SEQ ID NO: 92 or a fragment thereof, and / or may optionally include up to one, or up to two, or up to three conservative amino acid substitutions. SEQ ID NO: 92 is provided below:
[0148] [ka]
[0149] An exemplary nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO:92 is set forth in SEQ ID NO:93, provided below. [ka]
[0150] CD84 In certain embodiments, the transmembrane domain of the CAR of the present disclosure comprises a native or modified transmembrane domain of a CD84 polypeptide. The CD84 polypeptide may have an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to a sequence having NCBI reference number: NP_001171808.1 (SEQ ID NO: 1) or a fragment thereof, and / or may optionally include up to one, or up to two, or up to three conservative amino acid substitutions. In certain non-limiting embodiments, the CD84 polypeptide comprises or has an amino acid sequence that is a contiguous portion of SEQ ID NO: 1 that is at least 20, or at least 30, or at least 40, or at least 50, and up to 220 amino acids in length. Alternatively, or in addition, in various non-limiting embodiments, a CD84 polypeptide comprises or has an amino acid sequence of amino acids 1-220, 1-50, 50-100, 100-150, 114-220, 150-200, or 200-220 of SEQ ID NO: 1. In certain embodiments, a CD84 polypeptide comprised in the transmembrane domain of a CAR of the disclosure comprises or has an amino acid sequence of amino acids 226-250 of SEQ ID NO: 1. SEQ ID NO:1 is provided below: [ka]
[0151] In accordance with the subject matter of this disclosure, a "CD84 nucleic acid molecule" refers to a polynucleotide that encodes a CD84 polypeptide. In certain embodiments, a CD84 nucleic acid molecule that encodes a CD84 polypeptide having amino acids 226-250 of SEQ ID NO:1 comprises or has a nucleic acid having the sequence set forth in SEQ ID NO:2, provided below. [ka]
[0152] CD166 In certain embodiments, the transmembrane domain of the CAR of the present disclosure comprises a native or modified transmembrane domain of a CD166 polypeptide. The CD166 polypeptide may have an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the sequence having NCBI reference number: NP_001618.2 (SEQ ID NO: 3) or a fragment thereof, and / or may optionally include up to one, or up to two, or up to three conservative amino acid substitutions. In certain non-limiting embodiments, the CD166 polypeptide comprises or has an amino acid sequence that is a contiguous portion of SEQ ID NO: 3 that is at least 20, or at least 30, or at least 40, or at least 50, and up to 220 amino acids in length. Alternatively, or in addition, in various non-limiting embodiments, a CD166 polypeptide comprises or has the amino acid sequence of amino acids 1-220, 1-50, 50-100, 100-150, 114-220, 150-200, or 200-220 of SEQ ID NO: 3. In certain embodiments, a CD166 polypeptide comprised in the transmembrane domain of a CAR of the disclosure comprises or has the amino acid sequence of amino acids 528-553 of SEQ ID NO: 3. In certain embodiments, a CD166 polypeptide comprised in the transmembrane domain of a CAR of the disclosure comprises or has the amino acid sequence of amino acids 528-549 of SEQ ID NO: 3. SEQ ID NO:3 is provided below: [ka]
[0153] According to the subject matter of the present disclosure, a "CD166 nucleic acid molecule" refers to a polynucleotide that encodes a CD166 polypeptide. In certain embodiments, a CD166 nucleic acid molecule that encodes a CD166 polypeptide having amino acids 528-553 of SEQ ID NO:3 comprises or has a nucleic acid having the sequence set forth in SEQ ID NO:4, provided below. [ka]
[0154] CD8a In certain embodiments, the transmembrane domain of the CAR of the present disclosure comprises a native or modified transmembrane domain of a CD8a polypeptide. The CD8a polypeptide may have an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to a sequence having NCBI reference number: NP_001139345.1 (SEQ ID NO: 5) or a fragment thereof, and / or may optionally include up to one, or up to two, or up to three conservative amino acid substitutions. In certain non-limiting embodiments, the CD8a polypeptide comprises or has an amino acid sequence that is a contiguous portion of SEQ ID NO: 5 that is at least 20, or at least 30, or at least 40, or at least 50, and up to 220 amino acids in length. Alternatively, or in addition, in various non-limiting embodiments, a CD8a polypeptide comprises or has the amino acid sequence of amino acids 1-220, 1-50, 50-100, 100-150, 114-220, 150-200, or 200-220 of SEQ ID NO: 5. In certain embodiments, a CD8a polypeptide comprised in the transmembrane domain of a CAR of the disclosure comprises or has the amino acid sequence of amino acids 183-207 of SEQ ID NO:5. SEQ ID NO:5 is provided below: [ka]
[0155] In accordance with the subject matter of the present disclosure, a "CD8a nucleic acid molecule" refers to a polynucleotide that encodes a CD8a polypeptide. In certain embodiments, a CD8a nucleic acid molecule that encodes a CD8a polypeptide having amino acids 183-207 of SEQ ID NO:5 comprises or has a nucleic acid having the sequence set forth in SEQ ID NO:6, provided below. [ka]
[0156] CD8b In certain embodiments, the transmembrane domain of the CAR of the present disclosure comprises a native or modified transmembrane domain of a CD8b polypeptide. The CD8b polypeptide may have an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to a sequence having NCBI reference number: NP_742099.1 (SEQ ID NO: 7) or a fragment thereof, and / or may optionally include up to one, or up to two, or up to three conservative amino acid substitutions. In certain non-limiting embodiments, the CD8b polypeptide comprises or has an amino acid sequence that is a contiguous portion of SEQ ID NO: 7 that is at least 20, or at least 30, or at least 40, or at least 50, and up to 220 amino acids in length. Alternatively, or in addition, in various non-limiting embodiments, a CD8b polypeptide comprises or has the amino acid sequence of amino acids 1-220, 1-50, 50-100, 100-150, 114-220, 150-200, or 200-220 of SEQ ID NO: 7. In certain embodiments, a CD8b polypeptide comprised in the transmembrane domain of a CAR of the disclosure comprises or has the amino acid sequence of amino acids 171-195 of SEQ ID NO:7. SEQ ID NO:7 is provided below: [ka]
[0157] In accordance with the subject matter of the present disclosure, a "CD8b nucleic acid molecule" refers to a polynucleotide that encodes a CD8b polypeptide. In certain embodiments, a CD8b nucleic acid molecule that encodes a CD8b polypeptide having amino acids 171-195 of SEQ ID NO:7 comprises or has a nucleic acid having the sequence set forth in SEQ ID NO:8, provided below. [ka]
[0158] ICOS In certain embodiments, the transmembrane domain of the CAR of the present disclosure comprises a native or modified transmembrane domain of an ICOS polypeptide. The ICOS polypeptide may have an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the sequence having NCBI reference number: NP_036224.1 (SEQ ID NO: 9) or a fragment thereof, and / or may optionally include up to one, or up to two, or up to three conservative amino acid substitutions. In certain non-limiting embodiments, the ICOS polypeptide comprises or has an amino acid sequence that is a continuous portion of SEQ ID NO: 9 that is at least 20, or at least 30, or at least 40, or at least 50, and up to 220 amino acids in length. Alternatively, or in addition, in various non-limiting embodiments, an ICOS polypeptide comprises or has the amino acid sequence of amino acids 1-220, 1-50, 50-100, 100-150, 114-220, 150-200, or 200-220 of SEQ ID NO: 9. In certain embodiments, an ICOS polypeptide comprised in the transmembrane domain of a CAR of the present disclosure comprises or has the amino acid sequence of amino acids 141-165 of SEQ ID NO:9. SEQ ID NO:9 is provided below: [ka]
[0159] In accordance with the subject matter of the present disclosure, an "ICOS nucleic acid molecule" refers to a polynucleotide that encodes an ICOS polypeptide. In certain embodiments, an ICOS nucleic acid molecule that encodes an ICOS polypeptide having amino acids 141-165 of SEQ ID NO:9 comprises or has a nucleic acid having the sequence set forth in SEQ ID NO:10, provided below. [ka]
[0160] CTLA-4 In certain embodiments, the transmembrane domain of the CAR of the present disclosure comprises a native or modified transmembrane domain of a CTLA-4 polypeptide. The CTLA-4 polypeptide may have an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the sequence having NCBI reference number: NP_005205.2 (SEQ ID NO: 11) or a fragment thereof, and / or may optionally include up to one, or up to two, or up to three conservative amino acid substitutions. In certain non-limiting embodiments, the CTLA-4 polypeptide comprises or has an amino acid sequence that is a continuous portion of SEQ ID NO: 11 that is at least 20, or at least 30, or at least 40, or at least 50, and up to 220 amino acids in length. Alternatively, or in addition, in various non-limiting embodiments, a CTLA-4 polypeptide comprises or has the amino acid sequence of amino acids 1-220, 1-50, 50-100, 100-150, 114-220, 150-200, or 200-220 of SEQ ID NO: 11. In certain embodiments, a CTLA-4 polypeptide comprised in the transmembrane domain of a CAR of the present disclosure comprises or has the amino acid sequence of amino acids 162-186 of SEQ ID NO:11. SEQ ID NO:11 is provided below: [ka]
[0161] In accordance with the subject matter of the present disclosure, a "CTLA-4 nucleic acid molecule" refers to a polynucleotide that encodes a CTLA-4 polypeptide. In certain embodiments, a CTLA-4 nucleic acid molecule that encodes a CTLA-4 polypeptide having amino acids 162-186 of SEQ ID NO:11 comprises or has a nucleic acid having the sequence set forth in SEQ ID NO:12, provided below. [ka]
[0162] ICAM-1 In certain embodiments, the transmembrane domain of the CAR of the present disclosure comprises a native or modified transmembrane domain of an ICAM-1 polypeptide. The ICAM-1 polypeptide may have an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the sequence having NCBI reference number: NP_000192.2 (SEQ ID NO: 13) or a fragment thereof, and / or may optionally include up to one, or up to two, or up to three conservative amino acid substitutions. In certain non-limiting embodiments, the ICAM-1 polypeptide comprises or has an amino acid sequence that is a contiguous portion of SEQ ID NO: 13 that is at least 20, or at least 30, or at least 40, or at least 50, and up to 220 amino acids in length. Alternatively, or in addition, in various non-limiting embodiments, an ICAM-1 polypeptide comprises or has the amino acid sequence of amino acids 1-220, 1-50, 50-100, 100-150, 114-220, 150-200, or 200-220 of SEQ ID NO: 13. In certain embodiments, an ICAM-1 polypeptide comprised in the transmembrane domain of a CAR of the present disclosure comprises or has the amino acid sequence of amino acids 481-507 of SEQ ID NO: 13. SEQ ID NO:13 is provided below: [ka]
[0163] In accordance with the subject matter of the present disclosure, an "ICAM-1 nucleic acid molecule" refers to a polynucleotide that encodes an ICAM-1 polypeptide. In certain embodiments, an ICAM-1 nucleic acid molecule that encodes an ICAM-1 polypeptide having amino acids 481-507 of SEQ ID NO: 13 comprises or has a nucleic acid having the sequence set forth in SEQ ID NO: 14, provided below. [ka]
[0164] 2.2.3. Hinge / Spacer Region In certain non-limiting embodiments, the CAR may also include a hinge / spacer region that links the extracellular antigen-binding domain to the transmembrane domain. The hinge / spacer region may be flexible enough to orient the antigen-binding domain in different directions to facilitate antigen recognition. In certain non-limiting embodiments, the hinge / spacer region of the CAR may include a natural or modified hinge region of a CD8 polypeptide, a CD28 polypeptide, a CD3ζ polypeptide, a CD40 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, a CD84 polypeptide, a CD166 polypeptide, a CD8a polypeptide, a CD8b polypeptide, an ICOS polypeptide, an ICAM-1 polypeptide, a CTLA-4 polypeptide, a CD27 polypeptide, a CD40 / My88 peptide, an NKGD2 peptide, a synthetic polypeptide (not based on a protein associated with an immune response), or a combination thereof. The hinge / spacer region may be a hinge region derived from IgG1, or a CH of an immunoglobulin. 2 CH 3The region may be a portion of CD3, a portion of a CD28 polypeptide (e.g., a portion of SEQ ID NO:90), a portion of a CD8 polypeptide (e.g., a portion of SEQ ID NO:86, or a portion of SEQ ID NO:87), a variation of any of the above that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% homologous or identical thereto, or a synthetic spacer sequence.
[0165] CD28 In certain embodiments, the hinge / spacer region of a CAR of the disclosure comprises a native or modified hinge region of a CD28 polypeptide described herein. In certain embodiments, the CD28 polypeptide comprised in the hinge / spacer region of a CAR of the disclosure comprises or has the amino acid sequence of amino acids 114-152 of SEQ ID NO: 90. In certain embodiments, a CD28 nucleic acid molecule encoding a CD28 polypeptide having amino acids 114-152 of SEQ ID NO: 90 comprises or has a nucleic acid having the sequence set forth in SEQ ID NO: 15, provided below. IEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKP [SEQ ID NO: 15]
[0166] CD84 In certain embodiments, the hinge / spacer region of a CAR of the disclosure comprises a native or modified hinge region of a CD84 polypeptide described herein. In certain embodiments, a CD84 polypeptide comprised in a hinge / spacer region of a CAR of the disclosure comprises or has an amino acid sequence of amino acids 187-225 of SEQ ID NO: 1. In certain embodiments, a CD84 nucleic acid molecule encoding a CD84 polypeptide having amino acids 187-225 of SEQ ID NO: 1 comprises or has a nucleic acid having the sequence set forth in SEQ ID NO: 16, provided below. [ka]
[0167] CD166 In certain embodiments, the hinge / spacer region of a CAR of the disclosure comprises a native or modified hinge region of a CD166 polypeptide described herein. In certain embodiments, the CD166 polypeptide comprised in the hinge / spacer region of a CAR of the disclosure comprises or has amino acids 489-527 of SEQ ID NO: 3. In certain embodiments, a CD166 nucleic acid molecule encoding a CD166 polypeptide having amino acids 489-527 of SEQ ID NO: 3 comprises or has a nucleic acid having the sequence set forth in SEQ ID NO: 17, provided below. [ka]
[0168] In certain embodiments, a CD166 polypeptide comprised in a hinge / spacer region of a CAR of the disclosure comprises or has amino acids 484-527 of SEQ ID NO: 3. In certain embodiments, a CD166 polypeptide comprised in a hinge / spacer region of a CAR of the disclosure comprises or has amino acids 506-527 of SEQ ID NO: 3. In certain embodiments, a CD166 polypeptide comprised in a hinge / spacer region of a CAR of the disclosure comprises or has amino acids 517-527 of SEQ ID NO: 3. In certain embodiments, a CD166 polypeptide comprised in a hinge / spacer region of a CAR of the disclosure comprises or has the amino acid sequence set forth in SEQ ID NO: 109 or SEQ ID NO: 110. [ka]
[0169] In certain embodiments, the CD166 polypeptide contained in the hinge / spacer region and transmembrane domain of a CAR of the disclosure comprises or has the amino acid sequence set forth in SEQ ID NO: 111, 112, 113, 114, 115, 116, or 117. [ka]
[0170] CD8a In certain embodiments, the hinge / spacer region of a CAR of the disclosure comprises a native or modified hinge region of a CD8a polypeptide described herein. In certain embodiments, a CD8a polypeptide comprised in a hinge / spacer region of a CAR of the disclosure comprises or has amino acids 137-182 of SEQ ID NO:5. In certain embodiments, a CD8a nucleic acid molecule encoding a CD8a polypeptide having amino acids 137-182 of SEQ ID NO:5 comprises or has a nucleic acid having the sequence set forth in SEQ ID NO:18, provided below. [ka]
[0171] CD8b In certain embodiments, the hinge / spacer region of a CAR of the disclosure comprises a native or modified hinge region of a CD8b polypeptide described herein. In certain embodiments, a CD8b polypeptide comprised in a hinge / spacer region of a CAR of the disclosure comprises or has amino acids 132-170 of SEQ ID NO: 7. In certain embodiments, a CD8b nucleic acid molecule encoding a CD8b polypeptide having amino acids 132-170 of SEQ ID NO: 7 comprises or has a nucleic acid having a sequence set forth in SEQ ID NO: 19, provided below. [ka]
[0172] ICOS In certain embodiments, the hinge / spacer region of a CAR of the disclosure comprises a native or modified hinge region of an ICOS polypeptide described herein. In certain embodiments, the ICOS polypeptide comprised in the hinge / spacer region of a CAR of the disclosure comprises or has amino acids 102-140 of SEQ ID NO: 9. In certain embodiments, an ICOS nucleic acid molecule encoding an ICOS polypeptide having amino acids 102-140 of SEQ ID NO: 9 comprises or has a nucleic acid having a sequence set forth in SEQ ID NO: 20, provided below. [ka]
[0173] CTLA-4 In certain embodiments, the hinge / spacer region of a CAR of the disclosure comprises a native or modified hinge region of a CTLA-4 polypeptide described herein. In certain embodiments, the CTLA-4 polypeptide comprised in the hinge / spacer region of a CAR of the disclosure comprises or has amino acids 123-161 of SEQ ID NO: 11. In certain embodiments, a CTLA-4 nucleic acid molecule encoding a CTLA-4 polypeptide having amino acids 123-161 of SEQ ID NO: 11 comprises or has a nucleic acid having the sequence set forth in SEQ ID NO: 21, provided below. [ka]
[0174] ICAM-1 In certain embodiments, the hinge / spacer region of a CAR of the disclosure comprises a native or modified hinge region of an ICAM-1 polypeptide described herein. In certain embodiments, the ICAM-1 polypeptide comprised in the hinge / spacer region of a CAR of the disclosure comprises or has amino acids 442-480 of SEQ ID NO: 13. In certain embodiments, an ICAM-1 nucleic acid molecule encoding an ICAM-1 polypeptide having amino acids 442-480 of SEQ ID NO: 13 comprises or has a nucleic acid having the sequence set forth in SEQ ID NO: 22, provided below. [ka]
[0175] In certain embodiments, the CAR of the present disclosure comprises a hinge / spacer region. In certain embodiments, the hinge / spacer region is disposed between the extracellular antigen binding domain and the transmembrane domain. In certain embodiments, the hinge / spacer region comprises a CD8 polypeptide, a CD28 polypeptide, a CD3ζ polypeptide, a CD4 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, a CD166 polypeptide, a CD8a polypeptide, a CD8b polypeptide, an ICOS polypeptide, an ICAM-1 polypeptide, a CTLA-4 polypeptide, a CD27 polypeptide, a CD40 / My88 peptide, an NKGD2 peptide, a synthetic polypeptide (not based on a protein associated with immune response), or a combination thereof. In certain embodiments, the transmembrane domain comprises a CD8 polypeptide, a CD28 polypeptide, a CD3zeta polypeptide, a CD4 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, a CD166 polypeptide, a CD8a polypeptide, a CD8b polypeptide, an ICOS polypeptide, an ICAM-1 polypeptide, a CTLA-4 polypeptide, a CD27 polypeptide, a CD40 / My88 peptide, an NKGD2 peptide, a synthetic polypeptide (not based on a protein associated with an immune response), or a combination thereof.
[0176] In certain embodiments, the transmembrane domain and the hinge / spacer region are derived from the same molecule. In certain embodiments, the transmembrane domain and the hinge / spacer region are derived from different molecules. In certain embodiments, the hinge / spacer region of the CAR comprises a CD28 polypeptide, and the transmembrane domain of the CAR comprises a CD28 polypeptide. In certain embodiments, the hinge / spacer region of the CAR comprises a CD28 polypeptide, and the transmembrane domain of the CAR comprises a CD28 polypeptide. In certain embodiments, the hinge / spacer region of the CAR comprises a CD84 polypeptide, and the transmembrane domain of the CAR comprises a CD84 polypeptide. In certain embodiments, the hinge / spacer region of the CAR comprises a CD166 polypeptide, and the transmembrane domain of the CAR comprises a CD166 polypeptide. In certain embodiments, the hinge / spacer region of the CAR comprises a CD8a polypeptide, and the transmembrane domain of the CAR comprises a CD8a polypeptide. In certain embodiments, the hinge / spacer region of the CAR comprises a CD8b polypeptide, and the transmembrane domain of the CAR comprises a CD8b polypeptide. In certain embodiments, the hinge / spacer region of the CAR comprises a CD28 polypeptide and the transmembrane domain of the CAR comprises an ICOS polypeptide.
[0177] 2.2.4. CAR Intracellular Signaling Domain In certain non-limiting embodiments, the intracellular signaling domain of the CAR comprises a CD3ζ polypeptide that can activate or stimulate a cell (e.g., a cell of the lymphoid system, e.g., a T cell). Wild-type ("natural") CD3ζ comprises three immunoreceptor tyrosine-based activation motifs ("ITAMs") (e.g., ITAM1, ITAM2 and ITAM3), three basic residue-rich extension (BRS) regions (BRS1, BRS2 and BRS3), and transmits an activation signal to a cell (e.g., a cell of the lymphoid system, e.g., a T cell) after antigen binding. The intracellular signaling domain of the native CD3ζ chain is the main transmitter of signals from endogenous TCR. As used in the embodiments herein, CD3ζ is not a native CD3ζ but a modified CD3ζ. In certain embodiments, the modified CD3 zeta polypeptide comprises or has an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homologous or identical to a sequence having NCBI reference number: NP_932170 (SEQ ID NO: 94) or a fragment thereof. In certain non-limiting embodiments, the modified CD3 zeta polypeptide comprises or has an amino acid sequence that is a contiguous portion of SEQ ID NO: 94 that is at least 20, or at least 30, or at least 40, or at least 50, or at least 100, or at least 110, or at least 113, and up to 163 amino acids in length. Alternatively, or in addition, in various non-limiting embodiments, the modified CD3 ζ polypeptide comprises or has the amino acid sequence of amino acids 1-50, 50-100, 100-150, 50-164, 55-164, or 150-164 of SEQ ID NO: 94. In certain embodiments, the modified CD3 ζ polypeptide comprises or has the amino acid sequence of amino acids 52-164 of SEQ ID NO:94. SEQ ID NO:94 is provided below: [ka]
[0178] In certain embodiments, the intracellular signaling domain of the CAR comprises a modified human CD3 zeta polypeptide. The modified human CD3 zeta polypeptide may comprise or have an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homologous or identical to SEQ ID NO: 95 or a fragment thereof, and / or may optionally include up to one, or up to two, or up to three conservative amino acid substitutions. SEQ ID NO: 95 is provided below: [ka]
[0179] An exemplary nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO:95 is set forth in SEQ ID NO:96, provided below.
[0180] [ka]
[0181] Immunoreceptor tyrosine-based activation motifs (ITAMs) In certain non-limiting embodiments, the intracellular signaling domain of the CAR comprises a modified CD3ζ polypeptide comprising one, two or three ITAMs. In certain embodiments, the modified CD3ζ polypeptide comprises a native ITAM1 comprising the amino acid sequence set forth in SEQ ID NO:23. QNQLYNELNLGRREEYDVLDKR [SEQ ID NO: 23]
[0182] An exemplary nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO:23 is set forth in SEQ ID NO:24, provided below. [ka]
[0183] In certain embodiments, the modified CD3ζ polypeptide comprises an ITAM1 variant comprising one or more loss-of-function mutations. In certain embodiments, the modified CD3ζ polypeptide has an ITAM1 variant comprising two loss-of-function mutations. In certain embodiments, the loss-of-function mutation comprises a mutation of a tyrosine residue in ITAM1. In certain embodiments, the ITAM1 variant comprising two loss-of-function mutations comprises the amino acid sequence set forth in SEQ ID NO: 25 provided below. QNQLFNELNLGRREEFDVLDKR [SEQ ID NO: 25]
[0184] An exemplary nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO:25 is set forth in SEQ ID NO:26, provided below. [ka]
[0185] In certain embodiments, the modified CD3ζ polypeptide comprises a native ITAM2 comprising the amino acid sequence set forth in SEQ ID NO:27, provided below. QEGLYNELQKDKMAEAYSEIGMK [SEQ ID NO: 27]
[0186] An exemplary nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO:27 is set forth in SEQ ID NO:28, provided below. [ka]
[0187] In certain embodiments, the modified CD3ζ polypeptide comprises an ITAM2 variant comprising one or more loss-of-function mutations. In certain embodiments, the modified CD3ζ polypeptide has an ITAM2 variant comprising two loss-of-function mutations. In certain embodiments, the loss-of-function mutation comprises a mutation of a tyrosine residue in ITAM2. In certain embodiments, the ITAM2 variant comprising two loss-of-function mutations comprises the amino acid sequence set forth in SEQ ID NO: 29 provided below. QEGLFNELQKDKMAEAFSEIGMK [SEQ ID NO: 29]
[0188] An exemplary nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO:29 is set forth in SEQ ID NO:30, provided below. [ka]
[0189] In certain embodiments, the modified CD3ζ polypeptide comprises a native ITAM3 comprising the amino acid sequence set forth in SEQ ID NO:31, provided below. HDGLYQGLSTATKDTYDALHMQ [SEQ ID NO: 31]
[0190] An exemplary nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO:131 is set forth in SEQ ID NO:32, provided below. cacgatggcctttaccagggtctcagtacagccaccaaggacacctacgacgcccttcacatgcag [SEQ ID NO: 32]
[0191] In certain embodiments, the modified CD3ζ polypeptide comprises an ITAM3 variant comprising one or more loss-of-function mutations. In certain embodiments, the modified CD3ζ polypeptide has an ITAM3 variant comprising two loss-of-function mutations. In certain embodiments, the loss-of-function mutation comprises a mutation of a tyrosine residue in ITAM3. In certain embodiments, the ITAM3 variant comprising two loss-of-function mutations comprises the amino acid sequence set forth in SEQ ID NO: 33 provided below. HDGLFQGLSTATKDTFDALHMQ [SEQ ID NO: 33]
[0192] An exemplary nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO:33 is set forth in SEQ ID NO:34, provided below. [ka]
[0193] In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3ζ polypeptide that comprises, consists essentially of, or consists of an ITAM1 variant comprising one or more loss-of-function mutations, an ITAM2 variant comprising one or more loss-of-function mutations, an ITAM3 variant comprising one or more loss-of-function mutations, or a combination thereof. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3ζ polypeptide that comprises an ITAM2 variant comprising one or more (e.g., two) loss-of-function mutations and an ITAM3 variant comprising one or more (e.g., two) loss-of-function mutations. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3ζ polypeptide that comprises a native ITAM1, an ITAM2 variant comprising two loss-of-function mutations, and an ITAM3 variant comprising two loss-of-function mutations. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3ζ polypeptide comprising a native ITAM1 having the amino acid sequence set forth in SEQ ID NO: 23, an ITAM2 variant having the amino acid sequence set forth in SEQ ID NO: 29, and an ITAM3 variant having the amino acid sequence set forth in SEQ ID NO: 33 (e.g., a construct designated "1XX").
[0194] In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3ζ polypeptide comprising an ITAM1 variant comprising one or more (e.g., two) loss-of-function mutations and an ITAM3 variant comprising one or more (e.g., two) loss-of-function mutations. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3ζ polypeptide comprising an ITAM1 variant comprising two loss-of-function mutations, a native ITAM2, and an ITAM3 variant comprising two loss-of-function mutations. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3ζ polypeptide comprising an ITAM1 variant having the amino acid sequence set forth in SEQ ID NO:25, a native ITAM2 having the amino acid sequence set forth in SEQ ID NO:27, and an ITAM3 variant having the amino acid sequence set forth in SEQ ID NO:33 (e.g., a construct designated "X2X").
[0195] In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3ζ polypeptide comprising an ITAM1 variant comprising one or more (e.g., two) loss-of-function mutations and an ITAM2 variant comprising one or more (e.g., two) loss-of-function mutations. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3ζ polypeptide comprising an ITAM1 variant comprising two loss-of-function mutations, an ITAM2 variant comprising two loss-of-function mutations, and a native ITAM3. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3ζ polypeptide comprising an ITAM1 variant having the amino acid sequence set forth in SEQ ID NO:25, an ITAM2 variant having the amino acid sequence set forth in SEQ ID NO:29, and a native ITAM3 having the amino acid sequence set forth in SEQ ID NO:31 (e.g., a construct designated "XX3").
[0196] In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3ζ polypeptide comprising an ITAM1 variant comprising one or more (e.g., two) loss-of-function mutations. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3ζ polypeptide comprising an ITAM1 variant comprising two loss-of-function mutations, a native ITAM2, and a native ITAM3. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3ζ polypeptide comprising an ITAM1 variant having the amino acid sequence set forth in SEQ ID NO:27, a native ITAM2 having the amino acid sequence set forth in SEQ ID NO:29, and a native ITAM3 having the amino acid sequence set forth in SEQ ID NO:31 (e.g., a construct designated "X23").
[0197] In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3ζ polypeptide comprising a native ITAM1, a native ITAM2, and an ITAM3 variant comprising one or more (e.g., two) loss-of-function mutations. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3ζ polypeptide comprising a native ITAM1, a native ITAM2, and an ITAM1 variant comprising two loss-of-function mutations. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3ζ polypeptide comprising a native ITAM1 having the amino acid sequence set forth in SEQ ID NO:23, a native ITAM2 having the amino acid sequence set forth in SEQ ID NO:27, and an ITAM3 variant having the amino acid sequence set forth in SEQ ID NO:33 (e.g., a construct designated "12X").
[0198] In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3ζ polypeptide comprising a native ITAM1, an ITAM2 variant comprising one or more (e.g., two) loss-of-function mutations, and a native ITAM3. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3ζ polypeptide comprising a native ITAM1, an ITAM2 variant comprising two loss-of-function mutations, and a native ITAM3. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3ζ polypeptide comprising a native ITAM1 having the amino acid sequence set forth in SEQ ID NO:23, an ITAM2 variant having the amino acid sequence set forth in SEQ ID NO:29, and a native ITAM3 variant having the amino acid sequence set forth in SEQ ID NO:31 (e.g., a construct designated "1X3").
[0199] In certain embodiments, the intracellular signaling domain of CAR comprises a modified CD3ζ polypeptide comprising one or two ITAM deletions. In certain embodiments, the modified CD3ζ polypeptide comprises deletions of ITAM1 and ITAM2, for example, the modified CD3ζ polypeptide comprises a native ITAM3 or an ITAM3 variant, and does not comprise ITAM1 or ITAM2. In certain embodiments, the modified CD3ζ polypeptide comprises a native ITAM3 having the amino acid sequence set forth in SEQ ID NO:31, and does not comprise ITAM1 (native or modified) or ITAM2 (native or modified) (e.g., D12).
[0200] In certain embodiments, the modified CD3ζ polypeptide comprises a deletion of ITAM2 and ITAM3, for example, the modified CD3ζ polypeptide comprises a native ITAM1 or ITAM1 variant, and does not comprise ITAM2 or ITAM3. In certain embodiments, the modified CD3ζ polypeptide comprises a native ITAM1 having the amino acid sequence set forth in SEQ ID NO:23, and does not comprise ITAM2 (native or modified) or ITAM3 (native or modified) (e.g., D23).
[0201] In certain embodiments, the modified CD3ζ polypeptide comprises a deletion of ITAM1 and ITAM3, for example, the modified CD3ζ polypeptide comprises a native ITAM2 or ITAM2 variant, and does not comprise ITAM1 or ITAM3. In certain embodiments, the modified CD3ζ polypeptide comprises a native ITAM2 having the amino acid sequence set forth in SEQ ID NO:27, and does not comprise ITAM1 (native or modified) or ITAM3 (native or modified) (e.g., D13).
[0202] In certain embodiments, the modified CD3ζ polypeptide comprises a deletion of ITAM1, for example, the modified CD3ζ polypeptide comprises a native ITAM2 or ITAM2 variant, and a native ITAM3 or ITAM3 variant, and does not comprise ITAM1 (native or modified).
[0203] In certain embodiments, the modified CD3ζ polypeptide comprises a deletion of ITAM2, for example, the modified CD3ζ polypeptide comprises a native ITAM1 or ITAM1 variant, and a native ITAM3 or ITAM3 variant, and does not comprise ITAM2 (native or modified).
[0204] In certain embodiments, the modified CD3ζ polypeptide comprises a deletion of ITAM3, for example, the modified CD3ζ polypeptide comprises a native ITAM1 or ITAM1 variant, and a native ITAM2 or ITAM2 variant, and does not comprise ITAM3 (native or modified).
[0205] Basic residue-rich stretch (BRS) region In certain non-limiting embodiments, the intracellular signaling domain of the CAR comprises a modified CD3ζ polypeptide comprising one, two or three BRS regions (i.e., BRS1, BRS2, and BRS3). The BRS regions may be native BRS or modified BRS (e.g., BRS variants). In certain embodiments, the modified CD3ζ polypeptide comprises native BRS1 comprising the amino acid sequence set forth in SEQ ID NO: 35 provided below. KRRGR [SEQ ID NO: 35]
[0206] An exemplary nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO:35 is set forth in SEQ ID NO:36, provided below. aagagacgtggccgg [SEQ ID NO: 36]
[0207] In certain embodiments, the modified CD3ζ polypeptide comprises a BRS1 variant that comprises one or more loss-of-function mutations.
[0208] In certain embodiments, the modified CD3ζ polypeptide comprises a native BRS2 comprising the amino acid sequence set forth in SEQ ID NO:37. KPRRK [SEQ ID NO: 37]
[0209] An exemplary nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO:37 is set forth in SEQ ID NO:38, provided below. aagccgagaaggaag [SEQ ID NO: 38]
[0210] In certain embodiments, the modified CD3 zeta polypeptide comprises a BRS2 variant that includes one or more loss-of-function mutations.
[0211] In certain embodiments, the modified CD3ζ polypeptide comprises a native BRS3 comprising the amino acid sequence set forth in SEQ ID NO:39. KGERRRGK [SEQ ID NO: 39]
[0212] An exemplary nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO:39 is set forth in SEQ ID NO:40, provided below. aaaggcgagcgccggaggggcaag [SEQ ID NO: 40]
[0213] In certain embodiments, the modified CD3 zeta polypeptide comprises a BRS3 variant that includes one or more loss-of-function mutations.
[0214] In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3ζ polypeptide comprising all three BRS regions, i.e., the BRS1 region, the BRS2 region, and the BRS3 region. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3ζ polypeptide comprising native BRS1, native BRS2, and native BRS3. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3ζ polypeptide comprising native BRS1 having the amino acid sequence set forth in SEQ ID NO: 35, native BRS2 having the amino acid sequence set forth in SEQ ID NO: 37, and native BRS3 having the amino acid sequence set forth in SEQ ID NO: 39, for example, a modified CD3ζ polypeptide contained in construct 1XX.
[0215] In certain embodiments, the intracellular signaling domain of CAR comprises modified CD3ζ polypeptide comprising one or two, but not all three, BRS regions.In certain embodiments, modified CD3ζ polypeptide comprises BRS1 region and BRS2 region, but does not comprise BRS3 region.In certain embodiments, modified CD3ζ polypeptide comprises BRS1 region and BRS3 region, but does not comprise BRS2 region.In certain embodiments, modified CD3ζ polypeptide comprises BRS2 region and BRS3 region, but does not comprise BRS1 region.
[0216] In certain embodiments, modified CD3 ζ polypeptide comprises BRS1 region and does not comprise BRS2 region or BRS3 region. In certain embodiments, modified CD3 ζ polypeptide comprises native BRS1 having the amino acid sequence set forth in SEQ ID NO: 35 and does not comprise BRS2 region or BRS3 region, for example, modified CD3 ζ polypeptide is included in construct D23. In certain embodiments, modified CD3 ζ polypeptide comprises BRS2 region and does not comprise BRS1 region or BRS3 region. In certain embodiments, modified CD3 ζ polypeptide comprises BRS3 region and does not comprise BRS1 region or BRS2 region.
[0217] In certain embodiments, the modified CD3 zeta polypeptide does not contain a BRS region (native or modified BRS1, BRS2 or BRS3), e.g., all three BRS are deleted, e.g., the modified CD3 zeta polypeptide is contained in construct D12.
[0218] In certain non-limiting embodiments, the CAR comprises an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3ζ polypeptide, wherein the modified CD3ζ polypeptide lacks all or a portion of an immunoreceptor tyrosine-based activation motif (ITAM), and the ITAM is ITAM1, ITAM2, and ITAM3. In certain embodiments, the modified CD3ζ polypeptide lacks ITAM2 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide further lacks ITAM3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide further lacks ITAM1 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide lacks ITAM1 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide further lacks ITAM3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide lacks ITAM3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide lacks all or part of the basic residue-rich extension (BRS) region, and the BRS region is BRS1, BRS2, and BRS3. In certain embodiments, the modified CD3ζ polypeptide lacks BRS2 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide further lacks BRS3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide further lacks BRS1 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide lacks BRS1 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide further lacks BRS3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide lacks BRS3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide lacks BRS1 or a portion thereof, BRS2 or a portion thereof, and BRS3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide lacks ITAM2, ITAM3, BRS2, and BRS3. In certain embodiments, the CAR comprises the amino acid sequence set forth in SEQ ID NO:45 or SEQ ID NO:47.In certain embodiments, the CAR comprises an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3ζ polypeptide, wherein the modified CD3ζ polypeptide lacks all or a portion of a basic residue-rich extension (BRS) region, and the BRS region is BRS1, BRS2, and BRS3. In certain embodiments, the CAR comprises an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3ζ polypeptide, wherein the modified CD3ζ polypeptide comprises a BRS variant selected from a BRS1 variant, a BRS2 variant, and a BRS3 variant, and the BRS variant comprises one or more loss-of-function mutations.
[0219] Costimulatory Signaling Region In certain non-limiting embodiments, the intracellular signaling domain of the CAR further comprises at least a costimulatory signaling region. In certain embodiments, the costimulatory signaling region comprises at least one costimulatory molecule that can provide optimal lymphocyte activation.
[0220] As used herein, "costimulatory molecule" refers to a cell surface molecule other than an antigen receptor or its ligand that is required for an efficient response of lymphocytes to an antigen. The at least one costimulatory signaling region may include a CD28 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, an ICOS polypeptide, a DAP-10 polypeptide, a CD27 peptide, a CD40 / My88 peptide, an NKGD2 peptide, or a combination thereof. A costimulatory molecule can bind to a costimulatory ligand, which is a protein expressed on the cell surface that generates a costimulatory response, i.e., an intracellular response that results in the stimulation that is provided when an antigen binds to the CAR molecule, upon binding to its receptor. Costimulatory ligands include, but are not limited to, CD80, CD86, CD70, OX40L, and 4-1BBL. As an example, 4-1BB ligand (i.e., 4-1BBL) can, together with a CAR signal, signal the CAR. +It can bind to 4-1BB (also known as "CD137") to provide an intracellular signal that induces effector cell function of T cells. CARs that contain intracellular signaling domains that include costimulatory signaling regions that include 4-1BB, ICOS, or DAP-10 are disclosed in U.S. Patent No. 7,446,190, the entirety of which is incorporated herein by reference.
[0221] In certain embodiments, the intracellular signaling domain of the CAR comprises a costimulatory signaling region comprising a CD28 polypeptide. The CD28 polypeptide may comprise or have an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homologous or identical to a sequence having NCBI reference number: P10747 or NP_006130 (SEQ ID NO: 90) or a fragment thereof, and / or may optionally comprise up to one, or up to two, or up to three conservative amino acid substitutions. In certain non-limiting embodiments, the CD28 polypeptide comprises or has an amino acid sequence that is a continuous portion of SEQ ID NO: 90 that is at least 20, or at least 30, or at least 40, or at least 50, and up to 220 amino acids in length. Alternatively, or in addition, in various non-limiting embodiments, the CD28 polypeptide comprises or has the amino acid sequence of amino acids 1-220, 1-50, 50-100, 100-150, 114-220, 150-200, or 200-220 of SEQ ID NO: 90. In certain embodiments, the intracellular signaling domain of the CAR comprises a costimulatory signaling region that comprises a CD28 polypeptide that comprises or has the amino acid sequence of amino acids 180-220 of SEQ ID NO: 90.
[0222] In certain embodiments, the CD28 polypeptide comprises or has an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homologous or identical to a sequence having NCBI Reference Number: NP_031668.3 (SEQ ID NO: 97) or a fragment thereof, and / or may optionally contain up to one, or up to two, or up to three conservative amino acid substitutions. In certain non-limiting embodiments, the CD28 polypeptide comprises or has an amino acid sequence that is a contiguous portion of SEQ ID NO: 97 that is at least 20, or at least 30, or at least 40, or at least 50, and up to 218 amino acids in length. Alternatively, or in addition, in various non-limiting embodiments, a CD28 polypeptide comprises or has an amino acid sequence of amino acids 1-218, 1-50, 50-100, 100-150, 114-220, 150-200, 178-218, or 200-220 of SEQ ID NO: 97. In certain embodiments, a costimulatory signaling region of a CAR of the disclosure comprises a CD28 polypeptide that comprises or has amino acids 178-218 of SEQ ID NO:97. SEQ ID NO:97 is provided below: [ka]
[0223] In accordance with the subject matter of the present disclosure, a "CD28 nucleic acid molecule" refers to a polynucleotide that encodes a CD28 polypeptide. In certain embodiments, a CD28 nucleic acid molecule that encodes a CD28 polypeptide contained in a costimulatory signaling region of a CAR of the present disclosure (e.g., amino acids 178-218 of SEQ ID NO:97) comprises or has a nucleotide sequence set forth in SEQ ID NO:98, provided below. [ka]
[0224] In certain embodiments, the intracellular signaling domain of the CAR comprises the mouse intracellular signaling domain of CD28. The mouse intracellular signaling domain of CD28 may comprise or have an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homologous or identical to SEQ ID NO: 99 or a fragment thereof, and / or may optionally include up to one, or up to two, or up to three conservative amino acid substitutions. SEQ ID NO: 99 is provided below:
[0225] [ka]
[0226] An exemplary nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO:99 is set forth in SEQ ID NO:100, provided below. [ka]
[0227] In certain embodiments, the intracellular signaling domain of the CAR comprises the human intracellular signaling domain of CD28. The human intracellular signaling domain of CD28 may comprise or have an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homologous or identical to SEQ ID NO: 101 or a fragment thereof, and / or may optionally include up to one, or up to two, or up to three conservative amino acid substitutions. SEQ ID NO: 101 is provided below:
[0228] [ka]
[0229] An exemplary nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO:70 is set forth in SEQ ID NO:102, provided below. [ka]
[0230] In certain embodiments, the intracellular signaling domain of the CAR comprises a deimmunized human intracellular signaling domain of CD28. The deimmunized human intracellular signaling domain of CD28 may comprise or have an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homologous or identical to SEQ ID NO: 108 or a fragment thereof, and / or may optionally include up to one, or up to two, or up to three conservative amino acid substitutions. SEQ ID NO: 108 is provided below: [ka]
[0231] In certain embodiments, the intracellular signaling domain of the CAR comprises a costimulatory signaling region that comprises two costimulatory molecules, for example, the costimulatory signaling region of CD28 and 4-1BB or the costimulatory signaling region of CD28 and OX40.
[0232] 4-1BB may act as a tumor necrosis factor (TNF) ligand and have stimulatory activity. The 4-1BB polypeptide may comprise or have an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homologous or identical to a sequence having NCBI reference number: P41273 or NP_001552 (SEQ ID NO: 103) or a fragment thereof, and / or may optionally comprise up to one, or up to two, or up to three conservative amino acid substitutions. SEQ ID NO: 103 is provided below: [ka]
[0233] In accordance with the presently disclosed subject matter, a "4-1BB nucleic acid molecule" refers to a polynucleotide that encodes a 4-1BB polypeptide.
[0234] In certain embodiments, the intracellular signaling domain of the CAR comprises the intracellular signaling domain of 4-1BB. The intracellular signaling domain of 4-1BB may comprise or have an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homologous or identical to SEQ ID NO: 104 or a fragment thereof, and / or may optionally include up to one, or up to two, or up to three conservative amino acid substitutions. SEQ ID NO: 104 is provided below:
[0235] [ka]
[0236] An exemplary nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO:104 is set forth in SEQ ID NO:105, provided below. [ka]
[0237] The OX40 polypeptide may comprise or have an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homologous or identical to a sequence having NCBI reference number: P43489 or NP_003318 (SEQ ID NO: 106) or a fragment thereof, and / or may optionally contain up to one, or up to two, or up to three conservative amino acid substitutions. SEQ ID NO: 106 is provided below: [ka]
[0238] In accordance with the subject matter of this disclosure, an "OX40 nucleic acid molecule" refers to a polynucleotide that encodes an OX40 polypeptide.
[0239] An ICOS polypeptide may comprise or have an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homologous or identical to a sequence having NCBI Reference Number: NP_036224 (SEQ ID NO: 65) or a fragment thereof, and / or may optionally contain up to one, or up to two, or up to three conservative amino acid substitutions. SEQ ID NO:65 is provided below: [ka]
[0240] In accordance with the presently disclosed subject matter, an "ICOS nucleic acid molecule" refers to a polynucleotide that encodes an ICOS polypeptide.
[0241] In certain embodiments, the CAR of the present disclosure further comprises an inducible promoter for expressing the nucleic acid sequence in human cells. The promoter for use in expressing the CAR gene may be a constitutive promoter, such as the ubiquitin C (UbiC) promoter.
[0242] In certain embodiments, the mutation sites and / or junctions between domains / motifs / regions of the CAR from different proteins are deimmunized. The immunogenicity of the junctions between different CAR parts can be predicted using the NetMHC4.0 server. For each peptide containing at least one amino acid from the following parts, the binding affinity for HLA A, B and C for all alleles can be predicted. The immunogenicity score of each peptide can be assigned to each peptide. The immunogenicity score is calculated according to the formula: immunogenicity score = [(50 - binding affinity) * HLA frequency] n where n is the number of predictions for each peptide.
[0243] 1928z WT construct In certain embodiments, the CAR of the present disclosure comprises an extracellular antigen-binding domain that binds to a CD19 polypeptide (e.g., a human CD19 polypeptide), a transmembrane domain and hinge / spacer region derived from a CD28 polypeptide, an intracellular signaling domain that comprises a modified CD3ζ polypeptide (e.g., a modified human CD3ζ polypeptide) that comprises native ITAM1, native ITAM2, native ITAM3, native BRS1, native BRS2, and native BRS3, and a costimulatory signaling region that comprises a CD28 polypeptide (e.g., a human CD28 polypeptide). In certain embodiments, the CAR is named "1928z WT". In certain embodiments, the CAR (e.g., 1928z WT) comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:41 provided below. SEQ ID NO:41 contains a CD8 leader sequence at amino acids 1-18 and is capable of binding to CD19 (eg, human CD19).
[0244] [ka]
[0245] An exemplary nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO:41 is set forth in SEQ ID NO:42, provided below.
[0246] [ka]
[0247] 1XX Constructs In certain embodiments, the CAR of the present disclosure comprises an extracellular antigen-binding domain that binds to a CD19 polypeptide (e.g., a human CD19 polypeptide), a transmembrane domain and hinge / spacer region derived from a CD28 polypeptide, an intracellular signaling domain that comprises a modified CD3ζ polypeptide (e.g., a modified human CD3ζ polypeptide) that comprises a native ITAM1, a native BRS1, a native BRS2, a native BRS3, an ITAM2 variant with two loss-of-function mutations, and an ITAM3 variant with two loss-of-function mutations, and a costimulatory signaling region that comprises a CD28 polypeptide (e.g., a human CD28 polypeptide). In certain embodiments, the CAR is named "1XX". In certain embodiments, the CAR (e.g., an 1XX) comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:43 provided below. SEQ ID NO:43 contains a CD8 leader sequence at amino acids 1-18 and is capable of binding to CD19 (eg, human CD19).
[0248] [ka]
[0249] An exemplary nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO:43 is set forth in SEQ ID NO:44, provided below.
[0250] [ka]
[0251] D12 construct In certain embodiments, the CAR of the present disclosure comprises an extracellular antigen-binding domain that binds to a CD19 polypeptide (e.g., a human CD19 polypeptide), a transmembrane domain and hinge / spacer region derived from a CD28 polypeptide, an intracellular signaling domain that comprises a modified CD3ζ polypeptide (e.g., a modified human CD3ζ polypeptide), and a costimulatory signaling region that comprises a CD28 polypeptide (e.g., a human CD28 polypeptide), wherein the modified CD3ζ polypeptide comprises a native ITAM3 and does not comprise ITAM1 (native or modified), ITAM2 (native or modified), BRS1 (native or modified), BRS2 (native or modified), or BRS3 (native or modified). In certain embodiments, the CAR is named "D12". In certain embodiments, the CAR (e.g., D12) comprises an amino acid sequence that is at least about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% homologous to the amino acid sequence set forth in SEQ ID NO: 45 provided below. SEQ ID NO:45 contains a CD8 leader sequence at amino acids 1-18 and is capable of binding to CD19 (eg, human CD19).
[0252] [ka]
[0253] An exemplary nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO:45 is set forth in SEQ ID NO:46, provided below.
[0254] [ka]
[0255] D23 Construct In certain embodiments, the CAR of the present disclosure comprises an extracellular antigen-binding domain that binds to a CD19 polypeptide (e.g., a human CD19 polypeptide), a transmembrane domain and hinge / spacer region derived from a CD28 polypeptide, an intracellular signaling domain that comprises a modified CD3ζ polypeptide (e.g., a modified human CD3ζ polypeptide) that comprises deletions of ITAM1, BRS1, and ITAM2, ITAM3, BRS2, and BRS3, and a costimulatory signaling region that comprises a CD28 polypeptide (e.g., a human CD28 polypeptide), wherein the modified CD3ζ polypeptide comprises native ITAM1 and native BRS1, and does not comprise ITAM2 (native or modified), ITAM3 (native or modified), BRS2 (native or modified), or BRS3 (native or modified). In certain embodiments, the CAR is designated "D23". In certain embodiments, a CAR (e.g., D23) comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 47 provided below. SEQ ID NO: 47 comprises a CD8 leader sequence at amino acids 1-18 and is capable of binding to CD19 (e.g., human CD19).
[0256] [ka]
[0257] An exemplary nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO:47 is set forth in SEQ ID NO:48, provided below.
[0258] [ka]
[0259] XX3 Construct In certain embodiments, the CAR of the present disclosure comprises an extracellular antigen-binding domain that binds to a CD19 polypeptide (e.g., a human CD19 polypeptide), a transmembrane domain and hinge / spacer region derived from a CD28 polypeptide, an intracellular signaling domain that comprises a modified CD3ζ polypeptide (e.g., a modified human CD3ζ polypeptide) that comprises a native ITAM3, a native BRS1, a native BRS2, a native BRS3, an ITAM1 variant with two loss-of-function mutations, and an ITAM2 variant with two loss-of-function mutations, and a costimulatory signaling region that comprises a CD28 polypeptide (e.g., a human CD28 polypeptide). In certain embodiments, the CAR is named "XX3". In certain embodiments, the CAR (e.g., XX3) comprises an amino acid sequence that is at least about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% homologous to the amino acid sequence set forth in SEQ ID NO: 49 provided below. SEQ ID NO:49 contains a CD8 leader sequence at amino acids 1-18 and is capable of binding to CD19 (eg, human CD19).
[0260] [ka]
[0261] An exemplary nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO:49 is set forth in SEQ ID NO:50, provided below.
[0262] [ka]
[0263] X23 Construct In certain embodiments, the CAR of the present disclosure comprises an extracellular antigen-binding domain that binds to a CD19 polypeptide (e.g., a human CD19 polypeptide), a transmembrane domain and hinge / spacer region derived from a CD28 polypeptide, an intracellular signaling domain comprising a modified CD3ζ polypeptide (e.g., a modified human CD3ζ polypeptide) comprising a native ITAM2, a native ITAM3, a native BRS1, a native BRS2, a native BRS3, and an ITAM1 variant with two loss-of-function mutations, and a costimulatory signaling region comprising a CD28 polypeptide (e.g., a human CD28 polypeptide). In certain embodiments, the CAR is named "X23". In certain embodiments, the CAR (e.g., X23) comprises an amino acid sequence that is at least about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% homologous to the amino acid sequence set forth in SEQ ID NO:51 provided below. SEQ ID NO:51 contains a CD8 leader sequence at amino acids 1-18 and is capable of binding to CD19 (eg, human CD19).
[0264] [ka]
[0265] An exemplary nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO:51 is set forth in SEQ ID NO:52, provided below.
[0266] [ka]
[0267] X2X Construction In certain embodiments, the CAR of the present disclosure comprises an extracellular antigen-binding domain that binds to a CD19 polypeptide (e.g., a human CD19 polypeptide), a transmembrane domain and hinge / spacer region derived from a CD28 polypeptide, an intracellular signaling domain comprising a modified CD3ζ polypeptide (e.g., a modified human CD3ζ polypeptide) comprising a native ITAM2, a native BRS1, a native BRS2, a native BRS3, an ITAM1 variant with two loss-of-function mutations, and an ITAM3 variant with two loss-of-function mutations, and a costimulatory signaling region comprising a CD28 polypeptide (e.g., a human CD28 polypeptide). In certain embodiments, the CAR is designated "X2X". In certain embodiments, the CAR (e.g., X2X) comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:53 provided below. SEQ ID NO:53 contains a CD8 leader sequence at amino acids 1-18 and is capable of binding to CD19 (eg, human CD19).
[0268] [ka]
[0269] An exemplary nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO:53 is set forth in SEQ ID NO:54, provided below.
[0270] [ka]
[0271] 12X Construct In certain embodiments, the CAR of the present disclosure comprises an extracellular antigen-binding domain that binds to a CD19 polypeptide (e.g., a human CD19 polypeptide), a transmembrane domain and hinge / spacer region derived from a CD28 polypeptide, an intracellular signaling domain that comprises a modified CD3ζ polypeptide (e.g., a modified human CD3ζ polypeptide) that comprises a native ITAM1, a native ITAM2, a native BRS1, a native BRS2, a native BRS3, and an ITAM3 variant with two loss-of-function mutations, and a costimulatory signaling region that comprises a CD28 polypeptide (e.g., a human CD28 polypeptide). In certain embodiments, the CAR is named "12X". In certain embodiments, the CAR (e.g., 12X) comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:55 provided below. SEQ ID NO:55 contains a CD8 leader sequence at amino acids 1-18 and is capable of binding to CD19 (eg, human CD19).
[0272] [ka]
[0273] An exemplary nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO:55 is set forth in SEQ ID NO:56, provided below.
[0274] [ka]
[0275] D3 construct In certain embodiments, the CAR of the present disclosure comprises an extracellular antigen-binding domain that binds to a CD19 polypeptide (e.g., a human CD19 polypeptide), a transmembrane domain and hinge / spacer region derived from a CD28 polypeptide, an intracellular signaling domain that comprises a modified CD3ζ polypeptide (e.g., a modified human CD3ζ polypeptide) that comprises a deletion of ITAM1, ITAM2, BRS1, BRS2, and a portion of ITAM3 and BRS3, and a costimulatory signaling region that comprises a CD28 polypeptide (e.g., a human CD28 polypeptide), wherein the modified CD3ζ polypeptide comprises native ITAM1, native ITAM2, native BRS1, and native BRS2, and does not comprise ITAM3 (native or modified) or native BRS3. In certain embodiments, the CAR is designated "D3". In certain embodiments, a CAR (e.g., D3) comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 57 provided below. SEQ ID NO: 57 comprises a CD8 leader sequence at amino acids 1-18 and is capable of binding to CD19 (e.g., human CD19).
[0276] [ka]
[0277] An exemplary nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO:57 is set forth in SEQ ID NO:58, provided below.
[0278] [ka]
[0279] 19-166-28zConstruct In certain embodiments, the CAR of the present disclosure comprises an extracellular antigen-binding domain that binds to a CD19 polypeptide (e.g., a human CD19 polypeptide), a transmembrane domain and hinge / spacer region derived from a CD166 polypeptide, an intracellular signaling domain that comprises a modified CD3ζ polypeptide (e.g., a modified human CD3ζ polypeptide) that comprises native ITAM1, native ITAM2, native ITAM3, native BRS1, native BRS2, and native BRS3, and a costimulatory signaling region that comprises a CD28 polypeptide (e.g., a human CD28 polypeptide). In certain embodiments, the CAR is designated "19-166-28z". In certain embodiments, the CAR (e.g., 19-166-28z) comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:59 provided below. SEQ ID NO:59 contains a CD8 leader sequence at amino acids 1-18 and is capable of binding to CD19 (eg, human CD19).
[0280] [ka]
[0281] An exemplary nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO:59 is set forth in SEQ ID NO:60, provided below.
[0282] [ka]
[0283] 19-166-28z 1XX construct In certain embodiments, the CAR of the present disclosure comprises an extracellular antigen-binding domain that binds to a CD19 polypeptide (e.g., a human CD19 polypeptide), a transmembrane domain and hinge / spacer region derived from a CD166 polypeptide, an intracellular signaling domain that comprises a modified CD3ζ polypeptide (e.g., a modified human CD3ζ polypeptide) that comprises a native ITAM1, a native BRS1, a native BRS2, a native BRS3, an ITAM2 variant with two loss-of-function mutations, and an ITAM3 variant with two loss-of-function mutations, and a costimulatory signaling region that comprises a CD28 polypeptide (e.g., a human CD28 polypeptide). In certain embodiments, the CAR is designated "19-166-28z 1XX". In certain embodiments, a CAR (e.g., 19-166-28z 1XX) comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 61 provided below. SEQ ID NO: 61 comprises a CD8 leader sequence at amino acids 1-18 and is capable of binding to CD19 (e.g., human CD19).
[0284] [ka]
[0285] An exemplary nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO:61 is set forth in SEQ ID NO:62, provided below.
[0286] [ka]
[0287] 19-166-28z D23 Construct In certain embodiments, the CAR of the present disclosure comprises an extracellular antigen-binding domain that binds to a CD19 polypeptide (e.g., a human CD19 polypeptide), a transmembrane domain and hinge / spacer region derived from a CD166 polypeptide, an intracellular signaling domain that comprises a modified CD3ζ polypeptide (e.g., a modified human CD3ζ polypeptide) that comprises deletions of ITAM1, BRS1, and ITAM2, ITAM3, BRS2, and BRS3, and a costimulatory signaling region that comprises a CD28 polypeptide (e.g., a human CD28 polypeptide), wherein the modified CD3ζ polypeptide comprises native ITAM1 and native BRS1, and does not comprise ITAM2 (native or modified), ITAM3 (native or modified), BRS2 (native or modified), or BRS3 (native or modified). In certain embodiments, the CAR is designated "19-166-28z D23". In certain embodiments, a CAR (e.g., 19-166-28z D23) comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 63 provided below. SEQ ID NO: 63 comprises a CD8 leader sequence at amino acids 1-18 and is capable of binding to CD19 (e.g., human CD19).
[0288] [ka]
[0289] An exemplary nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO:63 is set forth in SEQ ID NO:64, provided below.
[0290] [ka]
[0291] 3. Immunoresponsive cells The subject matter of the present disclosure provides an immunoresponsive cell comprising one or more CARs disclosed herein.In certain embodiments, the CAR can activate the immunoresponsive cell.In certain embodiments, the CAR is expressed from an endogenous locus (e.g., TRAC).
[0292] In certain embodiments, the immunoresponsive cells comprising one or more CARs of the present disclosure show improved therapeutic efficacy compared to control cells. In certain embodiments, the immunoresponsive cells comprising one or more CARs of the present disclosure show similar cytolytic effects compared to control cells. In certain embodiments, the immunoresponsive cells comprising one or more CARs of the present disclosure show increased cell accumulation when administered to a subject compared to control cells. In certain embodiments, the immunoresponsive cells comprising one or more CARs of the present disclosure show reduced cell wasting when administered to a subject compared to control cells. Immunoresponsive cell wasting markers include, but are not limited to, TIM3, LAG3, and PD1. In certain embodiments, the immunoresponsive cells comprising one or more CARs of the present disclosure maintain a higher contingent of memory immune cells when administered to a subject compared to control cells. Memory immune cell markers include, but are not limited to, CD62L and CD45RA. In certain embodiments, the immunoresponsive cells comprising one or more CARs of the present disclosure secrete similar levels of cytokines compared to control cells. In certain embodiments, cytokines secreted by the immunoresponsive cells include, but are not limited to, TNFα, IFNγ, and IL2. In certain embodiments, the control cells comprise a CAR comprising an intracellular signaling domain comprising a modified CD3ζ polypeptide, the modified CD3ζ polypeptide comprising all-native ITAM1-3 and all-native BRS1-3.
[0293] 3.1 Immunoresponsive cells containing two or more CARs In certain embodiments, the immunoresponsive cell comprises two or more CARs.In certain embodiments, at least one of the two or more CARs is the CAR disclosed herein.In certain embodiments, the immunoresponsive cell comprises two CARs.In certain embodiments, the immunoresponsive cell comprises three CARs.
[0294] In certain embodiments, the immunoresponsive cell comprises: a) a first CAR comprising a first extracellular antigen binding domain that binds to a first antigen, a first transmembrane domain, and a first intracellular signaling domain that comprises a modified CD3ζ polypeptide (e.g., one of the modified CD3ζ polypeptides disclosed herein); and b) a second CAR comprising a second extracellular antigen binding domain that binds to a second antigen, a second transmembrane domain, and a second intracellular signaling domain. In certain embodiments, the first CAR further comprises a first hinge / spacer region. In certain embodiments, the second CAR further comprises a second hinge / spacer region.
[0295] In certain embodiments, the second intracellular signaling domain comprises a modified CD3ζ polypeptide (e.g., one of the modified CD3ζ polypeptides disclosed herein). In certain embodiments, the second intracellular signaling domain comprises a natural CD3ζ polypeptide. In certain embodiments, the modified CD3ζ polypeptide contained in the second intracellular signaling domain is the same as the modified CD3ζ polypeptide contained in the first intracellular signaling domain. In certain embodiments, the modified CD3ζ polypeptide contained in the second intracellular signaling domain is different from the modified CD3ζ polypeptide contained in the first intracellular signaling domain. In certain embodiments, the modified CD3ζ polypeptide is selected from the group consisting of a CD3ζ polypeptide comprising one native ITAM, a CD3ζ polypeptide comprising two native ITAMs, a CD3ζ polypeptide comprising three native ITAMs, a CD3ζ polypeptide comprising one ITAM variant disclosed herein, a CD3ζ polypeptide comprising two ITAM variants disclosed herein, a CD3ζ polypeptide comprising one native BRS region, a CD3ζ polypeptide comprising two native BRS regions, a CD3ζ polypeptide comprising three native BRS regions, a CD3ζ polypeptide lacking all or a portion of ITAM1, ITAM2, ITAM3 and / or any portion thereof, and any combination thereof.
[0296] In certain embodiments, the two or more CARs contained in the immunoresponsive cell are different (e.g., the first CAR is different from the second CAR). In certain embodiments, the two or more CARs contained in the immunoresponsive cell are the same (e.g., the first CAR is the same as the second CAR).
[0297] In certain embodiments, the two or more CARs bind different antigens (e.g., the first antigen is different from the second antigen).
[0298] In certain embodiments, two or more CARs comprise different intracellular signaling domains (e.g., the first intracellular signaling domain is different from the second intracellular signaling domain). In certain embodiments, two or more CARs comprise the same intracellular signaling domain (e.g., the first intracellular signaling domain is the same as the second intracellular signaling domain).
[0299] In certain embodiments, the intracellular signaling domains of two or more CARs comprise different costimulatory signaling regions.In certain embodiments, the costimulatory signaling region is selected from the group consisting of CD28 polypeptide, 4-1BB polypeptide, OX40 polypeptide, ICOS polypeptide, DAP-10 polypeptide, CD27 peptide, CD40 / My88 peptide, NKGD2 peptide, and combinations thereof.In certain embodiments, the intracellular signaling domains of two or more CARs comprise the same costimulatory signaling region.
[0300] In certain embodiments, the immunoresponsive cell comprises two, three or more CARs of the present disclosure. In certain embodiments, the intracellular signaling domains of the CARs are each independently selected from the group consisting of the intracellular signaling domains of 1928ζ, 19ζ, 1XX, X2X, XX3, X23, 12X, D3, D12 and D23.
[0301] The choice of which CAR to include in a cell may depend on the density of the antigen targeted by the CAR, the sum of all ITAMs, the distance between each ITAM, the transmembrane domain of the CAR, and / or the costimulatory signaling domain of the CAR, as these can determine the strength of the activation signal produced by each CAR.
[0302] In certain embodiments, the immunoresponsive cell comprises two CARs, where the first CAR comprises a first intracellular signaling domain and the second CAR comprises a second intracellular signaling domain. In certain embodiments, the first and second intracellular signaling domains are each selected from the group consisting of 1928ζ, 19ζ, 1XX, X2X, XX3, 12X, X23, D3, D12 and D23 intracellular signaling domains.
[0303] In certain embodiments, the first intracellular signaling domain is the same as the second intracellular signaling domain. In certain embodiments, the first and second intracellular signaling domains are 1XX intracellular signaling domains, respectively. In certain embodiments, the first and second intracellular signaling domains are 1XX intracellular signaling domains and D23 intracellular signaling domains. In certain embodiments, the first and second intracellular signaling domains are 1XX intracellular signaling domains and XX3 intracellular signaling domains. In certain embodiments, the first and second intracellular signaling domains are D23 intracellular signaling domains and XX3 intracellular signaling domains. In certain embodiments, the first and second intracellular signaling domains are 1XX intracellular signaling domains and X2X intracellular signaling domains. In certain embodiments, the first and second intracellular signaling domains are 1XX intracellular signaling domains and D12 intracellular signaling domains. In certain embodiments, the first intracellular signaling domain and the second intracellular signaling domain are 1XX intracellular signaling domain and 12X intracellular signaling domain.In certain embodiments, the first intracellular signaling domain and the second intracellular signaling domain are 1XX intracellular signaling domain and D3 intracellular signaling domain.In certain embodiments, the first intracellular signaling domain and the second intracellular signaling domain are X2X intracellular signaling domain and X2X intracellular signaling domain.In certain embodiments, the first intracellular signaling domain and the second intracellular signaling domain are 1928z intracellular signaling domain and 1XX intracellular signaling domain.
[0304] In certain embodiments, the first intracellular signaling domain comprises or has an ITAM2 variant and an ITAM3 variant, and the second intracellular signaling domain comprises or has an ITAM2 or a deletion of a portion thereof and an ITAM3 or a deletion of a portion thereof. In certain embodiments, the first intracellular signaling domain comprises or has an ITAM2 variant and an ITAM3 variant, and the second intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant.
[0305] In certain embodiments, the total number of native ITAMs present in the two CARs is about 5 or less, about 4 or less, about 3 or less, or about 2 or less.
[0306] In certain embodiments, the immunoresponsive cell comprises three CARs, where the first CAR comprises a first intracellular signaling domain, the second CAR comprises a second intracellular signaling domain, and the third CAR comprises a third intracellular signaling domain. In certain embodiments, the first, second, and third intracellular signaling domains are each independently selected from the group consisting of 1928ζ, 19ζ, 1XX, X2X, XX3, X23, 12X, D3, D12, and D23 intracellular signaling domains.
[0307] In certain embodiments, the first intracellular signaling domain, the second intracellular signaling domain, and the third intracellular signaling domain are 1XX intracellular signaling domain, D23 intracellular signaling domain, and XX3 intracellular signaling domain. In certain embodiments, the first intracellular signaling domain, the second intracellular signaling domain, and the third intracellular signaling domain are D23 intracellular signaling domain, D23 intracellular signaling domain, and XX3 intracellular signaling domain. In certain embodiments, the first intracellular signaling domain, the second intracellular signaling domain, and the third intracellular signaling domain are D23 intracellular signaling domain, XX3 intracellular signaling domain, and XX3 intracellular signaling domain. In certain embodiments, the first intracellular signaling domain, the second intracellular signaling domain, and the third intracellular signaling domain are XX3 intracellular signaling domain, XX3 intracellular signaling domain, and XX3 intracellular signaling domain. In certain embodiments, the first intracellular signaling domain, the second intracellular signaling domain and the third intracellular signaling domain are 1XX intracellular signaling domain, 1XX intracellular signaling domain and 1XX intracellular signaling domain.In certain embodiments, the first intracellular signaling domain, the second intracellular signaling domain and the third intracellular signaling domain are 1XX intracellular signaling domain, X2X intracellular signaling domain and X2X intracellular signaling domain.In certain embodiments, the first intracellular signaling domain, the second intracellular signaling domain and the third intracellular signaling domain are 1XX intracellular signaling domain, 1XX intracellular signaling domain and X2X intracellular signaling domain.In certain embodiments, the first intracellular signaling domain, the second intracellular signaling domain, and the third intracellular signaling domain are 1XX intracellular signaling domain, 1XX intracellular signaling domain, and D12 intracellular signaling domain.In certain embodiments, the first intracellular signaling domain, the second intracellular signaling domain, and the third intracellular signaling domain are 1XX intracellular signaling domain, 1XX intracellular signaling domain, and D23 intracellular signaling domain.In certain embodiments, the first intracellular signaling domain, the second intracellular signaling domain, and the third intracellular signaling domain are 1XX intracellular signaling domain, 1XX intracellular signaling domain, and 12X intracellular signaling domain.In certain embodiments, the first intracellular signaling domain, the second intracellular signaling domain, and the third intracellular signaling domain are 1XX intracellular signaling domain, 1XX intracellular signaling domain, and D3 intracellular signaling domain. In certain embodiments, the first intracellular signaling domain, the second intracellular signaling domain, and the third intracellular signaling domain are an X2X1 intracellular signaling domain, an X2X2 intracellular signaling domain, and an X2X3 intracellular signaling domain.
[0308] In certain embodiments, the first intracellular signaling domain comprises or has an ITAM2 variant and an ITAM3 variant, the second intracellular signaling domain comprises or has an ITAM2 or a deletion of a portion thereof and an ITAM3 or a deletion of a portion thereof, and the third intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant. In certain embodiments, the first intracellular signaling domain comprises or has an ITAM2 or a deletion of a portion thereof and an ITAM3 or a deletion of a portion thereof, the second intracellular signaling domain comprises or has an ITAM2 or a deletion of a portion thereof and an ITAM3 or a deletion of a portion thereof, and the third intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant. In certain embodiments, the first intracellular signaling domain comprises or has a deletion of ITAM2 or a portion thereof and a deletion of ITAM3 or a portion thereof, the second intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant, and the third intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant. In certain embodiments, the first intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant, the second intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant, and the third intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant.
[0309] In certain embodiments, the total number of native ITAMs present in the three CARs is about 5 or less, about 4 or less, about 3 or less.
[0310] In certain embodiments, the targets of the CARs are different from each other.
[0311] 3.1 Immunoreactive Cell Types The immunoresponsive cells of the subject matter of the present disclosure may be cells of the lymphoid system. The lymphoid system, including B, T and natural killer (NK) cells, allows for antibody production, regulation of the cell-mediated immune system, detection of foreign agents in the blood, detection of cells foreign to the host, and the like. Non-limiting examples of immunoresponsive cells of the lymphoid system include T cells, natural killer (NK) cells, embryonic stem cells and pluripotent stem cells (e.g., those capable of differentiating lymphoid cells). T cells may be lymphocytes that mature in the thymus and are primarily responsible for cell-mediated immunity. T cells participate in the adaptive immune system. The T cells of the subject matter of the present disclosure include helper T cells, cytotoxic T cells, memory T cells (central memory T cells, stem cell-like memory T cells (or stem-like memory T cells) and two types of effector memory T cells: e.g., T EM Cells and T EMRA The immunoresponsive cells may be any type of T cell, including, but not limited to, T cells, regulatory T cells (also known as suppressor T cells), natural killer T cells, mucosal-associated invariant T cells, and γδ T cells. Cytotoxic T cells (CTLs or killer T cells) are a subset of T lymphocytes capable of inducing the death of infected somatic or tumor cells. The patient's own T cells can be genetically modified to target specific antigens through the introduction of a CAR. In certain embodiments, the immunoresponsive cells are T cells. T cells are CD4 + T cells or CD8 + In certain embodiments, the T cells are CD4 + In certain embodiments, the T cells are CD8 + T cells.
[0312] Natural killer (NK) cells may be lymphocytes that are part of cell-mediated immunity and act during the innate immune response. NK cells do not require prior activation to carry out their cytotoxic effect on target cells.
[0313] The types of human lymphocytes of the presently disclosed subject matter include, but are not limited to, peripheral donor lymphocytes, e.g., Sadelain, M., et al. 2003 Nat RevCancer3:35-45 (disclosing peripheral donor lymphocytes genetically modified to express CARs), Morgan, RA, et al. 2006 Science314:126-129 (disclosing full-length tumor antigen-recognizing T cell receptor complexes including α and β heterodimers), and IL-16. (2000) discloses peripheral donor lymphocytes genetically modified to induce IL-19 expression in mice; Panelli, MC, et al. J Immunol 164:495-504; Panelli, MC, et al. 2000 J Immunol 164:4382-4392 (disclosing lymphocyte cultures derived from tumor infiltrating lymphocytes (TILs) in tumor biopsies), and Dupont, J., et al. 2005 Cancer Res 65:5417-5427; Papanicolaou, GA, et al. 2003 Blood 102:2498-2505 (disclosing selection using artificial antigen presenting cells (AAPCs) or pulsed dendritic cells). (discloses selectively in vitro expanded antigen-specific peripheral blood leukocytes). The immunoresponsive cells (e.g., T cells) can be autologous, non-autologous (e.g., allogeneic), or derived in vitro from engineered progenitor or stem cells.
[0314] The immunoresponsive cells of the present disclosure are capable of modulating the tumor microenvironment. Tumors have a microenvironment hostile to the host immune response, including a series of mechanisms by malignant cells to protect themselves from immune recognition and elimination. This "hostile tumor microenvironment" includes infiltration-regulating CD4 +Various immunosuppressive factors, including T cells (Tregs), myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), immunosuppressive cytokines including TGF-β, and expression of ligands that target immunosuppressive receptors expressed by activated T cells (CTLA-4 and PD-1). These mechanisms of immunosuppression play a role in maintaining tolerance and suppressing inappropriate immune responses, but within the tumor microenvironment, these mechanisms prevent effective antitumor immune responses. Taken together, these immunosuppressive factors can induce significant anergy or apoptosis of adoptively transferred CAR-modified T cells upon encounter with targeted tumor cells.
[0315] The unpurified source of CTL can be any known in the art, such as bone marrow, fetal, neonatal or adult or other hematopoietic cell source, such as fetal liver, peripheral blood or umbilical cord blood. A variety of techniques can be used to separate cells. For example, negative selection methods can first remove non-CTL. mAbs are particularly useful for identifying markers associated with specific cell lineages and / or stages of differentiation, for both positive and negative selection.
[0316] A large proportion of terminally differentiated cells can be initially removed by a relatively crude separation. For example, magnetic bead separation can be used initially to remove many irrelevant cells. In certain embodiments, at least about 80%, usually at least 70%, of the total hematopoietic cells are removed prior to cell isolation.
[0317] Isolation procedures include, but are not limited to, density gradient centrifugation; resetting; cell density These include coupling to particles that modify the mAb; magnetic separation with antibody-coated magnetic beads; affinity chromatography; cytotoxic agents linked to or used in conjunction with the mAb, including but not limited to complement and cytotoxins; and panning with antibodies attached to a solid matrix, e.g., a plate, chip, elutriation or any other convenient technique.
[0318] Separation and analysis techniques include, but are not limited to, flow cytometry, which can have various degrees of sophistication, e.g., multiple color channels, low and obtuse angle light scatter detection channels, impedance channels.
[0319] Cells can be selected for dead cells by using a dead cell associated dye such as propidium iodide (PI). In certain embodiments, cells are harvested in medium containing 2% fetal calf serum (FCS) or 0.2% bovine serum albumin (BSA), or any other suitable, e.g., sterile, isotonic, medium.
[0320] 4. Vector Genetic modification of immune responsive cells (e.g., T cells or NK cells) can be achieved by transducing a substantially homogeneous cell composition with a recombinant DNA construct. In certain embodiments, a retroviral vector (either gammaretrovirus or lentivirus) is used to introduce the DNA construct into cells. For example, a polynucleotide encoding a CAR can be cloned into a retroviral vector and expression can be caused from its endogenous promoter, from the retroviral terminal repeat sequence, or from a promoter that is specific to the target cell type of interest. Non-viral vectors can be used as well.
[0321] When initially genetically modifying immunoresponsive cells to contain a CAR, retroviral vectors are typically used for transduction, although any other suitable viral vector or non-viral delivery system can be used. CARs can be constructed in a single polycistronic expression cassette, in multiple expression cassettes in a single vector, or in multiple vectors with auxiliary molecules (e.g., cytokines). Examples of elements that create polycistronic expression cassettes include various viral and non-viral internal ribosome entry sites (IRES, e.g., FGF-1 IRES, FGF-2 IRES, VEGF IRES, IGF-II IRES, NF-κB IRES, RUNX1 IRES, VEGF ... IRES, p53 IRES, Hepatitis A IRES, Hepatitis C IRES, Pestivirus IRES, Aphthovirus IRES, Picornavirus IRES, Poliovirus IRES, and Encephalomyocarditis virus IRES), and cleavable linkers (e.g., 2A peptides, such as P2A, T2A, E2A, and F2A peptides). In certain embodiments, any vector or CAR disclosed herein may include a P2A peptide comprising the amino acid sequence of GSGATNFSLLKQAGDVEENPGP (SEQ ID NO: 107). If the capsid protein is functional to infect human cells, a combination of a retroviral vector and an appropriate packaging system is also suitable. A variety of amphotropic virus-producing cell lines are known, including, but not limited to, PA12 (Miller, et al. (1985) Mol. Cell. Biol. 5:431-437); PA317 (Miller, et al. (1986) Mol. Cell. Biol. 6:2895-2902); and CRIP (Danos, et al. (1988) Proc. Natl. Acad. Sci. USA 85:6460-6464). Non-amphotropic particles, such as particles pseudotyped with VSVG, RD114 or GALV envelopes, and any other particles known in the art, are also suitable.
[0322] Possible methods of transduction include, for example, those described in Bregni, et al. (1992) Blood 80:1418-1422. or by direct co-culture of the cells with the producing cells by the methods of, for example, Xu, et al. (1994) Exp. Hemat. 22:223-230; and Hughes, et al. (1992) J. Clin. Invest. 89:1817. , culture with viral supernatant alone or with concentrated vector stock with or without appropriate growth factors and polycations.
[0323] Other transducing viral vectors can be used to modify immune responsive cells. In certain embodiments, the vector selected exhibits high efficiency of infection and stable integration and expression (see, for example, Cayouette et al., Human Gene Therapy 8:423-430, 1997; Kido et al., Current Eye Research 15:833-844, 1996; Bloomer et al., Journal of Virology 71:6641-6649, 1997; Naldinietal., Science 272:263-267, 1996 and Miyoshi et al., Proc. Natl. Acad. Sci. USA 94:10319, 1997). Can be used Other viral vectors include, for example, adenovirus, lentivirus and adeno-associated virus vectors, vaccinia virus, bovine papilloma virus or herpes viruses such as Epstein-Barr virus (see, e.g., Miller, Human Gene Therapy 15-14, 1990; Friedman, Science 244:1275-1281, 1989; Eglitisetal., BioTechniques 6:608-614, 1988; Tolstoshev et al., Current Opinion in Biotechnology 1:55-61, 1990). ;Sharp, The Lancet 337:1277-1278, 1991;Cornetta et al., Nucleic Acid Research and Molecular Biology 36:311-322, 1987;Anderson, Science 226:401-409, 1984;Moen, Blood Cells 17:407-416, 1991;Miller et al., Biotechnology 7:980-990, 1989;LeGalLa Salle et al., Science 259:988-990, 1993 and Johnson, Chest 107:77S- 83S, 1995). Retroviral vectors have been particularly well developed and have been used in clinical settings (Rosenberg et al., N. Engl. J. Med 323:370, 1990; Anderson et al., U.S. Patent No. 5,399,346).
[0324] Non-viral approaches can also be used for genetic modification of immunoresponsive cells, for example, by administering nucleic acids in the presence of lipofection (Feigner et al., Proc. Natl. Acad. Sci. USA 84:7413, 1987; Ono et al., Neuroscience Letters 17:259, 1990;Brigham et al., Am. J. Med. Sci.298:278, 1989;Staubinger et al., Methods inEnzymology 101:512, 1983), asialoorosomucoid-polylysine conjugate Nucleic acid molecules can be introduced into immunocompetent cells by microinjection (Wuet al., Journal of Biological Chemistry 263:14621, 1988; Wu et al., Journal of Biological Chemistry 264:16985, 1989) or by microinjection under surgical conditions (Wolff et al., Science 247:1465, 1990). Other non-viral means for gene transfer include in vitro transfection using calcium phosphate, DEAE dextran, electroporation and protoplast fusion. Liposomes can also be potentially useful for delivery of DNA to cells. Transplantation of normal genes into diseased tissues of subjects can also be achieved by ex vivo introduction of normal nucleic acids into culturable cell types (e.g., autologous or heterologous primary cells or their progeny), and then the cells (or their progeny) are injected into the targeted tissue or injected systemically. Recombinant receptors can also be induced or obtained using transposases or targeted nucleases (e.g., zinc finger nucleases, meganucleases or TALE nucleases, CRISPR). Transient expression can be obtained by RNA electroporation.
[0325] The clustered regularly interspaced short palindromic repeats (CRISPR) system is a genome editing tool found in prokaryotic cells. When utilized for genome editing, the system includes Cas9 (a protein that can modify DNA using crRNA as its guide), CRISPR RNA (crRNA, containing the RNA used by Cas9 to guide it to the correct part of the host DNA along with a region that binds to tracrRNA (generally in the form of a hairpin loop) that forms an active complex with Cas9), transactivating crRNA (tracrRNA, which binds to crRNA to form an active complex with Cas9), and an optional portion of DNA repair template (DNA that induces the cell repair process allowing the insertion of a specific DNA sequence). CRISPR / Cas9 often uses a plasmid to transfect the target cell. The crRNA is the sequence that Cas9 uses to identify and directly bind to the target DNA in the cell and therefore needs to be designed for each application. The repair template with the CAR expression cassette also needs to be designed for each application as it must overlap with the sequences on either side of the cut and code for the insertion sequence. Multiple crRNAs and tracrRNAs can be packaged together to form a single guide RNA (sgRNA), which can be linked together with a Cas9 gene into a plasmid for transfection into cells.
[0326] Zinc finger nucleases (ZFNs) are artificial restriction enzymes that are generated by combining a zinc finger DNA binding domain with a DNA cleavage domain. The zinc finger domain can be engineered to target specific DNA sequences that allow the zinc finger nuclease to target desired sequences in the genome. The DNA binding domain of an individual ZFN typically contains multiple individual zinc finger repeats, each capable of recognizing multiple base pairs. The most common method of generating new zinc finger domains is to combine zinc finger "modules" of known less specificity. The most common cleavage domain in ZFNs is the non-specific cleavage domain from the type II restriction endonuclease FokI. ZFNs can be used to insert a CAR expression cassette into a genome using endogenous homologous recombination (HR) machinery and a homologous DNA template carrying the CAR expression cassette. When the targeting sequence is cleaved by the ZFN, the HR machinery searches for homology between the damaged chromosome and the homologous DNA template and then copies the sequence of the template between the two cut ends of the chromosome, thereby integrating the homologous DNA template into the genome.
[0327] Transcription activator-like effector nucleases (TALENs) are restriction enzymes that can be engineered to cleave specific sequences in DNA. TALEN systems work on much the same principle as ZFNs. They are generated by combining a transcription activator-like effector DNA binding domain with a DNA cleavage domain. Transcription activator-like effectors (TALEs) are composed of a repeating motif of 33-34 amino acids with two variable positions that have strong recognition for specific nucleotides. By assembling an array of these TALEs, the TALE DNA binding domain can be engineered to bind to a desired DNA sequence and thereby induce a nuclease to cleave at a specific location in the genome. cDNA expression for use in polynucleotide therapy can be derived from any suitable promoter (e.g., human cytomegalovirus (CMV), simian virus 40 (SV40) or metallothionein promoters) and can be regulated by any suitable mammalian regulatory element or intron (e.g., elongation factor 1a enhancer / promoter / intron structure). For example, if desired, enhancers known to preferentially induce gene expression in specific cell types can be used to induce the expression of nucleic acid.The enhancers used can include, but are not limited to, those characterized as tissue- or cell-specific enhancers.Alternatively, when genomic clones are used as therapeutic constructs, regulation can be mediated by homologous regulatory sequences or, if desired, by regulatory sequences from heterologous sources, including any of the promoters or regulatory elements described above.
[0328] The resulting cells can be grown under conditions similar to those for the unmodified cells, thereby allowing the modified cells to be expanded and used for a variety of purposes.
[0329] 5. Genome editing methods Any targeted genome editing method can be used to place the CAR of the present disclosure into one or more endogenous loci of the immunoresponsive cell of the present disclosure.In certain embodiments, the CRISPR system is used to deliver the CAR of the present disclosure into one or more endogenous loci of the immunoresponsive cell of the present disclosure.In certain embodiments, the zinc finger nuclease is used to deliver the CAR of the present disclosure into one or more endogenous loci of the immunoresponsive cell of the present disclosure.In certain embodiments, the TALEN system is used to deliver the CAR of the present disclosure into one or more endogenous loci of the immunoresponsive cell of the present disclosure.
[0330] The method for delivering genome editing agents / systems may vary according to need. In certain embodiments, the components of the selected genome editing method are delivered as DNA constructs in one or more plasmids. In certain embodiments, the components are delivered through viral vectors. Common delivery methods include, but are not limited to, electroporation, microinjection, gene gun, impalefection, hydrostatic pressure, continuous injection, sonication, magnetofection, adeno-associated virus, envelope protein pseudotyping of viral vectors, cis- and trans-acting elements of replication-competent vectors, herpes simplex virus, and chemical vehicles (e.g., oligonucleotides, lipoplexes, polymersomes, polyplexes, dendrimers, inorganic nanoparticles, and cell-penetrating peptides).
[0331] The CAR of the present disclosure can be placed at any endogenous locus.In certain embodiments, the endogenous locus is the TRAC locus, the TRBC locus, or the TRGC locus.In certain embodiments, the endogenous locus is the TRAC locus.In certain embodiments, the CAR is placed to destroy or disable the endogenous expression of TCR.
[0332] 6. Polypeptides and analogues The subject matter of the present disclosure also includes CD19, CD8, CD28, CD3zeta, CD40, 4-1BB, OX40, CD84, CD166, CD8a, CD8b, ICOS, ICAM-1, CD27, MY88, NKGD2, and CTLA-4 polypeptides or fragments thereof that are modified to enhance their antineoplastic activity when expressed in immunoresponsive cells.The subject matter of the present disclosure provides a method for optimizing amino acid or nucleic acid sequences by making changes in the sequence.Such changes can include certain mutations, deletions, insertions, or post-translational modifications. The subject matter of the present disclosure further includes analogs of any naturally occurring polypeptide disclosed herein, including, but not limited to, CD19, CD8, CD28, CD3zeta, CD40, 4-1BB, OX40, CD27, CD40 / My88, NKGD2, CD84, CD166, CD8a, CD8b, ICOS, ICAM-1, and CTLA-4. Analogs can differ from the naturally occurring polypeptides disclosed herein by amino acid sequence differences, by post-translational modifications, or both. Analogs can exhibit at least about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or more homology with all or a portion of the naturally occurring amino acid sequence of the subject matter of the present disclosure. The length of sequence comparison is at least 5, 10, 15 or 20 amino acid residues, for example, at least 25, 50 or 75 amino acid residues, or longer than 100 amino acid residues. Again, in an exemplary approach to determining the degree of identity, the BLAST program is used to select the sequence that indicates the closely related sequences. -3 From e -100Modifications include in vivo and in vitro chemical derivatization of polypeptides, such as acetylation, carboxylation, phosphorylation, or glycosylation, which may occur during polypeptide synthesis or processing, or following treatment with an isolated modifying enzyme. Analogs may also differ from naturally occurring polypeptides by changes in primary sequence. These include both natural and induced genetic variants (resulting from random mutagenesis, e.g., by exposure to radiation or ethane methyl sulfate, or by the use of genetic variants such as those described in Sambrook, Fritschand Maniatis, Molecular Cloning: A Laboratory Manual (2d ed.), CSH Press, 1989, or the site-specific mutations described in Ausubel et al., supra. Also included are cyclized peptides, molecules, and analogs that contain residues other than L-amino acids, e.g., D-amino acids or non-naturally occurring or synthetic amino acids, e.g., β or γ amino acids.
[0333] In addition to full-length polypeptides, the subject matter of the present disclosure also provides fragments of any one of the polypeptide or peptide domains disclosed herein. As used herein, the term "fragment" means at least 5, 10, 13, or 15 amino acids. In certain embodiments, the fragment comprises at least 20 contiguous amino acids, at least 30 contiguous amino acids, or at least 50 contiguous amino acids. In certain embodiments, the fragment comprises at least 60-80, 100, 200, 300, or more contiguous amino acids. Fragments can be generated by methods known to those of skill in the art or can result from normal protein processing (e.g., removal of amino acids from a nascent polypeptide that are not required for biological activity, or removal of amino acids by alternative mRNA splicing or alternative protein processing events).
[0334] Non-protein analogs have chemical structures designed to mimic the functional activity of the proteins disclosed herein. Such analogs may exceed the physiological activity of the original polypeptide. Methods for designing analogs are well known in the art, and the synthesis of analogs can be performed according to such methods by modifying the chemical structure so that the resulting analog increases the antineoplastic activity of the original polypeptide when expressed in an immunoresponsive cell. These chemical modifications include, but are not limited to, substituting alternative R groups and changing the degree of saturation of certain carbon atoms of the reference polypeptide. In certain embodiments, protein analogs are relatively resistant to degradation in vivo, resulting in a more sustained therapeutic effect when administered. Assays for measuring functional activity include, but are not limited to, the assays described in the Examples below.
[0335] 7. Administration The composition comprising the immunoresponsive cells of the present disclosure can be provided systemically or directly to a subject to induce and / or enhance immune response to an antigen and / or to treat and / or prevent neoplasms, pathogen infections or infectious diseases. In certain embodiments, the immunoresponsive cells of the present disclosure or a composition comprising the same are directly injected into an organ of interest (e.g., an organ affected by a neoplasm). Alternatively, the immunoresponsive cells of the present disclosure or a composition comprising the same are provided indirectly to an organ of interest, for example, by administration into the circulatory system (e.g., tumor vasculature). To increase the in vitro or in vivo generation of T cells, NK cells or CTL cells, expansion and differentiation agents can be provided before, during or after administration of the cells or compositions.
[0336] The immunoresponsive cells of the present disclosure can be administered in any physiologically acceptable vehicle, usually intravascularly, although they can also be introduced into bone or other convenient sites (e.g., the thymus) where the cells can find a suitable site for regeneration and differentiation. Typically, at least about 1×10 5The final number of cells administered was approximately 1 × 10 10 The immunoresponsive cells of the present disclosure may comprise a purified cell population. One of skill in the art can easily determine the percentage of the immunoresponsive cells of the present disclosure in a population using various well-known methods, such as fluorescence-activated cell sorting (FACS). Suitable ranges of purity in a population containing the immunoresponsive cells of the present disclosure are about 50% to about 55%, about 5% to about 60%, and about 65% to about 70%. In certain embodiments, the purity is about 70% to about 75%, about 75% to about 80%, or about 80% to about 85%. In certain embodiments, the purity is about 85% to about 90%, about 90% to about 95%, and about 95% to about 100%. The dosage can be easily adjusted by one of skill in the art (e.g., a decrease in purity may require an increase in dosage). The cells can be introduced by injection, catheter, etc.
[0337] The composition of the present disclosure may be a pharmaceutical composition comprising the immunoresponsive cells of the present disclosure or their progenitors and a pharma- ceutically acceptable carrier. Administration may be autologous or xenogeneic. For example, the immunoresponsive cells or progenitors may be obtained from one subject and administered to the same subject or to a different, compatible subject. The immunoresponsive cells or their progeny derived from peripheral blood (e.g., from in vivo, ex vivo or in vitro) may be administered via catheter administration, systemic injection, local injection, intravenous injection or local injection, including parenteral administration. When administering the therapeutic composition of the subject of the present disclosure (e.g., a pharmaceutical composition comprising the immunoresponsive cells of the present disclosure), it may be formulated into a unit dosage injection form (solution, suspension, emulsion).
[0338] 8. Preparation The compositions comprising the immunoresponsive cells of the present disclosure can be conveniently provided as sterile liquid preparations, such as isotonic aqueous solutions, suspensions, emulsions, dispersions or viscous compositions, which can be buffered to a selected pH. Liquid preparations are usually easier to prepare than gels, other viscous compositions and solid compositions. In addition, liquid compositions are somewhat more convenient to administer, especially by injection. On the other hand, viscous compositions can be formulated within an appropriate viscosity range to provide longer contact periods with specific tissues. Liquid or viscous compositions can include a carrier, which can be a solvent or dispersion medium, including, for example, water, saline, phosphate buffered saline, polyol (e.g., glycerol, propylene glycol, liquid polyethylene glycol, etc.) and suitable mixtures thereof.
[0339] Sterile injectable solutions can be prepared by incorporating the genetically modified immunoresponsive cells in the required amount of appropriate solvent together with various amounts of other ingredients as desired. Such compositions may be mixed with suitable carriers, diluents or excipients, such as sterile water, physiological saline, glucose, dextrose, and the like. The compositions may be lyophilized. The compositions may contain auxiliary substances, such as wetting, dispersing or emulsifying agents (e.g., methylcellulose), pH buffering agents, gelling or thickening additives, preservatives, flavoring agents, coloring agents, and the like, depending on the desired route of administration and preparation. Standard texts, such as "REMINGTON'S PHAARMACEUTICAL SCIENCE", 17th edition, 1985, which is incorporated herein by reference, can be consulted to prepare suitable preparations without undue experimentation.
[0340] Various additives can be added to enhance the stability and sterility of the composition, including antimicrobial preservatives, antioxidants, chelating agents and buffers. Prevention of microbial activity can be ensured by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, etc. Prolonged absorption of injectable pharmaceutical forms can be achieved by using agents that delay absorption, such as aluminum monostearate and gelatin. However, according to the subject matter of the present disclosure, any vehicle, diluent or additive used must be compatible with genetically modified immunoresponsive cells or their precursor cells.
[0341] The composition may be isotonic, i.e., they may have the same osmotic pressure as blood and tear fluid.The desired isotonicity of the composition may be achieved using sodium chloride or other pharma- ceutically acceptable agents, such as dextrose, boric acid, sodium tartrate, propylene glycol, or other inorganic or organic solutes.Sodium chloride may be especially for the buffer solution containing sodium ion.
[0342] The viscosity of the composition can be maintained at a selected level by using a pharma- ceutically acceptable thickening agent if desired. For example, methylcellulose is readily and economically available and easy to work with. Other suitable thickening agents include, for example, xanthan gum, carboxymethylcellulose, hydroxypropylcellulose, carbomer, etc. The concentration of the thickening agent may depend on the drug selected. The important point is to use an amount that achieves the selected viscosity. Obviously, the selection of suitable carriers and other additives depends on the exact route of administration and the nature of a particular dosage form, for example, a liquid dosage form (for example, whether the composition is formulated into a solution, suspension, gel, or another liquid form, for example, a time-release form or a liquid-filled form).
[0343] The amount of cells administered will vary with respect to the subject being treated. In one embodiment, about 10 4 ~about 10 10 pieces, about 10 5 ~about 109 Pieces, or about 10 6 ~about 10 8 Immunoresponsive cells of the present disclosure are administered to a human subject. More effective cells may be administered in even fewer numbers. In certain embodiments, at least about 1×10 8 pieces, approximately 2×10 8 pieces, about 3 x 10 8 pieces, about 4×10 8 Pieces, or about 5 x 10 8 Immunoresponsive cells of the present disclosure are administered to a human subject. In certain embodiments, about 1×10 7 ~5×10 8 The immunoresponsive cells of the present disclosure are administered to a human subject. The exact amount that is considered an effective dose may be based on individual factors for each subject, including the size, age, sex, weight, and condition of the particular subject. Dosage amounts can be easily ascertained by those skilled in the art from the present disclosure and knowledge in the art.
[0344] One of skill in the art can readily determine the amount of cells and optional additives, vehicles, and / or carriers to be administered in the compositions and methods. Typically, any additives (in addition to the active cells and / or agents) are present in an amount of 0.001 to 50% (by weight) solution in phosphate buffered saline, and the active ingredient is present on the order of micrograms to milligrams, e.g., about 0.0001 to about 5% by weight, about 0.0001 to about 1% by weight, about 0.0001 to about 0.05% by weight, or about 0.001 to about 20% by weight, about 0.01 to about 10% by weight, or about 0.05 to about 5% by weight. For any composition to be administered to animals or humans, the following can be determined: toxicity, such as by determination of the lethal dose (LD) and LD50 in a suitable animal model, e.g., rodents such as mice; dosage of the composition, concentrations of components therein, that elicit an appropriate response, and timing of administration of the composition. Such determinations would not require undue experimentation given the knowledge of one of ordinary skill in the art, this disclosure, and the documents cited herein, and the time of sequential administration can be ascertained without undue experimentation.
[0345] 9. Treatment Method The subject matter of the present disclosure provides a method for inducing and / or increasing an immune response in a subject in need thereof. The immunoresponsive cells of the present disclosure and compositions comprising the same can be used to treat and / or prevent a neoplasm in a subject. The immunoresponsive cells of the present disclosure and compositions comprising the same can be used to prolong the survival of a subject suffering from a neoplasm. The immunoresponsive cells of the present disclosure and compositions comprising the same can also be used to treat and / or prevent pathogen infection or other infectious disease in a subject, such as an immunocompromised human subject. In certain embodiments, the immunoresponsive cells comprising the CAR disclosed herein can be used to treat a subject with disease recurrence, the subject having undergone a treatment that results in residual tumor cells. In certain embodiments, the residual tumor cells have a low density of target molecules on the surface of the tumor cells. In certain embodiments, target molecules having a low density on the cell surface have less than about 10,000 molecules / cell, less than about 8,000 molecules / cell, less than about 6,000 molecules / cell, less than about 4,000 molecules / cell, less than about 2,000 molecules / cell, less than about 1,000 molecules / cell, less than about 500 molecules / cell, less than about 200 molecules / cell, or less than about 100 molecules / cell. In certain embodiments, target molecules having a low density on the cell surface have between about 4,000 and about 2,000 molecules / cell, or between about 2,000 and about 1,000 molecules / cell. In certain embodiments, the immunoresponsive cells comprising a CAR disclosed herein can be used to treat a subject with disease recurrence, where the subject has received an immunoresponsive cell (e.g., T cell) comprising a CAR (e.g., 4-1BBz CAR) comprising an intracellular signaling domain that comprises a costimulatory signaling domain comprising a 4-1BB polypeptide. In certain embodiments, the tumor cells have a low density of tumor-specific antigens on the surface of the tumor cells. In certain embodiments, the disease is CD19 +The tumor is ALL. In certain embodiments, the tumor cells have low density of CD19 on the tumor cells. Such methods include administering an effective amount of the immunoresponsive cells of the present disclosure, or a composition (e.g., pharmaceutical composition) comprising the same, to achieve a desired effect, alleviate an existing condition, or prevent recurrence. For treatment, the amount administered is an amount effective to produce a desired effect. An effective amount can be provided in one or a series of administrations. An effective amount can be provided by bolus or continuous perfusion.
[0346] An "effective amount" (or "therapeutically effective amount") is an amount sufficient to achieve a beneficial or desired clinical outcome from treatment. An effective amount can be administered to a subject in one or more doses. In terms of treatment, an effective amount is an amount sufficient to palliate, ameliorate, stabilize, reverse or slow down the progression of a disease, or otherwise reduce the pathological consequences of a disease. An effective amount is generally determined by a physician on a case-by-case basis and is within the skill of one of ordinary skill in the art. When determining the appropriate dosage to achieve an effective amount, several factors are generally considered. These factors include the age, sex, and weight of the subject, the condition being treated, the severity of the condition, and the form and effective concentration of the immunoresponsive cells administered.
[0347] For adoptive immunotherapy using antigen-specific T cells, approximately 10 6 ~10 10 (For example, about 10 9 A cell dose in the range of 100-200 mg / kg is typically injected. Upon administration of the cells of the present disclosure to the host and subsequent differentiation, T cells specifically directed against a specific antigen are induced. The immunoresponsive cells can be administered by any method known in the art, including but not limited to intravenous, subcutaneous, intranodal, intratumoral, intrathecal, intrapleural, intraperitoneal, and directly into the thymus.
[0348] The presently disclosed subject matter provides a method for treating and / or preventing a neoplasm in a subject, which can include administering to a subject having a neoplasm an effective amount of an immunoresponsive cell of the present disclosure or a composition comprising same.
[0349] Non-limiting examples of neoplasms include blood cancers (e.g., leukemia, lymphoma, and myeloma), ovarian cancer, breast cancer, bladder cancer, brain cancer, colon cancer, intestinal cancer, liver cancer, lung cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, glioblastoma, throat cancer, melanoma, neuroblastoma, adenocarcinoma, glioma, soft tissue sarcoma, and various carcinomas (including prostate and small cell lung cancer). Suitable carcinomas include astrocytoma, fibrosarcoma, myxosarcoma, liposarcoma, oligodendroglioma, ependymoma, medulloblastoma, primitive neuroectodermal tumor (PNET), chondrosarcoma, osteogenic sarcoma, pancreatic ductal adenocarcinoma, small and large cell lung adenocarcinoma, chordoma, angiosarcoma, endothelial sarcoma, squamous cell carcinoma, bronchioloalveolar carcinoma, epithelial adenocarcinoma and its liver metastases, lymphangiosarcoma, lymphangioendothelial sarcoma, hepatocellular carcinoma, cholangiocarcinoma, synovium, mesothelioma, Ewing's tumor, rhabdomyosarcoma, colon carcinoma, basal cell carcinoma, sweat gland carcinoma, papillary carcinoma, sebaceous gland carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, cholangiocarcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, testicular Further included are any known in the field of oncology, including, but not limited to, tumors, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma, retinoblastoma, leukemia, multiple myeloma, Waldenstrom's hypergammaglobulinemia, and heavy chain disease, breast tumors such as ductal and lobular adenocarcinoma, squamous cell and adenocarcinoma of the cervix, epithelial carcinoma of the uterus and ovary, prostate adenocarcinoma, transitional squamous cell carcinoma of the bladder, B and T cell lymphoma (nodular and diffuse) plasmacytoma, acute and chronic leukemia, malignant melanoma, soft tissue sarcoma, and leiomyosarcoma. In certain embodiments, the neoplasm is selected from the group consisting of hematological cancer (e.g., leukemia, lymphoma, and myeloma), ovarian cancer, prostate cancer, breast cancer, bladder cancer, brain cancer, colon cancer, intestinal cancer, liver cancer, lung cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, glioblastoma, and throat cancer. In certain embodiments, the immunoresponsive cells of the present disclosure and compositions comprising same can be used to treat and / or prevent hematological cancer (e.g., leukemia, lymphoma, and myeloma) or ovarian cancer that is not amenable to conventional therapeutic intervention.
[0350] The subject may have an advanced form of the disease, in which case the goal of treatment may include reducing or reversing disease progression and / or ameliorating side effects. The subject may have a history of a condition that has already been treated, in which case the goal of treatment will generally include reducing or delaying the risk of recurrence.
[0351] Suitable human subjects for therapy generally include two treatment groups that can be distinguished by clinical criteria. Subjects with "advanced disease" or "high tumor burden" are those with clinically measurable tumors. Clinically measurable tumors are those that can be detected based on tumor mass (e.g., palpation, CAT scan, sonograph, mammogram or X-ray; positive biochemical or histopathological markers are insufficient to identify this population by themselves). Pharmaceutical compositions are administered to these subjects to elicit an anti-tumor response with the aim of alleviating the subject's condition. Ideally, a reduction in tumor mass occurs as a result, but any clinical improvement constitutes a benefit. Clinical improvement includes a reduction in the risk or rate of tumor progression or a reduction in pathological consequences.
[0352] A second group of suitable subjects is known in the art as the "adjuvant group." These are individuals who have a history of neoplasms but are responsive to another mode of therapy. Prior therapy could include, but is not limited to, surgical resection, radiation therapy, and traditional chemotherapy. As a result, these individuals do not have clinically measurable tumors. However, they are suspected to be at risk for disease progression near the original tumor site or through metastasis. This group can be further subdivided into high-risk and low-risk individuals. Subdivision is based on characteristics observed before and after initial treatment. These characteristics are known in the clinical field and are appropriately defined for each different neoplasm. Common characteristics in the high-risk subgroup are those in which the tumor has invaded adjacent tissues or shows lymph node involvement.
[0353] Another group has a genetic predisposition to neoplasia, but has no proven clinical signs of neoplasia yet. For example, a woman who tests positive for a genetic mutation associated with breast cancer but is still of childbearing age may wish to receive one or more of the immunoresponsive cells described herein in a prophylactic treatment to prevent the development of neoplasia until it is appropriate to perform prophylactic surgery.
[0354] Furthermore, the subject matter of the present disclosure provides a method for treating and / or preventing a pathogen infection (e.g., a viral infection, a bacterial infection, a fungal infection, a parasitic infection, or a protozoan infection) in a subject, such as an immunocompromised subject. The method can include administering an effective amount of an immunoresponsive cell of the present disclosure or a composition comprising the same to a subject having a pathogen infection. Exemplary viral infections that are susceptible to treatment include, but are not limited to, cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), and influenza virus infection.
[0355] To avoid or minimize the risk of immunological complications (known as "malignant T cell transformation"), such as graft-versus-host disease (GvHD), or where healthy tissue expresses the same target antigen as tumor cells, leading to outcomes similar to GvHD, further modifications can be introduced into the immunoresponsive cells (e.g., T cells) of the present disclosure. A potential solution to this problem is to incorporate a suicide gene into the immunoresponsive cells of the present disclosure. Suitable suicide genes include, but are not limited to, herpes simplex virus thymidine kinase (hsv-tk), inducible caspase-9 suicide gene (iCasp-9), and truncated human epidermal growth factor receptor (EGFRt) polypeptide. In certain embodiments, the suicide gene is an EGFRt polypeptide. The EGFRt polypeptide allows for T cell elimination by administering an anti-EGFR monoclonal antibody (e.g., cetuximab). The EGFRt can be covalently linked upstream of the CAR of the present disclosure. The suicide gene may be included in a vector that includes a nucleic acid encoding a CAR of the present disclosure. Thus, administration of a prodrug designed to activate a suicide gene (e.g., a prodrug capable of activating iCasp-9 (e.g., AP1903)) during malignant T cell transformation (e.g., GVHD) induces apoptosis in suicide gene-activated CAR-expressing T cells. Incorporation of a suicide gene into the CAR of the present disclosure provides an additional level of safety by virtue of its ability to eliminate the majority of CAR T cells in a very short period of time. The immunoresponsive cells (e.g., T cells) of the present disclosure incorporating a suicide gene are capable of activating the CAR T cells, thereby inducing apoptosis in the T cells expressing the suicide gene. T cells can be preemptively eliminated at a given time point after infusion or eradicated at the earliest sign of toxicity.
[0356] 10. Kit The subject matter of the present disclosure provides a kit for inducing and / or enhancing immune response and / or treating and / or preventing neoplasm or pathogen infection in a subject.In certain embodiments, the kit comprises an effective amount of the immunoresponsive cell of the present disclosure or a pharmaceutical composition comprising the same.In certain embodiments, the kit comprises a sterile container, such container may be in the form of a box, an ampoule, a bottle, a vial, a tube, a bag, a sachet, a blister pack or other suitable container known in the art.Such containers can be made of plastic, glass, laminated paper, metal foil or other materials suitable for holding pharmaceuticals.In certain non-limiting embodiments, the kit comprises an isolated nucleic acid molecule encoding the CAR of the present disclosure against an antigen of interest in an expressible form, which can be optionally included in one or more vectors.
[0357] Optionally, the immunoresponsive cells and / or nucleic acid molecules are provided with instructions for administering the cells or nucleic acid molecules to a subject having or at risk of developing a neoplasm or a pathogen or an immune disorder. The instructions generally include information regarding the use of the composition for the treatment and / or prevention of a neoplasm or a pathogen infection. In certain embodiments, the instructions include at least one of the following: description of the therapeutic agent; dosage schedule and administration for the treatment or prevention of a neoplasm, a pathogen infection or an immune disorder or a symptom thereof; cautions; warnings; indications; contraindications; overdose information; adverse reactions; animal pharmacology; clinical trials; and / or references. The instructions can be printed directly on the container (if present), or as a label attached to the container, or as a separate sheet, pamphlet, card or folder provided in or with the container. EXAMPLES
[0358] The practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are well within the skill of one in the art. Such techniques are fully explained in such publications as "Molecular Cloning: A Laboratory Manual", second edition (Sambrook, 1989); "Oligonucleotide Synthesis" (Gait, 1984); "Animal Cell Culture" (Freshney, 1987); "Methods in Enzymology" "Handbook of Experimental Immunology" (Weir, 1996); "Gene Transfer Vectors for Mammalian Cells" (Miller and Calos, 1987); "Current Protocols in Molecular Biology" (Ausubel, 1987); "PCR: The Polymerase Chain Reaction", (Mullis, 1994); "Current Protocols in Immunology" (Coligan, 1991). These techniques are applicable to the production of the polynucleotides and polypeptides disclosed herein and therefore may be considered in making and practicing the subject matter of the present disclosure. Techniques that are particularly useful with respect to particular embodiments are discussed in the sections that follow.
[0359] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the disclosed cells and compositions, and are not intended to limit the scope of what the inventors regard as their invention.
[0360] Example 1 Introduction It has been proposed that multiple ITAMs in CD3ζ and the TCR complex amplify the TCR signal (PMID:20516133). Meanwhile, CD28 provides quantitative support for TCR signaling (PMID:14647476). Thus, the number and type of signaling domains are important in TCR signaling. In human T cells, CD28 and TCR / CD3ζ are approximately 6×10 4 and about 2 × 10 4 It is expressed in the molecule / cell (PMID:14647476). Thus, three molecules of CD28 can provide signaling support for one molecule of TCR / CD3ζ with three ITAMs. However, the second generation CAR 1928z has a design of fused CD28 and CD3ζ cytoplasmic domains, fixing their stoichiometric ratio to 1. With excellent killing and proliferation capabilities, 1928z CAR allows for rapid elimination of CD19-bearing cells in vitro, mouse models and patients. However, improvements of the current 1928z CAR are needed to overcome some problems in clinical trials. One problem is cytokine release syndrome (CRS), which is characterized by massive synchronous T cell activation and release of large amounts of cytokines. The mechanism of CRS is still elusive but may be related to excessive signaling of 1928z CAR T cells. Another problem is the exhaustion and persistence of CAR T cells. 1928z CAR T cells have been found to exist in low numbers and / or in a dysfunctional state expressing exhaustion markers, such as PD-1, weeks or months after infusion, which may explain some cases of relapse. It has been hypothesized that exhaustion is linked to excessive activation, which may be due to inherent properties of the 1928z CAR design (PMID:26331345).
[0361] Comparing 1928z CAR signaling to TCR signaling, several key differences due to the fusion of the two cytoplasmic domains are evident. First, in CARs, the CD28 signaling domain is in cis with the CD3ζ signaling domain, whereas CD28 is recruited to the synapse and colocalizes in trans with CD3ζ. Second, CD28 activation is simultaneous with CD3ζ activation in CARs, whereas CD28 costimulation occurs several seconds after TCR ligation. Third, three CD28 molecules assist one TCR, but the ratio is 1:1 in CARs. The first two differences are not easily modified under current CAR designs, whereas the third difference can be addressed by balancing costimulatory and activation signals, which may help to solve the current overstimulation problem. Although the CD28 / CD3ζ ratio cannot be directly altered by fusion design, the number of ITAMs in CD3ζ can be mutated to mimic the ratio of TCR signaling. The three ITAMs in CD3ζ differ in their primary amino acid sequence as well as their location relative to the plasma membrane (i.e., ITAM1, ITAM2, ITAM3 from membrane proximal to distal) and therefore in their ability to be phosphorylated by Lck or to bind to ZAP70 upon phosphorylation (PMID:23555234). Previous studies of ErbB2 CARs based on CD28 with only one ITAM at the second position showed reduced apoptosis in vitro (PMID:19843940), but further CAR characterization and in vivo studies were still lacking. Therefore, novel CARS based on the 1928z CAR design were designed that introduce a defined number and location of ITAMs to evaluate their functionality with respect to the above issues, including their impact on T cell persistence, differentiation, exhaustion, and antitumor activity, among others. We analyzed how each ITAM coupled to CD28 signaling in the context of the 1928z CAR affects overall CAR function in vitro and in vivo.ITAM1 coupled to CD28 was not only better than ITAM2 or ITAM3 coupled to CD28, but more importantly, it was better than the original 1928z CAR in terms of in vivo antitumor efficacy, making it a good candidate for clinical application. All studies were performed in human peripheral blood T cells.
[0362] result The CD3ζ ITAM domain in 1928ζ CAR is a qualitatively distinct CAR Exercising T cell function The first step was to explore whether each CD3ζ ITAM in the second generation 1928z-CAR construct contributes to a qualitatively unique function or whether the individual ITAMs exhibit overlapping functional redundant properties. To evaluate the contribution of each individual ITAM to the function of the 1928z CAR, 1928z CARs with only one single functional ITAM domain were generated (1XX, X2X, and XX3, see Figure 1A). Signaling of the remaining two ITAMs was disrupted by the insertion of point mutations that convert two tyrosines (Y) to phenylalanines (F), thus abolishing the phosphorylation and sequential recruitment of ZAP70 for full activation of downstream signaling pathways. T cells were effectively transduced using SFG retroviral vectors with comparable transduction rates between the different constructs (Figure 1B).
[0363] To compare the therapeutic potential of the generated 1928z variants, a suboptimal CAR T cell dose of 5 × 10 4 CARs + T cells were administered to a previously described NALM-6 mouse model of pre-B acute lymphoblastic leukemia and efficacy of treatment was compared to 1928z wild-type (1928z WT) mice (Figure 2).
[0364] Graded differences in tumor eradication and mouse survival were found in relation to the associated functional ITAM: unmodified ITAM1 (1XX) or ITAM2 (X2X) in their original 1928z CAR position showed improved antitumor activity compared to the original 1928z wild type (WT) as well as the three functional ITAMs. In contrast, ITAM3 (XX3) as the only functional ITAM in combination with dysfunctional ITAM1 and 2 performed poorly, with reduced tumor eradication and reduced mouse survival (Figure 3).
[0365] Thus, individual ITAMs in 1928z CARs exerted qualitatively differential functions when maintaining their original positions in the second generation 1928z structure. Tumor eradication efficacy gradually decreased as the position of each functional ITAM became more distal: 1XX consistently demonstrated rapid tumor eradication and achieved long-term complete remission, whereas treatment with X2X delayed tumor progression and was superior to 1928z WT, but eventually relapse occurred. XX3, which has its non-mutated (natural) ITAM at the most distal position, did not achieve tumor control, resulting in rapid tumor progression and reduced survival (Figure 3). In conclusion, 1928z CARs with one or two ITAMs at the second and third ITAM positions (XX3, X2X, X23) were less active or therapeutically less active (in vivo) than 1928z wild type.
[0366] One single functional CD3ζ ITAM at the correct location is sufficient for potent antitumor activity The next question to be addressed was whether the combination of two functional ITAMs at distal positions - ITAM2 and ITAM3 (X23, Figure 1A), which are imagined to have lower affinity for ZAP70 than ITAM1, together could improve the efficacy of its related single ITAM 1928ζ mutant (X2X / XX3). In vivo analysis revealed that the distal tumor clearance and survival of mice treated with X23 were comparable to the outcomes of mice treated with XX3 (Figures 2 and 3). In contrast, 1928z mutant CARs with only one single functional ITAM at either the first (1XX) or second (X2X) position were found to be superior to 1928z CARs with two (X23) or three (WT) functional ITAMs, as reflected in the course of tumor burden and survival. 1XX consistently proved to be the most potent 1928z mutant, achieving rapid and sustainable tumor eradication even at very low treatment doses. The results thus show that one single ITAM is sufficient for efficient killing, but also reveal significant differences in the therapeutic efficacy of CAR T cells depending on which ITAM within CD3ζ is functional.
[0367] We next analyzed whether the reduction in CAR function in XX3 was due to the individual specificity of ITAM3 in the context of second-generation CARs compared to its native location or related to the more distal location of ITAM3. Therefore, we generated 1928z mutant CARs with ITAM1 or ITAM3 at the exact same proximal CAR location (D12 and D23) and deletion of the remaining CD3 ζ chain, allowing a direct comparison of the two ITAMs in the context of 1928-CAR (Figure 1). The results demonstrated that ITAM3 at a more proximal location (D12) was sufficient for rapid and efficient long-term tumor clearance (Figures 2 and 3), showing comparable results to D23. Despite sharing the same ITAM (ITAM3), D12 clearly outperformed XX3 and achieved effective antitumor efficacy. Thus, the significant difference in therapeutic efficacy between D12 and XX3 demonstrates the impact of ITAM location within second-generation CARs. In conclusion, 1928z CAR with a single ITAM at the first ITAM position (ITAM1 at 1XX and D23, or ITAM3 at D12) was more therapeutically active than 1928z wild type (in vivo).
[0368] Although D23 and 1XX share ITAM1 as the only functional ITAM, 1XX showed improved functional properties compared to D23, resulting in higher T cell proliferation and favorable T cell phenotype (Figures 4 and 5), supporting that a basic residue-rich stretch (BRS) within the CD3 ζ chain, previously shown to mediate membrane association and modulate signal transduction, may be responsible for the functional properties of 1928z CAR (Figure 1B).
[0369] Therefore, additional mutations were inserted into the structure of 1XX CAR, thereby recombining BRS-2 and -3 (=1XX BRS negative ) signal transduction. 1XX BRS negativeshowed reduced proliferation and killing functions in vitro and in vivo, demonstrating that the BRS region is essential for the function of 1XX. Thus, we demonstrate the functional importance of the BRS region in 1XX.
[0370] CD3ζ ITAM Mutations Permit Enhanced T-Cell Proliferation and Limit T-Cell Differentiation and Exhaustion in 1928ζ CARs In vivo studies revealed enhanced CAR T-cell accumulation for all CAR groups with one functional ITAM and two mutated ITAM regions: XX3, X2X and 1XX cell numbers achieved significantly higher T-cell accumulation at the tumor site after 17 days compared to 1928z WT (Figure 4). T cells expressing mutant 1928z CARs containing a single ITAM (XX3, X2X, 1XX) accumulated at higher levels than T cells expressing wild-type 28z CAR in vivo. CARs containing two or more ITAMs (1928z and X23) showed reduced accumulation compared to T cells expressing single ITAM CARs (XX3, X2X, 1XX, D23, and D12).
[0371] Higher T cell accumulation is associated with CD4 + and CD8 + Central memory (CD62L+CD45RA-) in CAR T cells (T CM ) and effector (CD62L-CD45RA+) (T EFF ) cells: 1XX is associated with less T cell differentiation, as reflected by the percentage of T cells: 1XX is associated with improved in vivo proliferation capacity, a T cell phenotype, compared to 1928z WT. CM showed a significantly higher percentage of terminally differentiated T EFF Moreover, 1XX induced a significantly higher number of T cells in the bone marrow of treated mice at 17 days after CAR injection. CMThe results showed that 1XX and D23 induced the highest fraction of memory T cells and T cells expressing the memory-associated marker IL17R. Moreover, both T cell populations showed a significant increase from day 10 to day 17 after CAR administration (Figure 6). Overall, 1XX induced the highest fraction of memory T cells, while D23 was suboptimal in long-term in vitro assays. Delayed differentiation and an increase in IL7R-expressing CAR T cells were also observed in vitro with repeated exposure to antigen (data not shown).
[0372] Furthermore, 1928z mutants differed in the extent of T cell exhaustion as determined by co-expression of the inhibitory molecules PD1, TIM3 and LAG3, which are associated with reduced antitumor activity. The 1928z mutant groups (D12 and D23) with deletions of one single functional ITAM and two other ITAMs showed significantly lower expression of exhaustion markers (Figure 7).
[0373] XX3 exceeded 1928z WT in terms of the number of CARs at the tumor site (Figure 4), and T CM Although XX3-treated mice demonstrated a high percentage of tumors, these cells were unable to prevent tumor progression. XX3-treated mice demonstrated initial treatment response but relapsed shortly thereafter. In vitro functional analysis demonstrated reduced killing activity in XX3 as well as decreased Th1 cytokine and granzyme B (GrB) secretion (Figures 8 and 9). Figure 8 shows that in standard in vitro cytotoxicity assays, all CARs lyse tumor cells similarly, except for XX3, which shows reduced cytolytic activity. All constructs showed similar and potent cytotoxic activity after initial T cell transduction, but differences were observed after CAR expansion with repeated Ag exposure (Figure 8). Figure 9 shows that standard in vitro cytokine assays do not correlate with in vivo functional characteristics, but 1XX and D23 show a desirable profile (IL2 and anti-tumor cytokines such as IFNg and TNFa).
[0374] These findings indicate that effector and proliferation functions are not coupled in XX3, indicating that the expansion and persistence of CAR T cells was not sufficient for effective tumor eradication.In contrast, 1928z WT exerted high cytotoxic activity but acquired early differentiation into effector cells, increasing the upregulation of inhibitory molecules, leading to reduced attrition and persistence of 1928z CAR.
[0375] conclusion The functional redundancy and increased signaling by the combination of CD3ζ activation and CD28 costimulation in second generation 1928z CARs may lead to premature T cell differentiation and exhaustion, thus reducing antitumor activity. Therefore, the contribution of a single ITAM on CAR function was analyzed. The position, affinity, and number of ITAMs within the CD3ζ chain differentially affected the functional properties of 1928z CAR T cells. Overall, 1928z CARs containing a single ITAM orientated superior T cell accumulation, memory formation, and reduced exhaustion (Figures 4-7), whereas to provide the best therapeutic (antitumor) activity, a single ITAM must be placed in the first position (Figures 2-3). 1XX contained the most favorable properties of both effector and memory cells, thereby balancing activation and differentiation. 1XX regulated the strong activation of the combination of CD3ζ signaling and CD28 costimulation, fine-tuning the strength to the appropriate intracellular signal, thus modulating CAR-mediated signaling, which then leads to superior long-term tumor eradication.
[0376] Example 2 Alternative hinge / spacer regions and transmembrane domains of CAR Alternative hinge / spacer regions and transmembrane domains were tested in the CAR constructs. A schematic of 1XX CARs with different hinges (H) and transmembrane domains (TM) is shown in Figure 10. All hinges and transmembrane domains tested belong to the immunoglobulin superfamily (IgSF) and can form cell-surface homodimers. All constructs were cloned into a P2A bicistronic oncoretroviral vector (SFG) encoding CAR and LNGFR. Flow cytometry profiles show CAR and LNGFR expression using goat IgG anti-mouse IgG (F(ab')2) fragment and anti-LNGFR, respectively. T cells were obtained from PBMCs (peripheral blood mononuclear cells) of healthy donors, stably transduced 48 hours after activation, and analyzed for CAR expression at multiple time points. 1928z-LNGFR containing CD28 / CD28 H / TM regions CAR was used as a control.
[0377] Replacement of CD28 / CD28(H / TM) with ICOS / ICOS(H / TM), CTLA-4 / CTLA-4(H / TM), or ICAM-1 / ICAM-1(H / TM) hinges abolished cell-surface expression of CAR. However, fusing the CD28 hinge to an ICOS transmembrane (CD28 / ICOS;H / TM) restored CAR expression. However, the CD28 / CTLA-4(H / TM) configuration did not rescue CAR expression. These findings demonstrated that it is not trivial to find H / TM combinations that allow efficient CAR expression. In conclusion, 1XX CARs carrying either the CD84 / CD84, CD166 / CD166, CD8a / CD8a, CD8b / CD8b or CD28 / ICOS(H / TM) regions were similarly expressed on the T cell surface, but three of them, CD166-28z, CD8a-28z and CD8b-28z, are unable to dimerize with CD28.
[0378] 10 6Cumulative CAR T cell counts with weekly stimulation starting with 10 cells / ml of CAR T cells are shown in Figure 11. CAR T cell counts induced by weekly exposure to CD19 T cell proliferation was first assessed in vitro for 21 days. CAR T cells were cultured with irradiated CD19 T cells without the addition of any exogenous cytokines. + The cells were co-cultured with NIH 3T3. 6 cells / ml CAR + T cells were cultured using irradiated and fresh CD19 + NIH 3T3. 1928z-1XX-LNGFR CAR with CD28 / CD28(H / TM) was used as a reference. 19-CD166-28z proliferation in vitro was similar to 1928z wild type.
[0379] Data were generated based on CAR T cell surface detection. T cells transduced with CARs bearing ICOS / ICOS (H / TM), CTLA-4 / CTLA-4 (H / TM), ICAM-1 / ICAM-1 (or CD28 / CTLA-4 (H:TM) were CD19+ They were unable to accumulate after co-culture with NIH 3T3 cells. CAR T cells bearing CD84 / CD84 and CD8b / CD8b (H / TM) were able to accumulate after two rounds of stimulation. However, these cells lost their accumulation ability after the third round of stimulation. CAR T cells bearing CD166 (H / TM), CD8a (H / TM) domains, and CD28 / ICOS (H / TM) accumulate as effectively as control 1928Z-1XX CAR T cells.
[0380] The cytotoxic activity of CAR T cells was assessed at the end of the third stimulation (D21) for 4 h. 51Cr release assay was used and the results are shown in Figure 12. T cells and EL-4-CD19+ target cells were used at different effector:target ratios (E:T). EL-4-PSMA cells were used as a control. The in vitro cytotoxic potential of all fully expressed H / TM CD28 / CD3z variants was similar as expected. The cytotoxic potential of CAR T cells bearing CD166(H / TM), CD8a(H / TM) domains and CD28 / ICOS(H / TM) was comparable to CAR T cells bearing CD28 / CD28(H / TM).
[0381] The in vivo antitumor efficacy of different H / TM CAR T cells using NOD.Cg PrkdcscidIl2rgtm1Wjl / SzJ (immunodeficient NSG) mice is shown in Figure 13. Mice were injected with 5x10 5 FF Luc-GFP NALM6 cells (a pre-B ALL cell line) were injected, and 4 days later, 2 × 10 5 CAR T cells were injected. Tumor burden was tracked by weekly quantification of bioluminescence signal. All constructs selected for in vivo testing, CD166 / CD166(H / TM), CD8a / CD8a(H / TM), and CD28 / ICOS(H / TM), were able to completely eradicate tumor cells. No significant differences in tumor burden or survival were observed for any condition compared to the control group, 1928z CAR T cells.
[0382] Example 3 Deimmunization Strategies The proximity of the human sequence or its mutations carry the risk of creating neo-antigens. Therefore, the novel CD166 junctions and mutations in 1XX were deimmunized. The immunogenicity of the junctions between the different CAR parts was predicted using the NetMHC 4.0 server. A total of 26 amino acids were selected (13 amino acids from the first part and 13 amino acids from the second part). For each generated peptide (14, 13, 12, 11, 10, 9, and 8-mers) containing at least one amino acid from the neighboring part, the binding affinity to HLA A, B, and C of all alleles was predicted. The immunogenicity score of each peptide was assigned to each peptide. The immunogenicity score was calculated according to the formula of immunogenicity score = [(50-binding affinity) * The HLA frequency was calculated using [HLA frequency]n. 50nm was used as the cutoff for strong binding affinity. The HLA frequency in the Caucasian population was used. n = number of predictions for each peptide. HLA frequencies less than 1% in the total population were excluded. For junction deimmunization, shuffling of both amino acids forming the junction or deletion of amino acids on both sides of the junction were tested. A previously described strategy for predicting immunogenicity was used for each newly generated peptide. The junction with the lowest immunogenicity score was used to construct the deimmunized CAR. An exemplary deimmunization strategy is shown in Figure 14.
[0383] Example 4 Rescue of relapse of CD19 low ALL after treatment with 4-1BBz CAR T cells Introduction Adoptive immunotherapy using chimeric antigen receptors (CARs) is a promising immunotherapy that has shown remarkable clinical results in the treatment of leukemia and lymphoma and is in principle applicable to a wide range of cancers. Two promising CAR designs have been successfully introduced into the clinic, one utilizing the cytoplasmic domain of CD28 as a costimulatory component, and the other using the cytoplasmic domain of 4-1BB. In both examples, T cell activation is initiated through the fused cytoplasmic domain of the CD3 zeta chain. Although both designs have achieved remarkable results, clinical outcomes are limited by the shortcomings of these CAR structures. T cells expressing CD28-based CARs are potent but short-lived, whereas T cells expressing 4-1BB-based CARs are long-lived but allow antigen escape of tumor cells expressing low levels of the target antigen. Thus, novel CAR designs that extend T cell persistence without compromising function are needed.
[0384] result The CD28z CAR T cells of the present disclosure can rescue relapse of CD19 low ALL following treatment with 4-1BBz CAR T cells, which may be the main rescue pathway for many relapses that occur following treatment with 4-1BBz CAR T cells, except for cells that are stably CD19 negative.
[0385] 5 x 10 into the tail vein of NSG mice 5 FFLuc-GFP NALM6 cells (pre-B ALL cell line), and 4 days later, 2 × 10 5 19BBz CAR T cells were injected into the mice. Ten days after the first T cell injection (a non-effective dose that only slowed tumor progression), the mice were again injected with 19BBz CAR T cells or alternatively 1928z or (5×10 5 1928z-based CAR T cells were injected into the mice (19BBz / mouse). The different survival curves are shown in Figure 15. Only a new injection of 1928z-based CAR T cells (second injection) was able to rescue the mice treated with NALM-6 from relapse. No significant increase in survival rate was observed after the new injection of 19BBz CAR T cells.
[0386] In conclusion, CD28z CAR T cells can rescue the dysfunction of 4-1BBz CAR T cells. Considering the above examples, modified CD28z CAR T cells disclosed herein, such as 1XX, D23 and D12 CAR T cells (having various hinge / TM domains, such as CD166 hinge / TM domains), may be more effective than 1928z CAR T cells in rescuing the dysfunction of 4-1BBz CAR T cells.
[0387] Example 5 This example is an updated and further investigation of certain aspects of Example 1.
[0388] Chimeric antigen receptors (CARs) are synthetic receptors that target and reprogram T cells to acquire enhanced antitumor properties 1 CD28 and CD3ζ signaling motifs 2 CD19-specific CAR containing 3-5 and lymphoma 6 It has been recently approved by the U.S. Food and Drug Administration to induce significant responses in patients with 7 These CARs, despite the limited persistence they confer to T cells, 3-6,8 , mediating potent tumor elimination 4,8 Programming high-performance effector function. Extending the duration of function without compromising efficacy should improve current CAR therapies. Although strong T cell activation promotes attrition, 9,10 , which highlights the redundancy of CD28 and CD3ζ signaling 11,12 and second generation CAR 2This may be accentuated by the spatiotemporal constraints imparted by the structure of CD28. Thus, ...
Claims
[Claim 1] The invention as depicted in the drawings.
Citation Information
Patent Citations
T cell receptors, impaired T cell components
JP2015516818A
